#  @BiopharmIQ BiopharmIQ by Amp Several biotech companies have recently made significant announcements, including $INBX, which saw a 75% increase in stock value after releasing positive topline results for its chondrosarcoma trial. $RNA entered into an acquisition agreement for $12 billion, and $NVS is set to acquire $RNA's neuro pipeline. Additionally, $GMAB is acquiring $MRUS for $8 billion, expanding its portfolio with a phase [--] bispecific petosemtamab. ### Engagements: [------] [#](/creator/twitter::811036897883492352/interactions)  - [--] Week [-------] +8.70% - [--] Month [-------] -12% - [--] Months [---------] +33% - [--] Year [---------] -53% ### Mentions: [--] [#](/creator/twitter::811036897883492352/posts_active)  - [--] Week [---] -6.90% - [--] Month [---] +12% - [--] Months [---] +15% - [--] Year [-----] -33% ### Followers: [------] [#](/creator/twitter::811036897883492352/followers)  - [--] Week [------] +0.02% - [--] Month [------] +0.74% - [--] Months [------] +9.60% - [--] Year [------] +23% ### CreatorRank: [-------] [#](/creator/twitter::811036897883492352/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) 76.79% [finance](/list/finance) 22.02% [cryptocurrencies](/list/cryptocurrencies) #5347 [currencies](/list/currencies) 3.57% [exchanges](/list/exchanges) 2.98% [countries](/list/countries) 2.98% [financial services](/list/financial-services) 2.38% [technology brands](/list/technology-brands) 1.19% **Social topic influence** [$xbi](/topic/$xbi) #11, [$anro](/topic/$anro) #1, [$nktr](/topic/$nktr) #15, [$kod](/topic/$kod) #2, [$agio](/topic/$agio) #1, [$immp](/topic/$immp) #1, [data](/topic/data) #205, [acquisition](/topic/acquisition) #1539, [$rgnx](/topic/$rgnx) #1, [check out](/topic/check-out) 7.14% **Top accounts mentioned or mentioned by** [@wallstreet_dawg](/creator/undefined) [@mwb741](/creator/undefined) [@yaireinhorn](/creator/undefined) [@persimmonti](/creator/undefined) [@seedy19tron](/creator/undefined) [@biopharmiq](/creator/undefined) [@semodough](/creator/undefined) [@geneinvesting](/creator/undefined) [@quantumup1](/creator/undefined) [@biostocks](/creator/undefined) [@amaymd](/creator/undefined) [@pharmdca](/creator/undefined) [@doepkemichel](/creator/undefined) [@wassimlaroussi3](/creator/undefined) [@researchpulse1](/creator/undefined) [@wallstsai](/creator/undefined) [@biotech2k1](/creator/undefined) [@bioinvestor24](/creator/undefined) [@siemionowkris](/creator/undefined) [@maximusholla](/creator/undefined) **Top assets mentioned** [Alto Neuroscience, Inc. (ANRO)](/topic/$anro) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Atai Life Sciences B.V. (ATAI)](/topic/$atai) [PepGen Inc. (PEPG)](/topic/$pepg) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Merck & Co., Inc. (MRK)](/topic/$mrk) [ArriVent BioPharma, Inc. (AVBP)](/topic/$avbp) [Mineralys Therapeutics, Inc. (MLYS)](/topic/$mlys) [Edgewise Therapeutics, Inc. (EWTX)](/topic/$ewtx) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Taraxa (TARA)](/topic/$tara) [Upstream Bio, Inc. (UPB)](/topic/$upb) [Viridian Therapeutics, Inc. Common Stock (VRDN)](/topic/$vrdn) [Cogent Biosciences, Inc. Common Stock (COGT)](/topic/$cogt) [Roivant Sciences Ltd. Common Shares (ROIV)](/topic/$roiv) [Biofrontera Inc. (BFRI)](/topic/$bfri) [NovoCure Limited Ordinary Shares (NVCR)](/topic/$nvcr) [Evommune, Inc. (EVMN)](/topic/$evmn) [Tourmaline Bio, Inc. (TRML)](/topic/$trml) [uniQure N.V. (QURE)](/topic/$qure) [Incyte Corporation (INCY)](/topic/$incy) [Insmed, Inc. (INSM)](/topic/$insm) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [CalciMedica, Inc. (CALC)](/topic/$calc) [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) [Apogee Therapeutics, Inc. (APGE)](/topic/$apge) [Lantern Pharma Inc. (LTRN)](/topic/$ltrn) [Praxis Precision Medicines, Inc. (PRAX)](/topic/$prax) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [OS Therapies Incorporated (OSTX)](/topic/$ostx) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Arcellx, Inc. (ACLX)](/topic/$aclx) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [Eli Lilly and Company (LLY)](/topic/$lly) [Pharming Group N.V. (PHAR)](/topic/$phar) [Candel Therapeutics, Inc. (CADL)](/topic/$cadl) [AstraZeneca PLC (AZN)](/topic/$azn) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [ARS Pharmaceuticals, Inc. (SPRY)](/topic/$spry) [Rapport Therapeutics, Inc. (RAPP)](/topic/$rapp) [Adagene Inc. (ADAG)](/topic/$adag) [Xilio Therapeutics, Inc. (XLO)](/topic/$xlo) [Novartis AG (NVS)](/topic/novartis) [Nanobiotix S.A. (NBTX)](/topic/$nbtx) [MiNK Therapeutics, Inc. (INKT)](/topic/$inkt) [Centessa Pharmaceuticals plc (CNTA)](/topic/$cnta) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Xenon Pharmaceuticals Inc (XENE)](/topic/$xene) [Structure Therapeutics Inc. (GPCR)](/topic/$gpcr) [Enliven Therapeutics, Inc. (ELVN)](/topic/$elvn) ### Top Social Posts Top posts by engagements in the last [--] hours "🔔 Its the final day of #JPM2026 Catch the companies on your radar presenting today. Free access to the J.P. Morgan [----] conference calendar in the comments. 👇 $XBI smid-cap biopharmas presenting with commercial/marketed drugs: $VNDA $ADCT $LXRX ***** $NTLA at #JPM2026: New HAE safety disclosures Phase [--] enrollment expansion and clearer FDA dialogue. See @GeneInvesting post 👇 [----] JPM Conference- Intellia Therapeutics notes $NTLA Have dosed over [---] patients Excess of [--] years on some 1H [----] FDA approval estimate HAE 6b by end of decade HAE market 80% of HAE patients not attack free" [X Link](https://x.com/BiopharmIQ/status/2011746074965524940) 2026-01-15T10:23Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🚨 Likely to move the stock +/- by 20% $OCUL: AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Ph3 $NKTR: Rezpegaldesleukin (NKTR-358) Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2020121586909556791) 2026-02-07T13:04Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/10 @ Open $PHIO 53% Positive SMC wrap-up on PH-762 $EVMN 53% EVO301 Topline data $NKTR 44% REZOLVE-AD Maintenance Data $STRO 10% Pricing of $110M Offering $INMB 9% Advances CORDStrom for RDEB $AGEN 4% New data on BOT/BAL biomarkers $BCDA 2% Pre-Submission for FDA Approval $SPRY 2% Showcase Clinical Data on neffy $SEPN 2% Data from Ph1 Trial of SEP-631 $GNPX 2% Patent Intent for Reqorsa Gene Tx $LTRN 1% Present at Glioblastoma Drug Summit $CRDL 1% ARCHER Ph2 Trial Results Published $ENTA 1% Preclinical data for EDP-978 $PHVS 0% Present Clinical Data at AAAAI Mtg $COGT" [X Link](https://x.com/anyuser/status/2021255905829110044) 2026-02-10T16:12Z 28.9K followers, [----] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/anyuser/status/2021255912833392837) 2026-02-10T16:12Z 28.9K followers, [---] engagements "📌 Biotech Stock News 07/30 🧬 📽 $VRDN 11% Collaboration & License Agreement w/ Kissei Pharma $IMNN 8% First Patient Dosed in Ph3 Study $CELC 5% Pricing of Public Offering $MIRA 3% Topical Ketamir-2 Preclin Data $ACRS 2% Results from ATI-2138 Ph2a Trial $CRBP 2% CRB- [---] Ph1/2 Clinical Data at ESMO $TNYA 2% Safety Reviews for Gene Trials $LRMR 2% Pricing of Public Offering $ABBV 0% Ph3 Topline Results from Alopecia Trial $BIIB 0% New Data on Leqembi at AAIC $NAMS 0% Data from BROADWAY Trial at AAIC $SNSE 0% Clinical Data from Phase [--] Cohort at ESMO $MDGL 0% Exclusive Global License for GLP-1" [X Link](https://x.com/BiopharmIQ/status/1950670171124953346) 2025-07-30T21:29Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📈 📉 $RAPP RAP-219 $AMLX AMX0035 $IONS IONIS-APOCIII-LRx (Olezarsen) Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/1957135391330590962) 2025-08-17T17:40Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist 🎯 Ph2 & Ph3 readouts in Q3 [----]. $TRML Phase [--] $CGEM Phase [--] $PMVP Phase [--] $IMVT Phase [--] $ATYR Phase [--] $ARCT Phase [--] $IONS Phase [--] $MLTX Phase [--] $QURE Phase 2/3 $ENTA Phase [--] $KALA Phase 2b $LTRN Phase [--] $LRMR Phase [--] $ENTX Phase [--] $KAPA Phase [--] $RAPP Phase 2a $MTSR Phase 2b $PRAX Phase [--] $ATAI Phase 2b $GRI Phase 2a $HRMY Phase [--] $CLNN Phase [--] $FBIO Phase [--] $UPB Phase [--] $LGVN Phase 2a $SKYE Phase 2a Check out the image for more details https://twitter.com/i/web/status/1962194015820116329 https://twitter.com/i/web/status/1962194015820116329" [X Link](https://x.com/BiopharmIQ/status/1962194015820116329) 2025-08-31T16:41Z 28.9K followers, 49.3K engagements "🧬 Biotech Stock News 09/05 Brought to you by Barb [--] on the rise 📈 $ADAG 7% $HCM 6% $CGON 5% [--] under pressure 📉 $AMRX -1% $PALI -2% $DRUG -5% Catch the full breakdown in the latest video 🎥 🧬 Biotech Stock News 9/5 @ Open $ADAG 7% ADG126 Highlighted at CSCO Meeting $HCM 6% Clinical Data Presentation at CSCO $CGON 5% 24-month Durability and Tolerability Data $MLYS 3% Subgroup Analyses of Ph3 Trial $MLYS 3% Closing of $287.5M Offering $RGNX 2% 12-month Pivotal Data https://t.co/YAqey04vYz 🧬 Biotech Stock News 9/5 @ Open $ADAG 7% ADG126 Highlighted at CSCO Meeting $HCM 6% Clinical Data" [X Link](https://x.com/BiopharmIQ/status/1964072716689957130) 2025-09-05T21:06Z 28.9K followers, [----] engagements "🧬 Biotech Stock News 09/09 Brought to you by Barb [--] on the rise 📈 $TRML 58% $TELO 12% $XLO 11% [--] under pressure 📉 $TXG -4% $CTXR -4% $RAPP -11% Catch the full breakdown in the latest video 🎥 📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer Data on Prostate Cells $XLO 11% Initiation of Phase [--] Trial $MBRX 8% Accelerates Recruitment in Phase [--] Trial $AGEN 6% Reimbursed Compassionate Access for BOT/BAL $DNTH 5% Proposed https://t.co/DgMLkXfIC7 📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer" [X Link](https://x.com/BiopharmIQ/status/1965466714357072129) 2025-09-09T17:25Z 28.9K followers, [----] engagements "🧬 Biotech Weekly News 9/15/25 - 9/19/25 Major Movers 📈 $ETNB 85% Roche Acquires 89bio $NTLA 30% Enrollment in Ph3 Study Completed $NBTX 21% Ph1 Results for JNJ-1900 $HUMA 17% CTEV Preclinical Data Published $NKTR 15% New Data REZOLVE-AD Study 📉 $ATYR -83% Topline Data Ph3 Efzofitimod Study $REPL -39% Update Following Type A Meeting $RVPH -37% Pricing of $9M Public Offering $BCDA -24% Pricing of Up To $12M Offering $SPRB -21% Resumes Trading on Nasdaq ***** Roche buying 89bio $ETNB for $14.50/share + up to $6 CVR. Total deal value: $3.5B 💰 See our post below. Roche to acquire 89bio $ETNB" [X Link](https://x.com/BiopharmIQ/status/1969145858685124980) 2025-09-19T21:05Z 28.9K followers, 10.8K engagements "📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral Presentations at WMS $AVXL 3% Successful Development of Oral Tablet $AVXL 3% Positive Topline Results from Phase [--] Study $GLPG 1% Update on Strategic Alternatives for Cell Therapy $ETNB 1% Commences tender offer for shares $WGS 1% First U.S. National Genomic Newborn Screening $ATXS 1% Enrolling HAE Patients for Phase [--] Trial $HCM 1% Clinical Data at ESMO Congress [----] $CATX 1% First Patient Dosed in Phase Study $TEM 0% Improved EHR-Integrated Breast Cancer Risk Assessment $SNY 0%" [X Link](https://x.com/BiopharmIQ/status/1973781019376697442) 2025-10-02T16:04Z 28.9K followers, 14.6K engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $LQDA Phase [--] $ATAI Phase 2b $INBX Phase [--] $SVRA Phase [--] $IDYA Phase [--] $IDYA Phase 2/3 $KYTX Phase [--] $VOR Phase [--] $JAGX Phase [--] $ALXO Phase [--] $PROK Phase [--] $VRCA Phase [--] $KZR Phase 2a $IFRX Phase 2a $IFRX Phase 2b $ELDN Phase [--] $OSTX Phase 2b $NKTR Phase 2b $RZLT Phase [--] $PVLA Phase [--] $ARGX Phase [--] $INCY Phase [--] $WVE Phase [--] $EWTX Phase [--] $RNAC Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $ANRO Phase [--] $PRAX Phase 2/3 $BHVN Phase [--] $COGT Phase [--] $ALKS Phase [--] $MRUS Phase [--] $MRUS Phase [--] $MRUS Phase 2" [X Link](https://x.com/BiopharmIQ/status/1979988843597291585) 2025-10-19T19:11Z 28.9K followers, 50.1K engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (3/3). $CALT Phase [--] $JAZZ Phase [--] $GNFT Phase [--] $NAMS Phase [--] $PBYI Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $LSTA Phase 2b $INKT Phase [--] $STOK Phase [--] $ADAG Phase [--] $PBYI Phase [--] $CNTA Phase 2a $RLMD Phase [--] $NAMS Phase [--] $ACLX Phase [--] $ELDN Phase [--] $BIVI Phase 2b $KPTI Phase [--] $CRVS Phase [--] Check out the image for more details https://twitter.com/i/web/status/1985069251166904456 https://twitter.com/i/web/status/1985069251166904456" [X Link](https://x.com/BiopharmIQ/status/1985069251166904456) 2025-11-02T19:39Z 28.9K followers, [---] engagements "Avoro Capital 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 95.51% Qtr over Qtr Change**: 35.48% Top Holdings: $ASND $UTHR $MDGL $ARGX $KRYS $ARWR $KYMR $MRUS $RNA $APLS $CNTA $QURE $XENE $AKRO $VERA $SLNO $GPCR $TRML $OCUL $FOLD *Holdings as of 9/30/25 in SEC form 13F **Change in value of public company shares held See image for more details 👇 🚨 Hedge Fund Q3 holdings (13F) data drops tomorrow (11/14) We follow the top biopharma hedge funds. - capture their 13F data - & post it on our website Access our FREE biopharma hedge fund screener See comments below." [X Link](https://x.com/BiopharmIQ/status/1989368536977014819) 2025-11-14T16:23Z 28.9K followers, [----] engagements "RA Capital 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 82.27% Qtr over Qtr Change**: 36.72% Top Holdings: $ASND (25.0%) $RYTM (7.1%) $PCVX (5.3%) $RNA (4.6%) $CDTX (4.0%) $SION (3.8%) $ETNB (3.6%) $NAMS (3.6%) $MLYS (3.4%) $JANX (3.4%) $ACLX (3.1%) $LENZ (2.4%) $TYRA (2.1%) $EWTX (2.1%) $WVE (1.6%) $SEPN (1.6%) $DNTH (1.4%) $BCAX (1.4%) $GHRS (1.4%) $SPRY (1.3%) *Holdings as of 9/30/25 in SEC form 13F **Change in value of public company shares held See image for more details 👇 EcoR1 Capital 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 96.89% Qtr over" [X Link](https://x.com/BiopharmIQ/status/1989462851313160562) 2025-11-14T22:38Z 28.9K followers, [----] engagements "Baker Brothers Advisors 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 89.01% Qtr over Qtr Change**: 34.25% Top Holdings: $ONC (22%) $INCY (19%) $MDGL (7.1%) $INSM (7%) $ACAD (6.6%) $SMMT (5%) $RYTM (4.1%) $RVMD (3.2%) $CELC (2.8%) $KYMR (2.7%) $KOD (2%) $ALKS (1.8%) $ABCL (1%) $EWTX (0.9%) $KNSA (0.8%) $STOK (0.8%) $IMTX (0.7%) $GRAL (0.7%) $IDYA (0.6%) $IMVT (0.6%) *Holdings as of 9/30/25 in SEC form 13F **Change in value of public company shares held OrbiMed Advisors 🔔 🐳 Q3 25* Holdings Released Holdings: [---] Holdings in Top 20: 59.98% Qtr over Qtr Change**: 6.28% Top" [X Link](https://x.com/BiopharmIQ/status/1989473329401692336) 2025-11-14T23:19Z 28.9K followers, 20.4K engagements "🧬 Biotech Weekly News Largest single-day stock moves during the week ending 11/21/25 📈 $RPTX 32% XenoTherapeutics to acquire $RPTX $ANVS 29% New Biomarker Data on Cognitive Decline $ZYME 29% Positive Ph3 Results for HER2 Agent $VNDA 22% Tradipitant Results Reported $CTXR 15% Advance Commercial Launch with AI 📉 $AGIO -51% Topline Results RISE UP Trial $KTTA -30% Ph1 Data for PAS-004 $HCWB -21% HCW9302 FIH trial Initiation $PHGE -16% 1-for-19 Reverse Stock Split $ENSC -12% FDA Feedback on PF614 See image below. ***** $AGIO sat under $23 this week. See @seedy19trons post for why its being" [X Link](https://x.com/BiopharmIQ/status/1992004908074291305) 2025-11-21T22:59Z 28.9K followers, [----] engagements "🧬 Biotech Stock News 12/01 @ Open $QTTB 146% Sells Complement Inhibitor ADX-097 $MAIA 16% Open Market Purchases by CEO & Directors $BLTE 5% Positive Results from Phase [--] Trial $PMN 4% New Publication on Plasma pTau in Alzheimer's $RDHL 3% Regains Compliance with Nasdaq $OMER 2% Closing of Asset Purchase Agreement $AAPG 0% Webcast Highlighting Key Data from ASH [----] $BMY 0% Data Showcase Hematology Pipeline Potential $VTRS 0% Seeking Partnerships for Long-Acting Depot Drugs $MIRM 0% First Patient Enrolled in BLOOM Study $MNKD -1% FDA Review of FUROSCIX Autoinjector $BCDA -1% Present at Heart" [X Link](https://x.com/BiopharmIQ/status/1995521196180615335) 2025-12-01T15:51Z 28.9K followers, [----] engagements "📌 Biotech Stock News 12/3 @ Open $CAPR 246% Deramiocel Topline Results Reported $PHVS 17% Deucrictibant Topline Data Reported $TARA 8% TARA-002 Interim Data Reported $KURA 7% Virtual Investor Event on AML Data $CRNX 6% First Patient Dosed in Trial $CGTX 6% Zervimesine Full Enrollment Reached $RLMD 5% Presentation of NDV-01 Ph2 Data $BMY 5% Continuation of ADEPT-2 Ph3 Study $PYPD 5% D-PLEX FDA Pre-NDA Meeting Minutes $IXHL 4% FDA Fast Track for IHL-42X $XENE 3% Webinar on Azetukalner & Epilepsy Data $GLSI 3% Global Update on FLAMINGO-01 $BCRX 2% Early Termination of HSR Waiting Period $STRO" [X Link](https://x.com/BiopharmIQ/status/1996251665104851046) 2025-12-03T16:14Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $STOK Phase [--] $HRMY Phase [--] $RXRX Phase [--] $XCUR Phase [--] $IMMP Phase 2/3 $PVLA Phase [--] $LTRN Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $INSM Phase [--] $KMDA Phase [--] $MREO Phase [--] $RHHBY Phase [--] $TRAW Phase [--] $RARE Phase [--] $GPCR Phase 2b $ZBIO Phase [--] $SLS Phase [--] $MGTX Phase [--] $IDYA Phase 2/3 $DWTX Phase 2b $WVE Phase [--] $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $DBVT Phase [--] $VTGN Phase [--] $INBX Phase 2/3 $LSTA Phase 2a $ADVM Phase [--] $ALT Phase 2b $ACIU Phase [--] $RYTM Phase [--] $ATOS Phase 2" [X Link](https://x.com/BiopharmIQ/status/1997779928784519535) 2025-12-07T21:27Z 28.9K followers, 60.1K engagements "📣 Biotech Stock News 12/08 @ Open $WVE 124% Positive Interim Data from INLIGHT Trial $GPCR 86% Positive Topline Data from ACCESS Program $IMMP 58% Strategic Collaboration for Oncology Drug $KYMR 47% Positive Results from Phase 1b Trial $OCUL 25% Accelerate NDA Submission Timeline for AXPAXLI $DYN 16% Positive Topline Results from DELIVER Trial $ARWR 13% Phase 1/2a Study of ARO-MAPT $CHRS 10% JUPITER-02 Follow-up Results Show Survival Increase $PRME 10% Publication of PM359 Clinical Data $PRAX 7% Best-in-Class Potential in Epilepsies $GLSI 6% Completion of Enrollment in FLAMINGO-01 $ABEO 5%" [X Link](https://x.com/BiopharmIQ/status/1998076607886463368) 2025-12-08T17:06Z 28.9K followers, 14.5K engagements "📌 Biotech Stock News 12/10 @ Open $TERN 10% $650M Offering $DYN 9% $350M Public Offering $BRNS 3% VTP-1000 Trial Update $MDWD 3% Clinical Data on NexoBrid's Effectiveness $GPCR 3% Pricing of $650M Offering $SGMT 2% Denifanstat NDA Accepted by China NMPA $PTCT 1% Health Canada Approves Sephience $ALC 1% Response to Increased Acquisition Price $LXRX 1% ACSL5 Preclinical Data Publucation $PFE 1% TUKYSA Extends Survival 8mths $LLY 1% Build $6B facility in Alabama $KYMR 0% $602M Offering $AMRX 0% Epinephrine Injection FDA Approval $NCNA -1% NUC-7738 Latest Data $PRAX -1% Elsunersen Accelerated" [X Link](https://x.com/BiopharmIQ/status/1998792850193232042) 2025-12-10T16:32Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $LTRN Phase [--] $NKTR Phase 2b $PVLA Phase [--] $ARGX Phase [--] $INCY Phase [--] $ROIV Phase [--] $GLPG Phase [--] $BHVN Phase [--] $GNLX Phase [--] $VALN Phase [--] $IMCR Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV Phase 2a $DWTX Phase 2b $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $DBVT Phase [--] $VTGN Phase [--] $INBX Phase 2/3 $LSTA Phase 2a $ADVM Phase [--] $ALT Phase 2b $ATOS Phase [--] $INSM Phase [--] $MREO Phase [--] $RHHBY Phase [--] $TRAW Phase 2" [X Link](https://x.com/BiopharmIQ/status/2000297800941309958) 2025-12-14T20:12Z 28.9K followers, 58.1K engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (2/2). $IONS Phase [--] $REGN Phase 2/3 $CALT Phase [--] $GNFT Phase [--] $NAMS Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $INKT Phase [--] $ADAG Phase [--] $CNTA Phase 2a $NAMS Phase [--] $BIVI Phase 2b $CRVS Phase [--] Check out the image for more details https://twitter.com/i/web/status/2000297805605482863 https://twitter.com/i/web/status/2000297805605482863" [X Link](https://x.com/BiopharmIQ/status/2000297805605482863) 2025-12-14T20:12Z 28.9K followers, [---] engagements "December Biotech PDUFA Update 📡 Whats on the FDA radar Approved (7) $AXGN - Avance Nerve Graft $BMY - Breyanzi (lisocabtagene maraleucel) $GSK - BLUJEPA (gepotidacin) $BCRX - ORLADEYO Oral Granules $MIST - CARDAMYST (etripamil) nasal spray $INVA - NUZOLVENCE (zoliflodacin) $GSK - Exdensur (depemokimab) severe eosinophilic asthma only) Extended (3) $AGIO - PYRUKYND (mitapivat) - timeline TBD $ALDX - Reproxalap - extended to Mar [--] [----] $SNY - Tolebrutinib - extended to Q1 [----] Pending FDA Decisions (8) $OMER - Narsoplimab (OMS721) $CYTK - Aficamten $CORT - Relacorilant $VNDA - Tradipitant" [X Link](https://x.com/BiopharmIQ/status/2001383629235396732) 2025-12-17T20:06Z 28.9K followers, [----] engagements "📣 Biotech Stock News 12/23 @ Open $IMRX 9% 12-Month Survival Data for Atebimetinib $ATAI 7% Added to Nasdaq Biotechnology Index $IVVD 4% Fast Track Designation for VYD2311 $IVVD 4% Initiation of DECLARATION Clinical Trial $LIXT 2% Expand Clear Cell Ovarian Cancer Trial $PBYI 2% Added to NASDAQ Biotechnology Index $COYA 1% COYA [---] ALSTARS Trial Acceptance $REGN 1% Dupixent approved for children in Japan $REGN 1% Dupixent Approved for Children with Asthma $AMRX 0% FDA Approval of Denosumab Biosimilars $RLFTF 0% Global Approach to Reimbursement $NBIX 0% Update on Valbenazine Phase [--] Study" [X Link](https://x.com/BiopharmIQ/status/2003495542454911205) 2025-12-23T15:58Z 28.9K followers, [----] engagements "📌 Biotech Stock News 12/24 @ Open $OMER 65% FDA Approves YARTEMLEA for TA-TMA $DVAX 39% Sanofi to Acquire Dynavax $EWTX 23% Completion of EDG-7500 Ph2 Study $RPTX 19% Acquisition of RP-3467 for $30M $AGIO 16% FDA Approves AQVESME for Anemia $DRMA 13% Up to $12.4M Private Placement $JANX 1% Program Update on Ph1 JANX008 M&A watch 👀 Great breakdown by @PersimmonTI on $SNY's acquisition of $DVAX: Adds a marketed Hep B vaccine + a promising shingles candidate Strengthens $SNY's vaccines pipeline & commercial footprint 💉📈 See the image and comments for more details 👇 $XBI $SNY to acquire" [X Link](https://x.com/BiopharmIQ/status/2003862537226670381) 2025-12-24T16:17Z 28.9K followers, [----] engagements "🧬 Biotech Weekly News Largest single-day stock moves during the week ending 12/26/25 📈 $OMER 76% FDA Approves YARTEMLEA for TA-TMA $DVAX 38% Sanofi to Acquire Dynavax $EWTX 25% Completion of EDG-7500 Ph2 Study $AGIO 19% FDA Approves AQVESME for Anemia $RPTX 18% Acquisition of RP-3467 for $30M 📉 $RVPH -46% Regulatory Update on Brilaroxazine $DWTX -25% Reported Ph2b Trial Results $ASRT -10% 1-for-15 Reverse Stock Split $PHIO -6% Step Forward in PH-762 Development $AGEN -6% Durable Responses in Ovarian Cancer See image below. $OMER announces FDA approval of YARTEMLEA (narsoplimab-wuug) 🧬 ✅" [X Link](https://x.com/BiopharmIQ/status/2004694659533340688) 2025-12-26T23:23Z 28.9K followers, [----] engagements "🧬 Biopharma Weekly Recap 📝 This week in biotech: Bullish sentiment builds as FDA approvals hit [--] M&A chatter and options flow heat up obesity cash-pay shifts accelerate and a dense [----] catalyst calendar refocuses attention on data. @seedy19tron Saved the best for last - $SLNO: Bulletproof bull case (as promised) @LifeSciVC Biotech sentiment improves as cycle turns upward. @DrSamuelBHume [--] new medicines approved in [----] spanning first-in-disease and next-generation therapies. @NatRevDrugDisc FDA approves [--] new drugs in [----] despite regulatory turbulence. @BiopharmIQ Ph2 & Ph3 readouts in" [X Link](https://x.com/BiopharmIQ/status/2007479910445789668) 2026-01-03T15:51Z 28.9K followers, 21.4K engagements "How many of the [--] biopharma hedge funds have positions in any of the tickers mentioned above 🤔 Based on latest Q3 [--] data 📊 $ABVX 18/36 🔥 $PEPG 14/36 🔥 $QURE 12/36 🔥 $SLNO 9/36 🔥 Access our FREE screener to check your fave stocks 👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/BiopharmIQ/status/2007479913511805345) 2026-01-03T15:51Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist 📈 Ph2 & Ph3 readouts in Q1 [----] $ACTU Phase [--] $TRAW Phase [--] $DRUG Phase [--] $KOD Phase 2b $GOSS Phase [--] $AVBP Phase [--] $AGIO Phase 2b $IOVA Phase [--] $CRNX Phase [--] $CALC Phase [--] $BIVI Phase 2b $CRVS Phase [--] $KPTI Phase [--] $ALMS Phase [--] $IMMP Phase [--] $TBPH Phase [--] $VRDN Phase [--] $OCUL Phase [--] $QNCX Phase [--] $NMRA Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $PVLA Phase [--] $LSTA Phase 2b $NKTR Phase 2b $INSM Phase 2b $CADL Phase 2a $CMPX Phase 2/3 $IDYA Phase 2/3 $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $ANRO Phase [--] $PEPG Phase [--] $CLDX Phase [--] $NVCR Phase [--] $ZBIO" [X Link](https://x.com/BiopharmIQ/status/2007876813897498774) 2026-01-04T18:08Z 28.9K followers, 71.8K engagements "📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical Update on KB407 $MPLT 3% Topline Results Timing Update $CATX 2% 212PbVMT--NET Updated Interim Data $INKT 2% Ph1 Trial of AgenT-797 $ATHA 1% Name Change to LeonaBio Inc. $CLNN 1% Registered Direct Offering Over $28M $CRIS 0% Closing of Private Placement $LLY 0% Taltz & Zepbound show superior efficacy $ASND 0% COACH Trial Results in Achondroplasia $EBS 0% Delivery" [X Link](https://x.com/BiopharmIQ/status/2009664211421663542) 2026-01-09T16:31Z 28.9K followers, [----] engagements "1/ 📣 Biotech Stock News 01/12 @ Midday $BEAM 26% Strategic Priorities for Genetic Disease $DAWN 19% Preliminary [----] OJEMDA Revenue Guidance $BIOA 13% Positive Phase [--] Data for BGE-102 $MREO 11% Corporate Update $OCGN 9% Publication of Phase [--] GARDian1 Results $BMEA 6% Executing Icovamenib and BMF-650 Milestones $LPCN 5% Progress in LPCN [----] Phase [--] Trial $RGNX 5% Positive outcomes in Duchenne therapy $AMPH 5% Exclusive License for Synthetic Corticotropin $AGEN 5% Expands AAC Access for Botensilimab $CABA 5% [----] Strategic Priorities $CABA 5% IND Amendment Clearance for Rese-Cel $ORKA 4%" [X Link](https://x.com/BiopharmIQ/status/2010762291869073734) 2026-01-12T17:14Z 28.9K followers, [----] engagements "2/ 📣 Biotech Stock News 01/12 @ Midday $DTIL 0% Strategic Priorities for [----] $BMY 0% Positive results from SCOUT-HCM trial $ABBV 0% Exclusive Licensing for Bispecific Antibody $KNSA 0% Corporate Update $ABBV 0% Acquire Arizona Manufacturing Facility $SRRK -1% Highlights [----] Strategic Priorities $NTRA -1% Scale AI in Precision Medicine $BNTC -1% Positive results for BB-301 trial $CASI -1% Update on CID-103 Phase [--] Study $RLMD -1% Regulatory update on NDV-01 $IRON -1% Recent Achievements and Objectives for [----] $ORIC -1% Operational Highlights and Milestones $VKTX -1% Results from Phase 2" [X Link](https://x.com/BiopharmIQ/status/2010762296705040554) 2026-01-12T17:14Z 28.9K followers, [---] engagements "3/ 📣 Biotech Stock News 01/12 @ Midday $PRAX -5% Next Chapter Following Pivotal Year $LTRN -5% A.I. Center for RADR Platform $SLDB -5% First participant dosed in FALCON Trial $RIGL -5% Business Update and [----] Outlook $BCAX -6% Phase [--] Optimal Dose Announcement $NUVL -6% OnTarget [----] Plan Progress $ARQT -6% [----] Strategic Priorities and Milestones $TARA -6% Recent Updates and [----] Milestones $ANTX -8% FDA Clearance for Epetraborole Trial $AKBA -9% Corporate Updates and [----] Pipeline Outlook $ERAS -11% Early Clinical Data for ERAS-0015 $KPTI -12% Preliminary [----] Revenue and Phase [--] Data" [X Link](https://x.com/BiopharmIQ/status/2010762301708910683) 2026-01-12T17:14Z 28.9K followers, [---] engagements "#JPM2026 Day [--] 👉 Free access to the JPM [----] conference calendar in the comments 🗓 $XBI SMID-cap biopharmas with commercial/marketed drugs presenting today: $ACAD $ALKS $HRMY $TGTX $JAZZ $ZLAB $AMRX $CHRS *** $BBIO #JPM26 #ATTRUBY key nuggets. Momentum building See @semodough for details from yesterdays presentation. 👇 $BBIO #JPM26 #ATTRUBY KEY NUGGETS solid performance appears to be driven by an acceleration in momentum of new patient adds (1370 new Rxs between last Oct 29th data-cut and Dec 31st = [---] new patients added per week (vs previous updates in the [---] new Rx per week range))." [X Link](https://x.com/BiopharmIQ/status/2011072035766878632) 2026-01-13T13:45Z 28.9K followers, [----] engagements "$UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] Why verekitug is different Only clinical-stage TSLPR antagonist; fully human IgG1 enabling durable pathway blockade. Prior signal (VIBRANT Ph2 + Ph1 MAD) Ph2 met primary (NPS [---] p0.0001); key [--] incl. NCS [---] + 76% surgery/steroids Well tolerated; no SAEs Sustained TSLPR occupancy w/ FeNO & eos suppression up to 24w post-dose 4/7 https://twitter.com/i/web/status/2011123518633885713 https://twitter.com/i/web/status/2011123518633885713" [X Link](https://x.com/BiopharmIQ/status/2011123518633885713) 2026-01-13T17:09Z 28.9K followers, [---] engagements "$IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / Non-small cell lung carcinoma (1L NSCLC) / Phase [--] Why efti is different Activates APCs via MHC Class II and is positioned as complementary to ICIs like KEYTRUDA. Prior signal (Ph2 TACTI-002/KEYNOTE-798) ORR: 31.3% / 44.7% / 55.0% by PD-L1 TPS (1% / 1-49% / 50%) mPFS: [---] / [---] / [----] mo; mOS: [----] / [----] / NR 5/7 https://twitter.com/i/web/status/2011123522463285359 https://twitter.com/i/web/status/2011123522463285359" [X Link](https://x.com/BiopharmIQ/status/2011123522463285359) 2026-01-13T17:09Z 28.9K followers, [---] engagements "$KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR (NPDR) / Phase [--] Why tarcocimab is different Anti-VEGF ABC biologic engineered for high immediacy + long durability in the same therapy (unconjugated pulse + conjugated maintenance). Prior signal (Ph3 GLOW1 in DR) 2-step DRSS improvement @ W48: 41% vs [--] 90% risk reduction in pre-specified sight-threatening complications Potential for [--] doses/year after initiating doses 6/7 https://twitter.com/i/web/status/2011123526175232499 https://twitter.com/i/web/status/2011123526175232499" [X Link](https://x.com/BiopharmIQ/status/2011123526175232499) 2026-01-13T17:09Z 28.9K followers, [---] engagements "$APGE (Q1 2026) Zumilokibart (APG777) / Atopic dermatitis / Phase [--] Why APG777 is different Anti-IL-13 built for long-interval maintenance dosing (Q12W-Q24W) targeting just 2-4 injections/yr vs 26/yr for DUPIXENT. Prior signal (APEX Part A W16) EASI-75: 66.9% vs 24.6% PBO ( 42.5) IGA 0/1: 31.8% vs 6.0% ( 25.8) Rapid itch relief within 48h 7/7 https://twitter.com/i/web/status/2011123529765548373 https://twitter.com/i/web/status/2011123529765548373" [X Link](https://x.com/BiopharmIQ/status/2011123529765548373) 2026-01-13T17:09Z 28.9K followers, [----] engagements "January [----] Biotech PDUFA Update 📡 Whats on the FDA radar Recent Outcomes: $ATRA tab-cel (EBV+ PTLD) CRL $TVTX FILSPARI (FSGS) Extended 4/13/26 $FBIO ZYCUBO (copper histidinate) Approved Pending FDA Decisions: Jan [--] $AQST Anaphylm (Anaphylaxis) No AdCom Jan [--] $PHAR Joenja Pediatric APDS Priority Review See attached graphic for full January PDUFA calendar. January [----] Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Jan [--] $ATRA tab-cel (EBV+ PTLD) Priority Review Jan [--] $TVTX FILSPARI (FSGS) no AdCom Jan [--] $FBIO CUTX-101 (Menkes) Class [--] resubmission Jan [--] $AQST Anaphylm (anaphylaxis) no" [X Link](https://x.com/BiopharmIQ/status/2011828596554547669) 2026-01-15T15:51Z 28.9K followers, 23.1K engagements "#JPM2026 Takeaways 💼 This week in biotech: JPM sparks cautious optimism as funding rebounds AI and obesity pipelines advance late-stage readouts stack up and Big Pharma signals renewed M&A urgency. See interesting posts/ppl to check out 👇 @zerohedge JPMorgan No Longer Expects Fed Rate Cut Predicts Hike in [----] @Biotech2k1 Post JPM Biotech Report @seedy19tron JPM Day [--] takeaway: DAWN Q4 beat shifts launch narrative; pLGG monopoly asset screens undervalued. @mathlonning $TMDX JPM HEALTHCARE CONFERENCE NOTES @ky_lahucik JPM setup: biotech funding surges pre-conference as private and public" [X Link](https://x.com/BiopharmIQ/status/2012194227573391550) 2026-01-16T16:04Z 28.9K followers, [----] engagements "How many of the [--] biopharma hedge funds have positions in any of the tickers mentioned above that presented at #JPM26 🤔 Based on latest Q3 [--] data 📊 $INSM 8/36 🔥 $BBIO 6/36 🔥 $VKTX 6/36 🔥 $LQDA 4/36 $TMDX 0/36 🧊 Access our FREE screener 👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/BiopharmIQ/status/2012233795236245506) 2026-01-16T18:41Z 28.9K followers, [----] engagements "(March [--] 2026) KRESLADI (marne-cel; RP-L201) / Severe LAD-I / PDUFA Why KRESLADI is different One-time autologous LV gene-corrected HSC tx designed to restore CD18 & reconstitute immune function (potentially curative). Prior signal (pivotal LAD-I study) 9/9 survival w/ no graft failure; no drug-related SAEs 10% PMN CD18 expression at 1yr across cohort 100% HSCT-free survival + meaningful reduction in infection-related hospitalizations 3/7" [X Link](https://x.com/BiopharmIQ/status/2012295987579207713) 2026-01-16T22:48Z 28.9K followers, [---] engagements "$UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] Why verekitug is different Only clinical-stage TSLPR antagonist; fully human IgG1 enabling durable pathway blockade. Prior signal (VIBRANT Ph2 + Ph1 MAD) Ph2 met primary (NPS [---] p0.0001); key [--] incl. NCS [---] + 76% surgery/steroids Well tolerated; no SAEs Sustained TSLPR occupancy w/ FeNO & eos suppression up to 24w post-dose 4/7 https://twitter.com/i/web/status/2012295999583305747 https://twitter.com/i/web/status/2012295999583305747" [X Link](https://x.com/BiopharmIQ/status/2012295999583305747) 2026-01-16T22:48Z 28.9K followers, [---] engagements "$IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / Non-small cell lung carcinoma (1L NSCLC) / Phase [--] Why efti is different Activates APCs via MHC Class II and is positioned as complementary to ICIs like KEYTRUDA. Prior signal (Ph2 TACTI-002/KEYNOTE-798) ORR: 31.3% / 44.7% / 55.0% by PD-L1 TPS (1% / 1-49% / 50%) mPFS: [---] / [---] / [----] mo; mOS: [----] / [----] / NR 5/7 https://twitter.com/i/web/status/2012296011058921477 https://twitter.com/i/web/status/2012296011058921477" [X Link](https://x.com/BiopharmIQ/status/2012296011058921477) 2026-01-16T22:48Z 28.9K followers, [---] engagements "$KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR (NPDR) / Phase [--] Why tarcocimab is different Anti-VEGF ABC biologic engineered for high immediacy + long durability in the same therapy (unconjugated pulse + conjugated maintenance). Prior signal (Ph3 GLOW1 in DR) 2-step DRSS improvement @ W48: 41% vs [--] 90% risk reduction in pre-specified sight-threatening complications Potential for [--] doses/year after initiating doses 6/7 https://twitter.com/i/web/status/2012296023776051696 https://twitter.com/i/web/status/2012296023776051696" [X Link](https://x.com/BiopharmIQ/status/2012296023776051696) 2026-01-16T22:48Z 28.9K followers, [---] engagements "$APGE (Q1 2026) Zumilokibart (APG777) / Atopic dermatitis / Phase [--] Why APG777 is different Anti-IL-13 built for long-interval maintenance dosing (Q12W-Q24W) targeting just 2-4 injections/yr vs 26/yr for DUPIXENT. Prior signal (APEX Part A W16) EASI-75: 66.9% vs 24.6% PBO ( 42.5) IGA 0/1: 31.8% vs 6.0% ( 25.8) Rapid itch relief within 48h 7/7 https://twitter.com/i/web/status/2012296036036001880 https://twitter.com/i/web/status/2012296036036001880" [X Link](https://x.com/BiopharmIQ/status/2012296036036001880) 2026-01-16T22:48Z 28.9K followers, [----] engagements "🧬 Biotech Weekly News Largest single-day stock moves during the week ending 01/16/26 📈 $IBRX 34% Durable response w/ CD19 CAR-NK therapy $BIOA 27% Positive Phase [--] Data for BGE-102 $DAWN 27% Prelim. [----] OJEMDA Revenue Guidance $BEAM 22% Strategic Priorities for Genetic Disease $OCGN 19% Publication of Ph1 GARDian1 Results 📉 $ATRA -57% Regulatory & Business Update on EBVALLO $LYRA -45% Corporate Update $PSTV -38% Pricing of $15M Offering $LXEO -23% Phase 1/2 Data for LX2020 $AGEN -21% Advance BOT+BAL & Manufacturing Readiness See image below. $IBRX Announces Durable Complete Response of 15" [X Link](https://x.com/BiopharmIQ/status/2012497598775706063) 2026-01-17T12:09Z 28.9K followers, [----] engagements "🧬 Clinical & guidance headlines drove biotech this week: $IBRX $BIOA $OCGN positive clinical updates $DAWN $BEAM strategic/guidance catalysts $PSTV $LYRA offerings & corporate resets $ATRA $LXEO $AGEN regulatory/data pressure https://twitter.com/i/web/status/2012497605180420151 https://twitter.com/i/web/status/2012497605180420151" [X Link](https://x.com/BiopharmIQ/status/2012497605180420151) 2026-01-17T12:09Z 28.9K followers, [----] engagements "📣 Biotech Stock News 01/20 @ Open $CRVS 103% Positive data for Soquelitinib trial $IBRX 20% Regulatory Discussions on ANKTIVA $MAIA 16% Advances Ateganosine Cancer Treatment Program $BTAI 8% Supplemental Drug Application for IGALMI $NVAX 4% Entering License Agreement $BOLD 4% Advances Kinesin Degrader Program BBI-940 $THAR 3% Pricing of $55 Million Offering $COGT 3% NDA Submission for Bezuclastinib $BIOA 2% Indication Expansion for BGE-102 $LTRN 1% LP-284 Receives FDA Orphan Designation $RHHBY 1% Doubles Investment in Manufacturing Facility $QNRX 0% Breakthrough Medicine Designation for" [X Link](https://x.com/BiopharmIQ/status/2013655488685301851) 2026-01-20T16:50Z 28.9K followers, [----] engagements "📌 Biotech Stock News 1/21 @ Open $LSTA 86% To be Acquired by Kuva Labs $LXRX 12% Successful End-of-Ph2 for Pilavapadin $ARTV 6% Presentations on AlloNK cost-effectiveness $SCYX 5% FDA Designations for SCY-247 $ALGS 5% Ph2 B-SUPREME Study Updates $ENGN 4% Expanded $125M Debt Facility $CRVS 4% Proposed Public Offering and Warrants $ENTX 3% Upcoming Q1 [----] Priorities and Outlook $ACTU 3% Expand Clinical Pipeline for Elraglusib $ALC 3% Completes $750M Share Repurchase $GSK 1% Second Exit from Growth Fund III $IONS 1% Donidalorsen approved in EU for HA $XCUR 1% Data from Burixafor Ph2 Trial" [X Link](https://x.com/BiopharmIQ/status/2014000555941871714) 2026-01-21T15:42Z 28.9K followers, [----] engagements "🧬 Biotech M&A Is Back M&A roars back as $GSK buys $RAPT premiums surge across microcaps deal rumors swirl and sentiment-driven valuations reshape the $XBI landscape. See interesting posts/ppl to check out 👇 @LifeSciVC $RAPT acquired by GSK for $2.2B ($58/share) after late-stage pivot to anti-IgE allergy asset. @seedy19tron $RAPT surges on $GSK deal as biotech M&A re-emerges post-JPM; focus shifts to $XBI and new takeout speculation. @A_May_MD $ABVX M&A chatter debated as unusual call buying fuels questions around La Lettre reporting credibility. @RNAiAnalyst Macro tailwinds favor biotech" [X Link](https://x.com/BiopharmIQ/status/2014434393985843630) 2026-01-22T20:26Z 28.9K followers, [----] engagements "📢 M&A News: $BCRX Completes Acquisition of Astria Therapeutics $700M Implied transaction value Adds navenibart for HAE Expands portfolio to oral (ORLADEYO) + injectable prophylaxis options Acquires early-stage atopic dermatitis program STAR0310 (strategic alternatives planned) See images for more details 👇 📢 M&A News: $LSTA to be Acquired by Kuva Labs $4.00/sh all-cash tender offer + [--] CVRs ($1.00 each) up to 180% premium CVRs tied to certepetide milestones (China rights reversion + NDA filing) Lead asset certepetide: solid tumors Fast Track + Orphan designations https://t.co/ulcmwMXwhb 📢" [X Link](https://x.com/BiopharmIQ/status/2014742099414114778) 2026-01-23T16:48Z 28.9K followers, [----] engagements "🧬 Biopharma Weekly Recap 📝 This week in biotech: JPM buzz fuels M&A chatter AI drug discovery credibility rises GLP-1/oral obesity data accelerates stock-specific volatility and infrastructure gaps dominate sentiment. See interesting posts/ppl to check out 👇 @m_goes_distance Biotech VC overcrowded in therapeutics; infrastructure remains underfunded. @Mr_Derivatives $SMMT trades below insider buy level; M&A optionality cited. @Prof_Oak_ Scattered compilation of between-the-lines tidbits that stood out amongst the thousands of JPM slides ingested last week $XBI @yaireinhorn Prime Medicine's" [X Link](https://x.com/BiopharmIQ/status/2015101239714075085) 2026-01-24T16:35Z 28.9K followers, 12.8K engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $ASND: TransCon CNP PDUFA $NKTR: Rezpegaldesleukin (NKTR-358) Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2015101242784256347) 2026-01-24T16:35Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $PEPG PGN-EDODM1 $ANRO ALTO-101 $TBPH Ampreloxetine Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2015509550082978281) 2026-01-25T19:38Z 28.9K followers, [----] engagements "📣 Biotech Stock News 01/26 @ Open $SRPT 9% Positive EMBARK Results for ELEVIDYS $LGVN 4% FDA Grants Type C Meeting $NERV 3% Discussing Roluperidone for Schizophrenia $COGT 1% Breakthrough Therapy Designation for Bezuclastinib $MIST 1% U.S. Availability of CARDAMYST Nasal Spray $TRAW 1% Enrollment of Ratutrelvir Clinical Study $MNKD 1% FDA Approves Updated Afrezza Label $GRI 1% New U.S. Patent for Novel Compounds $ZVRA 1% Present Analyses on MIPLYFFA $NTRA 1% Landmark Study Advancing Lung Transplant $UTHR 1% Positive results from miroliverELAP study $BMRN 0% Proposed Private Offering of Notes" [X Link](https://x.com/BiopharmIQ/status/2015803708236562620) 2026-01-26T15:07Z 28.9K followers, [----] engagements "🧬 Biotech Conviction Board: [----] High-conviction longs to watch analyst top picks oral immunology momentum AI platforms and catalyst-loaded setups. $XBI $IBB See interesting posts/ppl to check out 👇 🔥 High Conviction @A_May_MD $TENX Underfollowed Biotech With [----] Catalyst Not an Official Pitch @princetongb #biopick2026 contest pick Kyverna Therapeutics $KYTX. @seedy19tron $Abvx (Long) Ph3 topline for Obe coming up. Exp early to mid Aug @WassimLaroussi3 Why $APGE is my number [--] pick in this race @Biotech2k1 My top pick is $PTGX as they are making oral forms of all these IL drugs." [X Link](https://x.com/BiopharmIQ/status/2016944961141559589) 2026-01-29T18:42Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🚨 Likely to move the stock +/- by 20% $AQST: Anaphylm (dibutepinephrine) sublingual film PDUFA $KOD: KSI-101 Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report below 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2016944964606054467) 2026-01-29T18:42Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/3 @ Open $PRLD 15% FDA Clearance for PRT12396 $IVVD 6% Ph3 Trial for VYD2311 $RLAY 5% Breakthrough Tx Desig for Zovegalisib $TOVX 4% Presentation of VCN-01 data $ATYR 3% Scheduling FDA Meeting for Efzofitimod $MGTX 2% Exclusive License for AAV Gene Therapy $RARE 2% Positive data for UX111 gene therapy $HOOK 1% Sale of Oncology Assets $VTRS 1% New data from Glatiramer Acetate $MIRA 1% Final Cohort of Ketamir-2 Study $AZN 1% Priority Review for datopotamab deruxtecan $ABBV 0% Regulatory Applications for Upadacitinib $ARDX 0% New Patent for Tenapanor $APLT 0% Cycle Pharma" [X Link](https://x.com/BiopharmIQ/status/2018720401690648953) 2026-02-03T16:17Z 28.9K followers, [----] engagements "💰 Cycle Group acquired $APLT Adds govorestat a CNS-penetrant ARI Expands into rare metabolic & CNS diseases Strengthens long-term orphan drug pipeline Check out our free biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun" [X Link](https://x.com/BiopharmIQ/status/2018720405721370687) 2026-02-03T16:17Z 28.9K followers, [----] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/BiopharmIQ/status/2018720408594522335) 2026-02-03T16:17Z 28.9K followers, [---] engagements "Check out our FREE biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun" [X Link](https://x.com/BiopharmIQ/status/2018728861576671495) 2026-02-03T16:50Z 28.9K followers, [----] engagements "🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175 Million Offering $ROIV 22% Mosliciguat & Brepocitinib Trial Updates $RNAZ 16% IND Amendment for Phase 2a Trial $PRLD 13% FDA Clearance for PRT12396 📉 $ANEB -39% Intention to Voluntarily Delist $SGMO -32% Pricing of $25 Million Offering $ADIL -26% Advancing Clinical Trial Endpoints $PHAR -17% Complete Response Letter for Joenja $SXTP -12% Expands Access to ARAKODA See image below. *** Decoding AQSTs clean CRL and the FDAs endgame for" [X Link](https://x.com/BiopharmIQ/status/2020089737126768875) 2026-02-07T10:58Z 28.9K followers, [----] engagements "🧬 Weekly & YTD Biotech Moves Week ending 02/06/26 $XBI: 0.61% ($125.51) 🟢 $IBB: 1.48% ($174.98) 🟢 Year-to-date $XBI: 2.94% 🟢 $IBB: 3.68% 🟢 See image below. 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175 Million Offering $ROIV 22% Mosliciguat & Brepocitinib Trial Updates $RNAZ 16% IND Amendment for Phase 2a Trial $PRLD 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175" [X Link](https://x.com/BiopharmIQ/status/2020091913404314022) 2026-02-07T11:06Z 28.9K followers, [----] engagements "Try BPIQ API Free Get catalyst & pipeline data integrate seamlessly craft custom spreadsheets 📊 🔑 Premium API access unlocks - Full platform access - Updated catalysts/pipeline data - Historical data for robust testing Check link below 👇 https://www.bpiq.com/bpiq-api https://www.bpiq.com/bpiq-api" [X Link](https://x.com/BiopharmIQ/status/2020091917166583835) 2026-02-07T11:06Z 28.9K followers, [----] engagements "$EVMN up 53% 📈 Ph2a of EVO301hit primary endpoint in AD Fast EASI improvements vs placebo (W4 W8 W12) Moving into Phase 2b dose-range trial Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2021255909956276478) 2026-02-10T16:12Z 28.9K followers, [----] engagements "6 Stocks Likely to Move Big in Q1 [--] See 🧵 for more details about each asset/readout: $RGNX (February [--] 2026) Clemidsogene lanparvovec (RGX-121) / Hunter syndrome (MPS II) / PDUFA $RCKT (March [--] 2026) KRESLADI (RP-L201) / Severe LAD-I / PDUFA $UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] $IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / 1L NSCLC) / Phase [--] $KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR / Phase [--] $APGE (Q1 2026) APG777 / Atopic dermatitis / Phase [--] 1/7 https://twitter.com/i/web/status/2012295963503902944 https://twitter.com/i/web/status/2012295963503902944" [X Link](https://x.com/BiopharmIQ/status/2012295963503902944) 2026-01-16T22:48Z 28.9K followers, 107.4K engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $KOD Phase 2b $MDNAF Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP Phase [--] $PVLA Phase [--] $ARQT" [X Link](https://x.com/BiopharmIQ/status/2018051066605220000) 2026-02-01T19:57Z 28.9K followers, 105.7K engagements "📌 Biotech Stock News 2/4 @ Open $ONCY 16% FDA Fast Track for Pelareorep $CPIX 7% FDA Fast Track for Ifetroban $BMY 2% Multi-Year Commercial Supply Agreement $ENTX 1% Advance Oral Long Acting PTH Tablet $INKT 1% New data on allo-iNKT Cell Therapy $SRPT 1% Approval of Clinical Trial for SRP-1005 $TEVA 1% Approval of AJOVY for Pediatric Migraine $ACLX 0% Late-Breaking Presentation on anito-cel $KOD -1% Final Ph1b Results for KSI-101 $CRBU -2% ASTCT and CIBMTR Presentations $SGMO -2% Data from STAAR Study in Fabry $IMUX -3% Ph2 CALLIPER Trial Data $ZVRA -3% Positive data on MIPLYFFA in NPC $ADIL" [X Link](https://x.com/BiopharmIQ/status/2019073627707306489) 2026-02-04T15:40Z 28.9K followers, [----] engagements "📣 Biotech Stock News 02/12 @ Open $NVCR 29% FDA Approves Optune Pax for Cancer $BBIO 9% Positive Phase [--] Results for Infigratinib $ANVS 6% DSMB Approval for Buntanetap Trial $TECX 5% Discussion of TX2100 for treatment $ANL 4% First Patient Enrolled in AN9025 Trial $NKTR 2% Pricing of $400 Million Offering $PCRX 1% New NOPAIN Act Survey Data $MRK 0% Advances in Bladder and Kidney Cancer $XLO 0% Pricing of Underwritten Offering $LYEL 0% Initiation of Patient Dosing $PCVX -1% Doses First Participants in OPUS-3 Trial $APRE -1% Strengthens Global Patent Portfolio $BTAI -2% Advances" [X Link](https://x.com/anyuser/status/2021972604748542219) 2026-02-12T15:40Z 28.9K followers, [----] engagements "6/ 👉 What this means: Our hedge-fund favorites framework has worked across start dates and market regimes This is not a one-off result. Its sustained outperformance across portfolios" [X Link](https://x.com/anyuser/status/2022031605838290984) 2026-02-12T19:34Z 28.9K followers, [---] engagements "📢 M&A News: Novartis ($NVS) to acquire Tourmaline Bio ($TRML) 💵 $48/sh in cash ($1.4B FD) closing expected Q4 [----] 🔬 Adds pacibekitug (anti-IL-6 mAb) Ph3-ready targeting ASCVD Ph2 data: 8586% hs-CRP reduction; safety comparable to placebo; convenient quarterly dosing 🫀 Strengthens Novartis cardiovascular pipeline tackling residual inflammatory risk See image for more info 👇 📢 M&A News: MannKind $MNKD Acquires scPharmaceuticals $SCPH $5.35/sh upfront + $1/sh CVR ($360M a 3136% premium); $SCPH up 14% at open Adds FUROSCIX FDA-approved CHF/CKD therapy with $10B U.S. market FUROSCIX" [X Link](https://x.com/BiopharmIQ/status/1965428751476637902) 2025-09-09T14:55Z 28.9K followers, 14.2K engagements "📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer Data on Prostate Cells $XLO 11% Initiation of Phase [--] Trial $MBRX 8% Accelerates Recruitment in Phase [--] Trial $AGEN 6% Reimbursed Compassionate Access for BOT/BAL $DNTH 5% Proposed $150 Million Public Offering $NKGN 5% Completion of Acquisition and Control $NKTR 4% REZOLVE-AD Phase 2b Results Presented $AVXL 4% Cognitive Resilience Results in Alzheimer's Trial $IONS 3% FDA Breakthrough Therapy designation for ION582 $EVFM 2% Anticipates Merger Approval at Meeting $ACRS 1% Late-Breaking Abstract" [X Link](https://x.com/BiopharmIQ/status/1965441608499036445) 2025-09-09T15:46Z 28.9K followers, 10K engagements "🧬 Biotech Weekly News 9/8/25 - 9/12/25 Major Movers 📈 $RAPP 119% Topline Data RAP-219 Ph2a Trial $TRML 58% Novartis Acquires Tourmaline Bio $MAZE 55% MZE782 Ph1 Trial Results $TVTX 26% FDA AdCom Meeting Update $ONCY 21% Highlights Data in CRC 📉 $SMMT -25% Longer-Term Data in NSCLC $ACTU -19% Pricing $15M Public Offering $IDYA -14% Multiple Trial Readouts $NUVB -11% New Data from NSCLC Studies $TIL -10% Presentation [----] Monotherapy Data ***** Impressive data drop from $RAPP 🔥 RAP-219 - strong seizure reduction in Focal Onset Epilepsy See @PersimmonTI post below. $XBI $RAPP $xbi RAP-219" [X Link](https://x.com/BiopharmIQ/status/1966634162250805517) 2025-09-12T22:44Z 28.9K followers, 11.3K engagements "📌 Biotech Stock News 10/10 @ Open $CDTX 4% Present @ 10th ESWI Influenza Conf. $AZN 0% Expand VA Manuf. Facility $OSTX 0% OST-HER2 Ph2b OS Data $JNJ 0% MDD Portfolio @ [----] ECNP Congress $CRSP 0% New Preclinical CTX460 Data $BIIB -1% New Zorevunersen Data @ 54th CNS Mtg. $BMY -2% To Acquire Orbital Therapeutics $ASMB -3% ABI-5366 Interim Ph1b Data @ IUSTI-EU $VIR -3% First Participant Dosed for VIR-5500 Trial $QNCX -4% Present Data @ 54th CNS Mtg. $CABA -9% Rese-cel Data @ ESGCT'25 $ANVS -21% $6M Direct Offering See the image and comments for more details" [X Link](https://x.com/BiopharmIQ/status/1976677600857887020) 2025-10-10T15:53Z 28.9K followers, [----] engagements "🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted 180-Day Extension by Nasdaq $OSTX 6% Overall & Event Free Survival Data $NRIX 5% Initiates Pivotal Study of Bexobrutideg $SMMT 2% Raises $500 Million in Placement $SNY 2% High-dose flu vaccine shows superior protection $ANL 2% Short Talk on AN4035 Preclinical Results $BIIB 1% Additional Results from Phase [--] Study $COLL 1% Poster Presentations at Conferences $ALKS 0% Agreement to Acquire Pharmaceuticals $IPSEY 0% Acquisition to strengthen oncology pipeline $EGRX 0% Results of [----] Annual" [X Link](https://x.com/BiopharmIQ/status/1981024004166258983) 2025-10-22T15:45Z 28.9K followers, 10K engagements "🧬 Biotech Stock News 10/22 Brought to you by Barb On the rise 📈 $GRTX 61% $IXHL 7% $OSTX 6% Under pressure 📉 $RAPT -12% $ALEC -51% $ARCT -58% Catch the full breakdown in the latest video 🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted 180-Day Extension by Nasdaq $OSTX 6% Overall & Event Free Survival Data $NRIX 5% Initiates Pivotal Study of Bexobrutideg $SMMT 2% Raises $500 Million in Placement $SNY 2% https://t.co/sFPloOyKuL 🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted" [X Link](https://x.com/BiopharmIQ/status/1981050784675672380) 2025-10-22T17:31Z 28.9K followers, [----] engagements "📌 Biotech Stock News 10/31 @ Open $NBTX 11% $71M Royalty Agreement $DNA 9% Ginkgo Bio & Bayer Multi-Year Partnership $OLMA 7% Palazestrant+Ribociclib Poster @ SABCS'25 $FDMT 4% 4D-150 Exclusive License Agreement $NTRA 3% Expansion to [--] Genes for NIPT $CLDX 2% CDX-622 Ph1 Trial Results $TRAW 2% Extended Ratutrelvir CMC Services Collab $SMMT 2% HARMONi-A OS Data @ SITC'25 $AMGN 1% Repatha Data @ AHA'25 $ATXS 1% Presenting @ ACAAI'25 $HOOK 1% Completion of Sale of Assets to Gilead $AZN 0% DESTINY-Lung06 Ph3 Trial Initiated $ADAG -1% First Patient Dosed in Ph2 Study $VERU -3% Presenting Two" [X Link](https://x.com/BiopharmIQ/status/1984290190857531670) 2025-10-31T16:03Z 28.9K followers, [----] engagements "📌 Biotech Stock News 11/12 @ Open $LPTX 121% Rebrands as Cypherpunk $CNTA 13% $250M Public Offering $NXTC 11% $21.5M Private Placement $MOLN 7% MP0712 New Data $PEPG 7% PGN-EDODM1 U.S. Patent $IMTX 6% IMA402 & IMA401 Achieves PoC $DBVT 6% VITESSE Ph3 Trial LPLV $RVPH 3% Brilaroxazine Data @ Neuroscience'25 $MBRX 3% Annamycin Grant @ UNC-Chapel Hill $ABBV 2% New Data @ ASDS $LGVN 1% U.S. Patent for Proprietary Stem Cell Tx $TELO 1% Telomir-1 Outperforms Gold-Standard Chelator $APLS 1% 5-Year GALE Data on SYFOVRE $IONS 1% $700M Convertible Offering $COGT -2% $200M Public Offerings $ANIX -3%" [X Link](https://x.com/BiopharmIQ/status/1988645997292167301) 2025-11-12T16:32Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $LGVN Phase 2a $INMB Phase [--] $AVXL Phase 2/3 $STOK Phase [--] $ACLX Phase [--] $IRON Phase [--] $GLPG Phase [--] $NRIX Phase [--] $XCUR Phase [--] $PVLA Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $ARGX Phase [--] $INCY Phase [--] $EWTX Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $BHVN Phase [--] $ZNTL Phase [--] $IOVA Phase [--] $GNLX Phase [--] $RXRX Phase [--] $PRTA Phase [--] $VALN Phase [--] $CGON Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $IMVT Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV" [X Link](https://x.com/BiopharmIQ/status/1995242784832565668) 2025-11-30T21:25Z 28.9K followers, 75.6K engagements "📣 Biotech Stock News 12/18 @ Open $KMDA 5% Extension of Canadian Supply Tender $IMRX 5% Dosing First Patient in Atebimetinib Trial $COCP 5% IRB Approval for CDI-988 Study $CRMD 4% Positive Data DefenCath Study $CYBN 3% Transfer U.S. Stock Exchange Listing $ABVX 3% [--] Abstracts on Obefazimod at ECCO $SGMO 3% Rolling Submission of BLA for ST-920 $TELO 2% Favorable IND-Enabling Safety Results $LLY 2% Orforglipron maintains weight loss $MRNA 2% Fund Phase [--] Trial for mRNA Vaccine $AVXL 1% Request for EMA Re-Examination $BFRI 1% Transfer of Ameluz and RhodoLED $MNOV 1% Completion of Enrollment" [X Link](https://x.com/BiopharmIQ/status/2001683876272623853) 2025-12-18T16:00Z 28.9K followers, [----] engagements "📌 Biotech Stock News 12/22 @ Open $CYTK 12% MYQORZO FDA Approval $ENTX 7% EB612 program New Data $IMMP 5% IMP761 Update $GLSI 5% FLAMINGO-01 Updates $KALV 4% EKTERLY Approval in Japan $AVBP 3% ALPACCA Trial First Patient Dosed $SVRA 3% MOLBREEVI BLA Resubmission $CRSP 3% Zugocaptagene Geleucel (zugo-cel) Update $VRDN 2% Veligrotug BLA Acceptance $PTCT 2% Sephience Approval in Japan $AVIR 1% Completes Patient Enrollment in Ph3 Trial $ALVO 1% Simponi Launch in Europe $ASMB 1% Helicase-Primase Inhibitor Licensing $AZN 0% ENHERTU FDA BTxD; Ph3 Trial Initiated $GSK 0% Samsung Expands U.S. Manuf." [X Link](https://x.com/BiopharmIQ/status/2003134261315142036) 2025-12-22T16:03Z 28.9K followers, [----] engagements "📣 Biotech Stock News 12/29 @ Open $PRAX 14% FDA Grants Breakthrough for Ulixacaltamide $PHGE 9% Private Placement of $3M $TOVX 5% Positive EMA Advice on VCN-01 Trial $TNXP 3% Program Updates on TNX-4800; Pricing of $20M Offering $TLSA 2% Files Annual Safety Report for Foralumab $SPRY 1% neffy Approved for Allergic Reactions $UNCY 1% Resubmission of NDA for OLC $JNJ 1% Acquisition to revolutionize cancer treatment $ZVRA 0% Distribution Agreement for MIPLYFFA $SXTP -1% Detection of Babesia in Patients $SLS -1% Update on Phase [--] REGAL Trial $GMAB -1% Portfolio Prioritization Update $HCM -3% NDA" [X Link](https://x.com/BiopharmIQ/status/2005669028166295776) 2025-12-29T15:55Z 28.9K followers, [----] engagements "🟢 Praxis Precision Medicines $PRAX +14% - FDA grants Breakthrough Therapy Designation to ulixacaltamide HCl in essential tremor - supported by positive Essential3 Ph3 topline data 🔴 Ultragenyx Pharmaceutical $RARE -90% - Ph3 Orbit and Cosmic studies of setrusumab (UX143) missed the primary fracture endpoint despite statistically significant improvements in BMD https://twitter.com/i/web/status/2005669032230584715 https://twitter.com/i/web/status/2005669032230584715" [X Link](https://x.com/BiopharmIQ/status/2005669032230584715) 2025-12-29T15:55Z 28.9K followers, [---] engagements "📢 M&A News: $LLY to Acquire $VTYX Lilly to acquire Ventyx Biosciences for $14.00/sh ($1.2B). Adds oral small-molecule programs targeting inflammatory diseases. Strengthens $LLY's immunology & inflammation pipeline. Transaction expected to close in 1H [----] subject to approvals. See images for more details 👇 📢 M&A News: $MRK to Acquire $CDTX Merck to complete acquisition of Cidara Therapeutics Brings in CD388 a Ph3 long-acting antiviral for influenza prevention. Strengthens $MRK infectious disease portfolio. Transaction expands $MRK's reach in seasonal & pandemic https://t.co/I6pTPt7ivU 📢" [X Link](https://x.com/BiopharmIQ/status/2009041641357889795) 2026-01-07T23:17Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $KOD Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP" [X Link](https://x.com/BiopharmIQ/status/2010439367370977604) 2026-01-11T19:51Z 28.9K followers, 126.8K engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $KOD Tarcocimab (KSI-301) $UPB Verekitug $ANRO ALTO-101 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2010439370504106164) 2026-01-11T19:51Z 28.9K followers, [----] engagements "Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $KOD 6/34 🔥 $UPB 6/34 🔥 $ANRO 3/34 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/BiopharmIQ/status/2010439372622201224) 2026-01-11T19:51Z 28.9K followers, [----] engagements "6 Stocks Likely to Move Big in Q1 [--] 📈 📉 See 🧵 for more details about each asset/readout 👇 $RGNX (February [--] 2026) Clemidsogene lanparvovec (RGX-121) / Hunter syndrome (MPS II) / PDUFA $RCKT (March [--] 2026) KRESLADI (RP-L201) / Severe LAD-I / PDUFA $UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] $IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / 1L NSCLC) / Phase [--] $KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR / Phase [--] $APGE (Q1 2026) APG777 / Atopic dermatitis / Phase [--] 1/7 https://twitter.com/i/web/status/2011123506180935882" [X Link](https://x.com/BiopharmIQ/status/2011123506180935882) 2026-01-13T17:09Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📉📈 Prev. Qtr Movers: 🟢 $COGT 119.03% 🟢 $ANRO 80.92% 🔴 $VKTX -40.00% 🔴 $ALEC -50.62% Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lp https://www.offers.bpiq.com/big-mover-lp" [X Link](https://x.com/BiopharmIQ/status/2011123533020282977) 2026-01-13T17:09Z 28.9K followers, [----] engagements "#JPM2026 Day [--] 🗓 Free access to the J.P. Morgan [----] conference calendar in the comments. 👇 $XBI smid-cap biopharmas presenting today with commercial/marketed drugs: $AGIO $IMCR $NVCR $VCEL $MIRM $PCRX $ESPR $AMPH $IRON $RIGL $NVAX $EBS $OPK $LEGN ***** Great thread by @yaireinhorn breaking down @BeamTxs #JPM26 presentation. Clear overview of BEAMs pipeline regulatory progress with the FDA and key [----] milestones. Well worth the read. 🧵👇 1/@BeamTxs #JPM26 excellent presentation emphasised its strategic priorities & future milestones for [----]. Heres my🧵👇which elaborates on BEAMs current" [X Link](https://x.com/BiopharmIQ/status/2011401332910145667) 2026-01-14T11:33Z 28.9K followers, [----] engagements "The 44th J.P. Morgan Healthcare Conference runs through tomorrow in San Francisco CA 🔍 $NTLA $FDMT $IMCR $LEGN $SANA are presenting today Access our free #JPM2026 Conference Calendar. See link below 👇 https://www.bpiq.com/jpmorgan-conference-sign-up https://www.bpiq.com/jpmorgan-conference-sign-up" [X Link](https://x.com/BiopharmIQ/status/2011401335359639692) 2026-01-14T11:33Z 28.9K followers, [----] engagements "📌 Biotech Stock News 1/14 @ Open $IBRX 8% Accelerated Approval for ANKTIVA $SLDB 6% AAV-SLB101 Expanded Access $ANRO 3% ALTO-207 New Patent $SLS 3% SLS009 Expansion in EU $CCCC 2% Cemsidomide Strategic Milestones $EBS 1% NARCAN Nasal Spray FDA Approval $REVB 0% Present @ AKI & CRRT [----] $SNTI 0% Present AML data & RMAT Designation $IPSEY 0% Data @ TOXINS & IPN60340 BTD $TVTX -3% FDA Extends Review of FILSPARI $NRXP -5% 70K Patient Data on Ketamine $PSTV -39% Pricing of $15M Offering 🚀 SGT-003 update via @semodough $SLDB (2026 outlook) INSPIRE DUCHENNE fully enrolled [--] pts dosed in Ph1/2" [X Link](https://x.com/BiopharmIQ/status/2011467363808604271) 2026-01-14T15:56Z 28.9K followers, [----] engagements "$RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) BSID-III skill acquisition/stability at 1Y Wk16 CSF HS D2S6 strongly correlated w/ 1Y cognition (r 0.97) 2/7 https://twitter.com/i/web/status/2012295973645729889 https://twitter.com/i/web/status/2012295973645729889" [X Link](https://x.com/BiopharmIQ/status/2012295973645729889) 2026-01-16T22:48Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📉📈 Prev. Qtr Movers: 🟢 $COGT 119.03% 🟢 $ANRO 80.92% 🔴 $VKTX -40.00% 🔴 $ALEC -50.62% Access our FREE Big Mover Report 👇 https://offers.bpiq.com/big-mover-lp https://offers.bpiq.com/big-mover-lp" [X Link](https://x.com/BiopharmIQ/status/2012296038644859135) 2026-01-16T22:48Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $KOD Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP" [X Link](https://x.com/BiopharmIQ/status/2012962441622401137) 2026-01-18T18:56Z 28.9K followers, 62.5K engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $IBRX Phase [--] $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KOD Phase 2b $MDNAF Phase 2b $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR" [X Link](https://x.com/BiopharmIQ/status/2015509546706604491) 2026-01-25T19:38Z 28.9K followers, 54.9K engagements "Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $PEPG 14/36 🔥🔥 $ANRO 3/36 $TBPH 1/36 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/BiopharmIQ/status/2015509552142430522) 2026-01-25T19:38Z 28.9K followers, [----] engagements "📌 Biotech Stock News 1/28 @ Open $PDSB 10% Preliminary results for PDS01ADC $OKYO 9% Successful Type C Meeting with FDA $GKOS 7% FDA Approval for iDose TR $JNJ 1% Quadruplet regimen approved for myeloma $NTRA -1% ACES-EMB enrollment completion $SPRB -1% Data Presentations @ WORLDSymp $INSM -1% Treprostinil presentation @ PVRI $BIIB -2% Litifilimab receives FDA BTD $SCYX -2% SCY-247 presentation @ IMARI $ABBV -2% New data on facial injectables $ARDX -2% First Patient Dosed in ACCEL Study $ENSC -4% Enrollment update on PF614 trial $GRI -6% Ph2a Gene Expression Data $ALT -7% Pricing of $75M" [X Link](https://x.com/BiopharmIQ/status/2016543644707078561) 2026-01-28T16:07Z 28.9K followers, [----] engagements "$RGNX down -18% 📉 FDA clinical holds on RGX-111 & RGX-121 (MPS) Single neoplasm finding under review RGX-202 (DMD) unaffected; pivotal data in early Q2 Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2016543649438507133) 2026-01-28T16:07Z 28.9K followers, [----] engagements "📌 Biotech Stock News 1/30 @ Open $ALXO 11% Pricing of $150M; Evorpacept Data $PLX 8% Positive CHMP Opinion for Elfabrio $MNOV 2% [---] Patients Enrolled in MN-166 Study $ALT 2% Closing of $75M Offering $DNLI 1% TransportVehicle Enzyme Presentation $COYA -1% $11.1M Private Placement $INCY -1% Positive CHMP Opinion for Zynyz $PCVX -3% Pricing of $550M Offering $BMRN -3% Pricing of Private Offering $SCLX -3% Preventive Diagnosis Strategic Investment $RARE -4% UX111 Tx BLA Resubmission $MRNA -4% mRNA-3927 Commercial Collaboration $TNXP -4% Ph3 RESILIENT Data on TONMYA $KZIA -12% Preclinical data" [X Link](https://x.com/BiopharmIQ/status/2017266540073353700) 2026-01-30T15:59Z 28.9K followers, [----] engagements "$ALXO up 11% 📈 CD47 levels predict response to evorpacept + Ziihera Supports biomarker-driven patient selection Strengthens confidence in ongoing HER2+ trials Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://twitter.com/i/web/status/2017266543848296584 https://www.offers.bpiq.com/big-mover-lpmo=jun https://twitter.com/i/web/status/2017266543848296584 https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2017266543848296584) 2026-01-30T15:59Z 28.9K followers, [----] engagements "📢 M&A News: Cycle Group Acquires $APLT Cycle completes acquisition of $APLT Adds govorestat for rare metabolic & neurologic diseases Targets Classic Galactosemia CMT-SORD & PMM2-CDG (no FDA-approved therapies) Deal funded with cash on hand See images for more details 👇 📢 M&A News: $BCRX Completes Acquisition of Astria Therapeutics $700M Implied transaction value Adds navenibart for HAE Expands portfolio to oral (ORLADEYO) + injectable prophylaxis options Acquires early-stage atopic dermatitis program STAR0310 (strategic alternatives https://t.co/FORmlQBoMf 📢 M&A News: $BCRX Completes" [X Link](https://x.com/BiopharmIQ/status/2018728858217034102) 2026-02-03T16:50Z 28.9K followers, [----] engagements "📣 Biotech Stock News 02/05 @ Open $RNAZ 37% IND Amendment for Phase 2a Trial $XCUR 6% Rapid Stem Cell Mobilization with Burixafor $CGTX 5% Extends Access Program for Zervimesine $MRK 3% Health Canada approves ENFLONSIA $IMNN 2% Focus on pivotal phase [--] study $ALVO 1% Positive results for proposed biosimilar $LGVN 1% Passage of Pediatric Disease Act $ATOS 1% Strong market position for (Z)-Endoxifen $OSTX -1% Reauthorization of Pediatric Priority Review $TELO -1% New data on epigenetic modulation $MIRM -1% Health Canada Authorizes LIVMARLI Tablet $MIRM -1% Health Canada Authorizes LIVMARLI See" [X Link](https://x.com/BiopharmIQ/status/2019426980027076908) 2026-02-05T15:04Z 28.9K followers, [----] engagements "Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $XENE XEN1101 $INSM Brensocatib $ANRO ALTO-101 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/BiopharmIQ/status/2020573164078768610) 2026-02-08T18:59Z 28.9K followers, [----] engagements "Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $XENE 8/36 🔥 $INSM 8/36 🔥 $ANRO 3/36 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/BiopharmIQ/status/2020573166935105713) 2026-02-08T18:59Z 28.9K followers, [----] engagements "📣 M&A News: 🧬 Eli Lilly and Company $LLY to acquire Orna Therapeutics a private in vivo cell engineering biotech Deal boosts in vivo CAR-T programs targeting B celldriven autoimmune diseases Orna tech: circular RNA (oRNA) + LNPs enabling the body to generate its own cell therapies 🧪 Lead asset ORN-252: clinical-ready CD19-targeting in vivo CAR-T Orna shareholders eligible for up to $2.4B (upfront + milestones) 💰 See image for more details 👇 📢 M&A News: Cycle Group Acquires $APLT Cycle completes acquisition of $APLT Adds govorestat for rare metabolic & neurologic diseases Targets Classic" [X Link](https://x.com/BiopharmIQ/status/2020887434553446436) 2026-02-09T15:48Z 28.9K followers, [----] engagements "📣 Biotech Stock News 02/09 @ Open $HUMA 26% New Defense Funding for Blood Vessels $VRCA 3% Launch of YCANTH in Japan $MNKD 2% First Patient Enrolled in INHALE-1ST $ZBIO 2% Phase [--] results for Obexelimab $SLDB 1% Positive FDA feedback for SGT-003 $TMDX 1% FDA IDE Approval for OCS Heart Trial $LLY 1% Acquire Orna Therapeutics for therapies $ASND 0% Health Canada Approval of Yorvipath $KRYS 0% RMAT Designation for KB707 Granted $RHHBY 0% Fenebrutinib reduces disability progression $JNJ 0% Early Outcomes from OMNY-AF Study $NUVB -1% Pivotal Phase [--] Trial for Safusidenib $LXRX -2% Closing of" [X Link](https://x.com/BiopharmIQ/status/2020890070077902859) 2026-02-09T15:58Z 28.9K followers, [----] engagements "Humacyte Inc. $HUMA secures new FY26 U.S. Department of Defense funding - funding supports procurement of bioengineered blood vessels for traumatic vascular injuries Check out our catalyst calendar 📅 👇 & stay on top of key biopharma readouts https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar" [X Link](https://x.com/BiopharmIQ/status/2020895555879407635) 2026-02-09T16:20Z 28.9K followers, [----] engagements "$RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) BSID-III skill acquisition/stability at 1Y Wk16 CSF HS D2S6 strongly correlated w/ 1Y cognition (r 0.97) 2/7 https://twitter.com/i/web/status/2011123510970892403 https://twitter.com/i/web/status/2011123510970892403" [X Link](https://x.com/BiopharmIQ/status/2011123510970892403) 2026-01-13T17:09Z 28.9K followers, [----] engagements "Check out our FREE biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun" [X Link](https://x.com/BiopharmIQ/status/2020890195034542563) 2026-02-09T15:59Z 28.9K followers, [----] engagements "1/ BPIQ Model Portfolios continue to crush biotech benchmarks 🧬📈 $XBI $IBB Since launching our first consensus-based portfolio (Top 20s) on April [--] [----] our hedge-fund consensus strategy has consistently outperformed. Heres the data 👇 https://twitter.com/i/web/status/2022031587945447559 https://twitter.com/i/web/status/2022031587945447559" [X Link](https://x.com/anyuser/status/2022031587945447559) 2026-02-12T19:34Z 28.9K followers, [----] engagements "7/ Want access to our portfolio holdings and other portfolios info/tools to help you make better biopharma investment decisions Upgrade to Elite or APEX today. 💌 Limited-Time Valentines Sale: 50% OFF Elite 40% OFF APEX https://www.bpiq.com/pricingmo=021226 https://www.bpiq.com/pricingmo=021226" [X Link](https://x.com/anyuser/status/2022031608065536031) 2026-02-12T19:34Z 28.9K followers, [---] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $PTGX Phase 2b $EVAX Phase [--] $DCTH Phase [--] $CELC Phase [--] $IDYA Phase [--] $IDYA Phase 2/3 $KYTX Phase [--] $VOR Phase [--] $INBX Phase [--] $ATAI Phase 2b $LQDA Phase [--] $PROK Phase [--] $KZR Phase 2a $ALXO Phase [--] $ELDN Phase [--] $IFRX Phase 2a $IFRX Phase 2b $NKTR Phase 2b $RZLT Phase [--] $PVLA Phase [--] $BDTX Phase [--] $RNA Phase [--] $CAPR Phase [--] $TARA Phase [--] $ZVSA Phase 2a $CGON Phase [--] $VTYX Phase [--] $DBVT Phase [--] $PHVS Phase [--] $VTGN Phase [--] $TERN Phase [--] $ALEC Phase [--] $ZBIO Phase [--] $IRON Phase [--] $INBX Phase 2/3 $MLTX Phase [--] $ANAB Phase 2" [X Link](https://x.com/BiopharmIQ/status/1974933700845715618) 2025-10-05T20:24Z 28.9K followers, 56.1K engagements "🧬 Biotech Stock News 10/13 Brought to you by Barb On the rise 📈 $CGEN13% $RCUS7% $ANAB6% Under pressure 📉 $ADCT-2% $FDMT-3% $PALI-12% Catch the full breakdown in the latest video. 📌 Biotech Stock News 10/13 @ Midday $CGEN 13% COM701 Pooled Analysis $RCUS 7% Median OS Data in Ph2 Study $ANAB 6% Late-Breaking Presentation at ACR $BCAX 3% Ficerafusp Alfa Granted Breakthrough Designation $MNKD 3% FDA Review for Inhaled Insulin in Youth $ADGM 3% Preliminary https://t.co/q5BWCrtydz 📌 Biotech Stock News 10/13 @ Midday $CGEN 13% COM701 Pooled Analysis $RCUS 7% Median OS Data in Ph2 Study $ANAB" [X Link](https://x.com/BiopharmIQ/status/1977788430097772905) 2025-10-13T17:28Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $INAB Phase [--] $CRDL Phase [--] $ACLX Phase [--] $IRON Phase [--] $NUVL Phase [--] $XCUR Phase [--] $STOK Phase [--] $GLPG Phase [--] $NRIX Phase [--] $PVLA Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $ARGX Phase [--] $INCY Phase [--] $EWTX Phase [--] $RNAC Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $PRAX Phase 2/3 $BHVN Phase [--] $ZNTL Phase [--] $IOVA Phase [--] $GNLX Phase [--] $RXRX Phase [--] $PRTA Phase [--] $VALN Phase [--] $CGON Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $IMVT Phase [--] $BMEA Phase [--] $EXEL Phase [--] $JAZZ Phase [--] $HOOK" [X Link](https://x.com/BiopharmIQ/status/1990156659042529711) 2025-11-16T20:34Z 28.9K followers, 32.6K engagements "📌 Biotech Stock News 1/2 @ Open $CORT 9% Complete Response Letter for Relacorilant $BCAB 4% Advance Ozuriftamab Vedotin into Trial $JAGX 2% FDA Grant for Canalevia-CA1 $CYBN 1% Initiates At-The-Market Equity Program $RARE 0% Rolling Submission for DTX401 BLA $LNTH 0% Closing of SPECT Business Sale $DCTH 0% Publication of FOCUS Study Analyses $ALVO -3% Secures Term Loan Facility $AXSM -3% AXS-05 & AXS-12 FDA Updates $VNDA -4% FDA Approves NEREUS for MS $OTLK -58% Regulatory Update on ONS-5010 🔍 Worth a closer look 👀 via @BioStocks on $OTLK: New BLA data does not change FDA view Confirmatory" [X Link](https://x.com/BiopharmIQ/status/2007113295719972937) 2026-01-02T15:34Z 28.9K followers, [----] engagements "📣 Biotech Stock News 01/08 @ Open $ELVN 46% Positive Ph1b Data for ELVN-001 $ARDX 16% Preliminary [----] Revenue & [----] Outlook $ALXO 6% Clinical Trials for Evorpacept & ALX2004 $GLUE 5% Proposed Public Offering and Warrants $RANI 4% Phase [--] Study of RT-114 $PHAR 3% Preliminary [----] revenues announced $GRI 2% Positive Data from Phase 2a Study $COYA 2% Results of LD IL-2 and CTLA4-Ig $KRYS 2% Interim Clinical Update on KB407 $ENSC 2% EU Patent for ADHD Therapy $SGMT 2% Poster Presentation at MASH-TAG [----] $XLO 1% Upcoming Milestones and Updates $ARWR 1% Prices Upsized Offerings of Notes $BFRI" [X Link](https://x.com/BiopharmIQ/status/2009308436698435628) 2026-01-08T16:57Z 28.9K followers, [----] engagements "$RCKT (March [--] 2026) KRESLADI (marne-cel; RP-L201) / Severe LAD-I / PDUFA Why KRESLADI is different One-time autologous LV gene-corrected HSC tx designed to restore CD18 & reconstitute immune function (potentially curative). Prior signal (pivotal LAD-I study) 9/9 survival w/ no graft failure; no drug-related SAEs 10% PMN CD18 expression at 1yr across cohort 100% HSCT-free survival + meaningful reduction in infection-related hospitalizations 3/7 https://twitter.com/i/web/status/2011123515072921907 https://twitter.com/i/web/status/2011123515072921907" [X Link](https://x.com/BiopharmIQ/status/2011123515072921907) 2026-01-13T17:09Z 28.9K followers, [---] engagements "🧬 Biotech Stock News 08/26 Brought to you by Barb [--] stocks on the rise 📈 $IXHL $JUNS $PSTV [--] under pressure 📉 $LPCN $MRKR $EPIX Catch the full breakdown in the latest video 🎥 📣 Biotech Stock News 8/26 @ Open $IXHL 15% Positive Ph2 Results for PSX-001 $JUNS 8% Launches Nugevia Website & Pre-Orders $PSTV 6% Regains Compliance with Nasdaq Criteria $LCTX 6% Research Collaboration for Hearing Loss $OSTX 6% Terminates Equity Line of Credit $CYBN 4% https://t.co/cVxFjAxmsj 📣 Biotech Stock News 8/26 @ Open $IXHL 15% Positive Ph2 Results for PSX-001 $JUNS 8% Launches Nugevia Website & Pre-Orders" [X Link](https://x.com/BiopharmIQ/status/1960394795534188824) 2025-08-26T17:31Z 28.9K followers, [----] engagements "🧬 Biotech Stock News 09/11 Brought to you by Barb On the rise 📈 $MAZE 43% $GRI39% $RVMD 15% Under pressure 📉 $VXRT -1% $KAPA -10% $BDSX -17% Catch the full breakdown in the latest video 🎥 🧬 Biotech Stock News 09/11 @ Open $MAZE 43% MZE782 Ph1 Trial Results $GRI 39% 6-Week Interim Lung Function Data $RVMD 15% New Daraxonrasib Clinical Results $TEM 14% FDA Clearance for Updated Device $PSNL 11% Trial Launched for ctDNA-Guided Treatment $MAIA 5% Efficacy Data from https://t.co/dVDH3iBWIh 🧬 Biotech Stock News 09/11 @ Open $MAZE 43% MZE782 Ph1 Trial Results $GRI 39% 6-Week Interim Lung" [X Link](https://x.com/BiopharmIQ/status/1966237161327587496) 2025-09-11T20:27Z 28.9K followers, [----] engagements "🧬 Biotech Stock News 10/02 Brought to you by Barb On the rise 📈 $TSHA 41% $NBTX 9% $PEPG 4% Under pressure 📉 $SION -5% $DNTH -6% $BOLT -13% Catch the full breakdown in the latest video. 📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral Presentations at WMS $AVXL 3% Successful Development of Oral Tablet $AVXL 3% Positive Topline Results from Phase [--] Study $GLPG 1% Update on Strategic Alternatives for https://t.co/V3R1mSRELl 📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral" [X Link](https://x.com/BiopharmIQ/status/1973802847159660749) 2025-10-02T17:30Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist 🎯 Ph2 & Ph3 readouts in Q4 [----] $LTRN Phase [--] $ARGX Phase [--] $INCY Phase [--] $ROIV Phase [--] $GLPG Phase [--] $BHVN Phase [--] $GNLX Phase [--] $VALN Phase [--] $IMCR Phase [--] $GNLX Phase [--] $EXEL Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV Phase 2a $DWTX Phase 2b $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $LSTA Phase 2a $ALDX Phase [--] $ALNY Phase [--] $LLY Phase [--] $MRNA Phase [--] $IONS Phase [--] $REGN Phase 2/3 $CALT Phase [--] $GNFT Phase [--] $NAMS Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $INKT" [X Link](https://x.com/BiopharmIQ/status/2002827511336698293) 2025-12-21T19:44Z 28.9K followers, 104.7K engagements "📌 Biotech Stock News 1/23 @ Open $ADAG 7% Business Update and [----] Objectives $BCRX 4% Completes Acquisition of Astria Tx $PCVX 2% Advances Programs for VAX-31 Vaccine $IBRX 2% Survival Not Yet Reached in Glioblastoma $OKYO 0% FDA Approves Urcosimod for Pain $OCGN -2% Closing of $22.5M Offering $ELDN -2% Long-Term Ph1b Data for Tegoprubart $THAR -2% Closing of $55M Offering $CRNX -2% Ph2/3 Trial for Atumelnant $TRVI -4% Publication of nalbuphine ER data 🚀 Shoutout to @doepke_michel on $BCRX announcement of the planned acquisition of Astria Tx: Deal officially closed today (1-23-26) $700M" [X Link](https://x.com/BiopharmIQ/status/2014725333518516432) 2026-01-23T15:42Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/6 @ Open $ROIV 18% Mosliciguat & Brepocitinib Trial Updates $DNLI 5% TransportVehicle Progress Update $IOVA 5% Amtagvi Treatment RWD $QURE 4% Updated AMT-191 Ph1/2a Data $SPRB 4% Tralesinidase Alfa shows potential $PFE 2% Priority Review for HYMPAVZI $TGTX 1% Presentation of Data for BRIUMVI $GILD 0% Label update for Yescarta approved $IMMP 0% TACTI-004 Trial 50% Enrolment $NTRA -1% Launches EDEN Study on Preeclampsia $AAPG -2% APG-3288 IND Clearance $ANEB -33% Intention to Voluntarily Delist See the image and comments for more details 👇 $ROIV Positive Phase [--] Results" [X Link](https://x.com/BiopharmIQ/status/2019795742156804461) 2026-02-06T15:30Z 28.9K followers, [----] engagements "2/ We expanded the hedge-fund favorites framework across: Run-Up Top [--] Top [--] Top [--] (refined Nov 2024) The results have been clear. And consistent" [X Link](https://x.com/BiopharmIQ/status/2022031590097137864) 2026-02-12T19:34Z 28.9K followers, [---] engagements "🧬 Biotech Weekly News Largest single-day stock moves during the week ending 01/09/26 📈 $ALMS 95% Envudeucitinib leads in skin clearance $ELVN 50% Positive Ph1b Data ELVN-001 $GLUE 45% Positive Ph1 Data MRT-8102 $CGON 29% Updated Timeline PIVOT-006 Data $ARDX 20% Prelim. [----] Revenue & [----] Outlook 📉 $ZBIO -52% Results for Obexelimab trial $TIL -46% AXN-2510 Clinical Dev Discontinuation $IMRX -43% OS 64% in Pancreatic Cancer $AQST -37% Regulatory Development for Anaphylm $JSPR -19% Data from Briquilimab studies See image below. ***** $ALMS Envudeucitinib PASI 75/90/100 data versus oral TYK2" [X Link](https://x.com/BiopharmIQ/status/2010008084916449457) 2026-01-10T15:17Z 28.9K followers, [----] engagements "Clinical data driving moves this week: $ALMS Envudeucitinib PASI skin clearance data $ELVN $GLUE $CYCN Positive Ph1/2 readouts $RDHL $RZLT $DRUG Mid-stage efficacy updates Track upcoming readouts with our catalyst calendar 📅 $XBI $IBB https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar" [X Link](https://x.com/BiopharmIQ/status/2010008089056203239) 2026-01-10T15:17Z 28.9K followers, [----] engagements "Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $MDNAF Phase 2b $GOSS Phase [--] $BFRI Phase [--] $MLTX Phase [--] $BFRI Phase [--] $BCDA Phase [--] $KPTI Phase [--] $IOVA Phase [--] $XENE Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP Phase [--] $PVLA" [X Link](https://x.com/BiopharmIQ/status/2020573160345940394) 2026-02-08T18:59Z 28.9K followers, [----] engagements "$UPB down -52% 📉 Ph2 VALIANT met primary endpoint in severe asthma AAER 56% (100 mg q12w) & 39% (400 mg q24w) vs placebo Advancing to Ph3 in asthma & CRSwNP Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2021622571213705383) 2026-02-11T16:29Z 28.9K followers, [----] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/anyuser/status/2021622573478658223) 2026-02-11T16:29Z 28.9K followers, [---] engagements "$BBIO +9% 🟢 Infigratinib delivers a home run 🏆 - Phase [--] hits primary + key secondary endpoints first-ever improvement in body proportionality in achondroplasia. - NDA planned H2 [----]. Check out our catalyst calendar below. 📅 https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar" [X Link](https://x.com/anyuser/status/2021972608179483081) 2026-02-12T15:40Z 28.9K followers, [---] engagements "4/ 📊 Since 12/31/2023 Every portfolio outperformed $XBI and $IBB [--] XBI [----] IBB (see image [--] 👇)" [X Link](https://x.com/BiopharmIQ/status/2022031598200533059) 2026-02-12T19:34Z 28.9K followers, [--] engagements "5/ 📊 [----] Performance (Since 12/31/2024) Every portfolio outperformed $XBI and $IBB 1.451.80 XBI 1.63.4 IBB Top [--] delivered 200% of both benchmarks (see image [--] 👇)" [X Link](https://x.com/BiopharmIQ/status/2022031602407375280) 2026-02-12T19:34Z 28.9K followers, [--] engagements "📣 Biotech Stock News 01/22 @ Midday $SXTP 135% Partnership for ARAKODA Access $CRVS 16% Pricing of Upsized Public Offering $GLSI 14% FDA Approves Commercially Manufactured GP2 $CORT 14% Overall Survival Met in ROSELLA Trial $JANX 9% Collaboration for Tumor-Activated Therapeutic $TARA 6% Updated Interim Data for TARA-002 $PDSB 5% New U.S. Patent for PDS0101 $IVVD 3% Partnership to Educate on Antibodies $ERAS 2% Pricing of Upsized Public Offering $GILD 2% Trodelvy Plus Keytruda in Breast Cancer $IPSEY 2% Arbitration upholds R&D agreement termination $ATXS 0% Stockholders Approve Acquisition" [X Link](https://x.com/BiopharmIQ/status/2014395297418600857) 2026-01-22T17:50Z 28.9K followers, [----] engagements "February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder / schizophrenia) Feb [--] $ETON ET-600 (central diabetes insipidus) Feb [--] $ASND TransCon CNP (achondroplasia) Priority Review Feb [--] $BMRN PALYNZIQ (PKU adolescents) Priority Review (label expansion) See the attached graphic for the full February PDUFA calendar. https://twitter.com/i/web/status/2016215337554083884" [X Link](https://x.com/anyuser/status/2016215337554083884) 2026-01-27T18:22Z 28.9K followers, 85.9K engagements "📣 Biotech Stock News 02/02 @ Open $AQST 45% FDA Issues Complete Response Letter $CATX 31% Pricing of $175 Million Offering $CRMD 10% Share Repurchase Program Announced $SGMT 6% Positive 52-Week Data for ASC40 $PVLA 5% Scientific Publication on Porokeratosis $MLTX 5% FDA Fast Track for Sonelokimab $MOLN 5% First Imaging Data of MP0712 $DNLI 4% Webcast on Enzyme TransportVehicle Programs $VTVT 3% Amends License Agreement for HPP737 $ETON 3% Licensing of Rare Disease Product $REGN 2% EYLEA HD clinical profile presentation $DWTX 2% 50% Enrollment in Halneuron Phase 2b $WVE 2% Accelerate" [X Link](https://x.com/BiopharmIQ/status/2018356493670887516) 2026-02-02T16:11Z 28.9K followers, [----] engagements "❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration; resubmission planned as early Q3 [----]. $PHAR also received an FDA CRL for Joenja pediatric sNDA (ages 411) citing the need for additional pediatric PK data and clarification on analytical testing method. See images for details. 👇 January [----] Biotech PDUFA Update 📡 Whats on the FDA radar Recent Outcomes: $ATRA tab-cel (EBV+ PTLD) CRL $TVTX FILSPARI (FSGS) Extended 4/13/26 $FBIO ZYCUBO (copper histidinate) Approved Pending FDA Decisions: Jan [--] $AQST Anaphylm (Anaphylaxis) No" [X Link](https://x.com/BiopharmIQ/status/2018372259208159449) 2026-02-02T17:13Z 28.9K followers, 10.5K engagements "FDA CRLs issued to $AQST and $PHAR different issues different paths forward. 👇 https://x.com/BiopharmIQ/status/2018372259208159449 ❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration; resubmission planned as early Q3 [----]. $PHAR also received an FDA CRL for Joenja pediatric sNDA (ages 411) citing the need for additional pediatric PK data and https://t.co/4jrSzXa7pP https://x.com/BiopharmIQ/status/2018372259208159449 ❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration;" [X Link](https://x.com/BiopharmIQ/status/2018375578819473894) 2026-02-02T17:26Z 28.9K followers, [----] engagements "FDA decisions move markets 🎯 $AQST +42% on CRL $PHAR 18% on CRL Track upcoming PDUFAs CRLs & approvals with our free PDUFA Report 👇 https://www.offers.bpiq.com/pdufa-report https://www.offers.bpiq.com/pdufa-report" [X Link](https://x.com/BiopharmIQ/status/2018375581466014123) 2026-02-02T17:26Z 28.9K followers, [----] engagements "🧬 Biopharma Weekly Recap 📝 This week in biotech: $ANL financing sparks biopick buzz M&A chatter heats up GLP-1 differentiation sharpens OX40 stumbles gene therapy debate grows XBI inflows strong. See interesting posts/ppl to check out 👇 @seedy19tron $ANL Raises $140M @ $6.50; Top Funds In $525M MC vs $ERAS ($3.7B) IND-Cleared US Trial Next; Preclin Data Fuels Biopick [----] Buzz @PersimmonTI $XBI the M&A Playbook GPCRMRK ABVXLLY CTMXMRK CYTKNVS MLYSPFE/NVO RYTMNVO TERNBMY NKTRAMGN ORICJNJ SNDXINCY RCUSGILD RVMDJNJ @yaireinhorn CRISPR/Gene Tx Blocked by Economics Not Science: David Liu ($BEAM" [X Link](https://x.com/BiopharmIQ/status/2020121583478862133) 2026-02-07T13:04Z 28.9K followers, [----] engagements "$RGNX -15% 🔴 FDA issued a CRL for RGX-121 in MPS II / Hunter syndrome ⚠ Key issues: pt selection external control comparability and CSF biomarker not accepted as surrogate. ❌ No approval; FDA suggests more data/new study. Plans BLA resubmission. See image for details. February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder https://t.co/jRQJdkbvdw February Biotech PDUFA Pulse: 📡 Whats on" [X Link](https://x.com/anyuser/status/2021278233963245614) 2026-02-10T17:40Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/11 @ Open $NKTR 17% Proposed Public Offering $AZN 4% Programs to improve healthcare access $DTIL 4% FDA Clearance for PBGENE-DMD $OTLK 2% Submits Type A Meeting Request $MRK 1% KEYTRUDA and Paclitaxel Approved $SNTI 1% Enrollment in Ph1 Trial of SENTI-202 $BCRX 1% New HAE Data from ORLADEYO $MDGL -2% Exclusive Licensing for Novel siRNA $STOK -4% First Patient Dosed in STK-002 Study $CADL -6% Present at Glioblastoma Drug Summit $GLTO -6% Pricing of $275M Offering $BFRI -6% FDA Filing Acceptance for Ameluz $DBVT -7% Additional data from VITESSE study $OKYO -7% Transition" [X Link](https://x.com/anyuser/status/2021622567187235127) 2026-02-11T16:29Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/13 @ Open $IMUX 26% $400M Private Placement $EVMN 14% $125M Private Placement $ANRO 5% Completion of Ph2 Study ALTO-101 $EBS 3% sNDA Approval for NARCAN Nasal Spray $GLTO 2% Closing of Public Offering $AZN 1% Results from KALOS and LOGOS trials $PTCT 0% Regulatory Update on Translarna $ITRM -5% Business Update $CHRS -13% Pricing of Public Offering $OKYO -25% Pricing of $20M Offering See the image and comments for more details 👇 https://twitter.com/i/web/status/2022352228829532451 https://twitter.com/i/web/status/2022352228829532451" [X Link](https://x.com/anyuser/status/2022352228829532451) 2026-02-13T16:48Z 28.9K followers, [----] engagements "$ANRO up 5% 📈 Completed Ph2 PoC enrollment for ALTO-101 in CIAS Novel transdermal PDE4 inhibitor targeting cognitive deficits in schizophrenia Topline data by end of Q1 Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2022352232373719552) 2026-02-13T16:48Z 28.9K followers, [---] engagements "February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder / schizophrenia) Feb [--] $ETON ET-600 (central diabetes insipidus) Feb [--] $ASND TransCon CNP (achondroplasia) Priority Review Feb [--] $BMRN PALYNZIQ (PKU adolescents) Priority Review (label expansion) See the attached graphic for the full February PDUFA calendar. https://twitter.com/i/web/status/2016215337554083884" [X Link](https://x.com/anyuser/status/2016215337554083884) 2026-01-27T18:22Z 28.9K followers, 85.9K engagements "🚨 Hedge Fund Q4 holdings (13F) data drops next week (2/17) We follow the top biopharma hedge funds. - capture their 13F data - & post it on our website Access our FREE biopharma hedge fund screener See comments below" [X Link](https://x.com/anyuser/status/2022439826088505644) 2026-02-13T22:36Z 28.9K followers, [---] engagements "Check out our biopharma hedge fund screener & get insights on top biopharma funds💡 Which of them own your favorite smid-caps Start by checking out our free screener.👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds" [X Link](https://x.com/anyuser/status/2022439828990914675) 2026-02-13T22:36Z 28.9K followers, [---] engagements "Part of being a content creator on should be to promote other valuable creators as much as possible. So here is a list of top tier accounts who create exceptional content & who are A MUST FOLLOW in BioTech and the financial markets👇 BioTech: @Biotech2k1 @BiopharmIQ @Maximus_Holla @Pharmdca @BiomedicalRX @learnbiotech @CrisprGlenn @Andre_AGTC @ablidy @AppleHelix @JessieChimni @TohJah7809 @JohnPDalyJr @BowTiedBiotech @3primeAnalytica @jfais20 @drrichjlaw @GeneInvesting @zhaoweiasu @chuminhua432 Global Economy & Financial Markets: @LeoNelissen @WallStSai @BrandonVanZee @erwtrades @jimbo6607" [X Link](https://x.com/anyuser/status/2022390720901103935) 2026-02-13T19:21Z 18.5K followers, [----] engagements "📌 Biotech Stock News 2/13 @ Open $IMUX 26% $400M Private Placement $EVMN 14% $125M Private Placement $ANRO 5% Completion of Ph2 Study ALTO-101 $EBS 3% sNDA Approval for NARCAN Nasal Spray $GLTO 2% Closing of Public Offering $AZN 1% Results from KALOS and LOGOS trials $PTCT 0% Regulatory Update on Translarna $ITRM -5% Business Update $CHRS -13% Pricing of Public Offering $OKYO -25% Pricing of $20M Offering See the image and comments for more details 👇 https://twitter.com/i/web/status/2022352228829532451 https://twitter.com/i/web/status/2022352228829532451" [X Link](https://x.com/anyuser/status/2022352228829532451) 2026-02-13T16:48Z 28.9K followers, [----] engagements "$ANRO up 5% 📈 Completed Ph2 PoC enrollment for ALTO-101 in CIAS Novel transdermal PDE4 inhibitor targeting cognitive deficits in schizophrenia Topline data by end of Q1 Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2022352232373719552) 2026-02-13T16:48Z 28.9K followers, [---] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/anyuser/status/2022352235821437057) 2026-02-13T16:48Z 28.9K followers, [---] engagements "1/ BPIQ Model Portfolios continue to crush biotech benchmarks 🧬📈 $XBI $IBB Since launching our first consensus-based portfolio (Top 20s) on April [--] [----] our hedge-fund consensus strategy has consistently outperformed. Heres the data 👇 https://twitter.com/i/web/status/2022031587945447559 https://twitter.com/i/web/status/2022031587945447559" [X Link](https://x.com/anyuser/status/2022031587945447559) 2026-02-12T19:34Z 28.9K followers, [----] engagements "6/ 👉 What this means: Our hedge-fund favorites framework has worked across start dates and market regimes This is not a one-off result. Its sustained outperformance across portfolios" [X Link](https://x.com/anyuser/status/2022031605838290984) 2026-02-12T19:34Z 28.9K followers, [---] engagements "7/ Want access to our portfolio holdings and other portfolios info/tools to help you make better biopharma investment decisions Upgrade to Elite or APEX today. 💌 Limited-Time Valentines Sale: 50% OFF Elite 40% OFF APEX https://www.bpiq.com/pricingmo=021226 https://www.bpiq.com/pricingmo=021226" [X Link](https://x.com/anyuser/status/2022031608065536031) 2026-02-12T19:34Z 28.9K followers, [---] engagements "📣 Biotech Stock News 02/12 @ Open $NVCR 29% FDA Approves Optune Pax for Cancer $BBIO 9% Positive Phase [--] Results for Infigratinib $ANVS 6% DSMB Approval for Buntanetap Trial $TECX 5% Discussion of TX2100 for treatment $ANL 4% First Patient Enrolled in AN9025 Trial $NKTR 2% Pricing of $400 Million Offering $PCRX 1% New NOPAIN Act Survey Data $MRK 0% Advances in Bladder and Kidney Cancer $XLO 0% Pricing of Underwritten Offering $LYEL 0% Initiation of Patient Dosing $PCVX -1% Doses First Participants in OPUS-3 Trial $APRE -1% Strengthens Global Patent Portfolio $BTAI -2% Advances" [X Link](https://x.com/anyuser/status/2021972604748542219) 2026-02-12T15:40Z 28.9K followers, [----] engagements "$BBIO $XBI Infigratinib with home run data: BridgeBio Reports Positive Phase [--] Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - NDA and MAA submissions planned in second half of [----] for achondroplasia; oral infigratinib is the only therapeutic option in development for achondroplasia to have Breakthrough Therapy Designation from the FDA - Given the strength of these data BridgeBio plans to accelerate the development of oral infigratinib in hypochondroplasia and is enrolling the observational run-in for the" [X Link](https://x.com/anyuser/status/2021926695771476311) 2026-02-12T12:37Z 10.9K followers, [----] engagements "$BBIO +9% 🟢 Infigratinib delivers a home run 🏆 - Phase [--] hits primary + key secondary endpoints first-ever improvement in body proportionality in achondroplasia. - NDA planned H2 [----]. Check out our catalyst calendar below. 📅 https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar" [X Link](https://x.com/anyuser/status/2021972608179483081) 2026-02-12T15:40Z 28.9K followers, [---] engagements "📌 Biotech Stock News 2/11 @ Open $NKTR 17% Proposed Public Offering $AZN 4% Programs to improve healthcare access $DTIL 4% FDA Clearance for PBGENE-DMD $OTLK 2% Submits Type A Meeting Request $MRK 1% KEYTRUDA and Paclitaxel Approved $SNTI 1% Enrollment in Ph1 Trial of SENTI-202 $BCRX 1% New HAE Data from ORLADEYO $MDGL -2% Exclusive Licensing for Novel siRNA $STOK -4% First Patient Dosed in STK-002 Study $CADL -6% Present at Glioblastoma Drug Summit $GLTO -6% Pricing of $275M Offering $BFRI -6% FDA Filing Acceptance for Ameluz $DBVT -7% Additional data from VITESSE study $OKYO -7% Transition" [X Link](https://x.com/anyuser/status/2021622567187235127) 2026-02-11T16:29Z 28.9K followers, [----] engagements "$UPB down -52% 📉 Ph2 VALIANT met primary endpoint in severe asthma AAER 56% (100 mg q12w) & 39% (400 mg q24w) vs placebo Advancing to Ph3 in asthma & CRSwNP Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2021622571213705383) 2026-02-11T16:29Z 28.9K followers, [----] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/anyuser/status/2021622573478658223) 2026-02-11T16:29Z 28.9K followers, [---] engagements "$RGNX -15% 🔴 FDA issued a CRL for RGX-121 in MPS II / Hunter syndrome ⚠ Key issues: pt selection external control comparability and CSF biomarker not accepted as surrogate. ❌ No approval; FDA suggests more data/new study. Plans BLA resubmission. See image for details. February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder https://t.co/jRQJdkbvdw February Biotech PDUFA Pulse: 📡 Whats on" [X Link](https://x.com/anyuser/status/2021278233963245614) 2026-02-10T17:40Z 28.9K followers, [----] engagements "📌 Biotech Stock News 2/10 @ Open $PHIO 53% Positive SMC wrap-up on PH-762 $EVMN 53% EVO301 Topline data $NKTR 44% REZOLVE-AD Maintenance Data $STRO 10% Pricing of $110M Offering $INMB 9% Advances CORDStrom for RDEB $AGEN 4% New data on BOT/BAL biomarkers $BCDA 2% Pre-Submission for FDA Approval $SPRY 2% Showcase Clinical Data on neffy $SEPN 2% Data from Ph1 Trial of SEP-631 $GNPX 2% Patent Intent for Reqorsa Gene Tx $LTRN 1% Present at Glioblastoma Drug Summit $CRDL 1% ARCHER Ph2 Trial Results Published $ENTA 1% Preclinical data for EDP-978 $PHVS 0% Present Clinical Data at AAAAI Mtg $COGT" [X Link](https://x.com/anyuser/status/2021255905829110044) 2026-02-10T16:12Z 28.9K followers, [----] engagements "$NKTR upcoming milestones. https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88 https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88" [X Link](https://x.com/doepke_michel/status/2021208502526517569) 2026-02-10T13:03Z [----] followers, [----] engagements "$EVMN up 53% 📈 Ph2a of EVO301hit primary endpoint in AD Fast EASI improvements vs placebo (W4 W8 W12) Moving into Phase 2b dose-range trial Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun" [X Link](https://x.com/anyuser/status/2021255909956276478) 2026-02-10T16:12Z 28.9K followers, [----] engagements "📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958" [X Link](https://x.com/anyuser/status/2021255912833392837) 2026-02-10T16:12Z 28.9K followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@BiopharmIQ BiopharmIQ by Amp
Several biotech companies have recently made significant announcements, including $INBX, which saw a 75% increase in stock value after releasing positive topline results for its chondrosarcoma trial. $RNA entered into an acquisition agreement for $12 billion, and $NVS is set to acquire $RNA's neuro pipeline. Additionally, $GMAB is acquiring $MRUS for $8 billion, expanding its portfolio with a phase [--] bispecific petosemtamab.
Engagements: [------] #
- [--] Week [-------] +8.70%
- [--] Month [-------] -12%
- [--] Months [---------] +33%
- [--] Year [---------] -53%
Mentions: [--] #
- [--] Week [---] -6.90%
- [--] Month [---] +12%
- [--] Months [---] +15%
- [--] Year [-----] -33%
Followers: [------] #
- [--] Week [------] +0.02%
- [--] Month [------] +0.74%
- [--] Months [------] +9.60%
- [--] Year [------] +23%
CreatorRank: [-------] #
Social Influence
Social category influence stocks 76.79% finance 22.02% cryptocurrencies #5347 currencies 3.57% exchanges 2.98% countries 2.98% financial services 2.38% technology brands 1.19%
Social topic influence $xbi #11, $anro #1, $nktr #15, $kod #2, $agio #1, $immp #1, data #205, acquisition #1539, $rgnx #1, check out 7.14%
Top accounts mentioned or mentioned by @wallstreet_dawg @mwb741 @yaireinhorn @persimmonti @seedy19tron @biopharmiq @semodough @geneinvesting @quantumup1 @biostocks @amaymd @pharmdca @doepkemichel @wassimlaroussi3 @researchpulse1 @wallstsai @biotech2k1 @bioinvestor24 @siemionowkris @maximusholla
Top assets mentioned Alto Neuroscience, Inc. (ANRO) Agios Pharmaceuticals, Inc. (AGIO) Atai Life Sciences B.V. (ATAI) PepGen Inc. (PEPG) Iovance Biotherapeutics, Inc. Common Stock (IOVA) Merck & Co., Inc. (MRK) ArriVent BioPharma, Inc. (AVBP) Mineralys Therapeutics, Inc. (MLYS) Edgewise Therapeutics, Inc. (EWTX) BridgeBio Pharma, Inc. Common Stock (BBIO) Taraxa (TARA) Upstream Bio, Inc. (UPB) Viridian Therapeutics, Inc. Common Stock (VRDN) Cogent Biosciences, Inc. Common Stock (COGT) Roivant Sciences Ltd. Common Shares (ROIV) Biofrontera Inc. (BFRI) NovoCure Limited Ordinary Shares (NVCR) Evommune, Inc. (EVMN) Tourmaline Bio, Inc. (TRML) uniQure N.V. (QURE) Incyte Corporation (INCY) Insmed, Inc. (INSM) Bristol-Myers Squibb Co (BMY) CalciMedica, Inc. (CALC) ImmunityBio, Inc. Common Stock (IBRX) Celldex Therapeutics, Inc (CLDX) Apogee Therapeutics, Inc. (APGE) Lantern Pharma Inc. (LTRN) Praxis Precision Medicines, Inc. (PRAX) ALX Oncology Holdings Inc (ALXO) IDEAYA Biosciences, Inc. Common Stock (IDYA) OS Therapies Incorporated (OSTX) Denali Therapeutics Inc. Common Stock (DNLI) Arcellx, Inc. (ACLX) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Crinetics Pharmaceuticals, Inc. (CRNX) Summit Therapeutics Inc. Common Stock (SMMT) Eli Lilly and Company (LLY) Pharming Group N.V. (PHAR) Candel Therapeutics, Inc. (CADL) AstraZeneca PLC (AZN) Ocular Therapeutix, Inc. (OCUL) ARS Pharmaceuticals, Inc. (SPRY) Rapport Therapeutics, Inc. (RAPP) Adagene Inc. (ADAG) Xilio Therapeutics, Inc. (XLO) Novartis AG (NVS) Nanobiotix S.A. (NBTX) MiNK Therapeutics, Inc. (INKT) Centessa Pharmaceuticals plc (CNTA) Krystal Biotech, Inc. Common Stock (KRYS) Xenon Pharmaceuticals Inc (XENE) Structure Therapeutics Inc. (GPCR) Enliven Therapeutics, Inc. (ELVN)
Top Social Posts
Top posts by engagements in the last [--] hours
"🔔 Its the final day of #JPM2026 Catch the companies on your radar presenting today. Free access to the J.P. Morgan [----] conference calendar in the comments. 👇 $XBI smid-cap biopharmas presenting with commercial/marketed drugs: $VNDA $ADCT $LXRX ***** $NTLA at #JPM2026: New HAE safety disclosures Phase [--] enrollment expansion and clearer FDA dialogue. See @GeneInvesting post 👇 [----] JPM Conference- Intellia Therapeutics notes $NTLA Have dosed over [---] patients Excess of [--] years on some 1H [----] FDA approval estimate HAE 6b by end of decade HAE market 80% of HAE patients not attack free"
X Link 2026-01-15T10:23Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🚨 Likely to move the stock +/- by 20% $OCUL: AXPAXLI (OTX-TKI) (axitinib intravitreal implant) Ph3 $NKTR: Rezpegaldesleukin (NKTR-358) Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-07T13:04Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/10 @ Open $PHIO 53% Positive SMC wrap-up on PH-762 $EVMN 53% EVO301 Topline data $NKTR 44% REZOLVE-AD Maintenance Data $STRO 10% Pricing of $110M Offering $INMB 9% Advances CORDStrom for RDEB $AGEN 4% New data on BOT/BAL biomarkers $BCDA 2% Pre-Submission for FDA Approval $SPRY 2% Showcase Clinical Data on neffy $SEPN 2% Data from Ph1 Trial of SEP-631 $GNPX 2% Patent Intent for Reqorsa Gene Tx $LTRN 1% Present at Glioblastoma Drug Summit $CRDL 1% ARCHER Ph2 Trial Results Published $ENTA 1% Preclinical data for EDP-978 $PHVS 0% Present Clinical Data at AAAAI Mtg $COGT"
X Link 2026-02-10T16:12Z 28.9K followers, [----] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-10T16:12Z 28.9K followers, [---] engagements
"📌 Biotech Stock News 07/30 🧬 📽 $VRDN 11% Collaboration & License Agreement w/ Kissei Pharma $IMNN 8% First Patient Dosed in Ph3 Study $CELC 5% Pricing of Public Offering $MIRA 3% Topical Ketamir-2 Preclin Data $ACRS 2% Results from ATI-2138 Ph2a Trial $CRBP 2% CRB- [---] Ph1/2 Clinical Data at ESMO $TNYA 2% Safety Reviews for Gene Trials $LRMR 2% Pricing of Public Offering $ABBV 0% Ph3 Topline Results from Alopecia Trial $BIIB 0% New Data on Leqembi at AAIC $NAMS 0% Data from BROADWAY Trial at AAIC $SNSE 0% Clinical Data from Phase [--] Cohort at ESMO $MDGL 0% Exclusive Global License for GLP-1"
X Link 2025-07-30T21:29Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📈 📉 $RAPP RAP-219 $AMLX AMX0035 $IONS IONIS-APOCIII-LRx (Olezarsen) Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2025-08-17T17:40Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist 🎯 Ph2 & Ph3 readouts in Q3 [----]. $TRML Phase [--] $CGEM Phase [--] $PMVP Phase [--] $IMVT Phase [--] $ATYR Phase [--] $ARCT Phase [--] $IONS Phase [--] $MLTX Phase [--] $QURE Phase 2/3 $ENTA Phase [--] $KALA Phase 2b $LTRN Phase [--] $LRMR Phase [--] $ENTX Phase [--] $KAPA Phase [--] $RAPP Phase 2a $MTSR Phase 2b $PRAX Phase [--] $ATAI Phase 2b $GRI Phase 2a $HRMY Phase [--] $CLNN Phase [--] $FBIO Phase [--] $UPB Phase [--] $LGVN Phase 2a $SKYE Phase 2a Check out the image for more details https://twitter.com/i/web/status/1962194015820116329 https://twitter.com/i/web/status/1962194015820116329"
X Link 2025-08-31T16:41Z 28.9K followers, 49.3K engagements
"🧬 Biotech Stock News 09/05 Brought to you by Barb [--] on the rise 📈 $ADAG 7% $HCM 6% $CGON 5% [--] under pressure 📉 $AMRX -1% $PALI -2% $DRUG -5% Catch the full breakdown in the latest video 🎥 🧬 Biotech Stock News 9/5 @ Open $ADAG 7% ADG126 Highlighted at CSCO Meeting $HCM 6% Clinical Data Presentation at CSCO $CGON 5% 24-month Durability and Tolerability Data $MLYS 3% Subgroup Analyses of Ph3 Trial $MLYS 3% Closing of $287.5M Offering $RGNX 2% 12-month Pivotal Data https://t.co/YAqey04vYz 🧬 Biotech Stock News 9/5 @ Open $ADAG 7% ADG126 Highlighted at CSCO Meeting $HCM 6% Clinical Data"
X Link 2025-09-05T21:06Z 28.9K followers, [----] engagements
"🧬 Biotech Stock News 09/09 Brought to you by Barb [--] on the rise 📈 $TRML 58% $TELO 12% $XLO 11% [--] under pressure 📉 $TXG -4% $CTXR -4% $RAPP -11% Catch the full breakdown in the latest video 🎥 📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer Data on Prostate Cells $XLO 11% Initiation of Phase [--] Trial $MBRX 8% Accelerates Recruitment in Phase [--] Trial $AGEN 6% Reimbursed Compassionate Access for BOT/BAL $DNTH 5% Proposed https://t.co/DgMLkXfIC7 📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer"
X Link 2025-09-09T17:25Z 28.9K followers, [----] engagements
"🧬 Biotech Weekly News 9/15/25 - 9/19/25 Major Movers 📈 $ETNB 85% Roche Acquires 89bio $NTLA 30% Enrollment in Ph3 Study Completed $NBTX 21% Ph1 Results for JNJ-1900 $HUMA 17% CTEV Preclinical Data Published $NKTR 15% New Data REZOLVE-AD Study 📉 $ATYR -83% Topline Data Ph3 Efzofitimod Study $REPL -39% Update Following Type A Meeting $RVPH -37% Pricing of $9M Public Offering $BCDA -24% Pricing of Up To $12M Offering $SPRB -21% Resumes Trading on Nasdaq ***** Roche buying 89bio $ETNB for $14.50/share + up to $6 CVR. Total deal value: $3.5B 💰 See our post below. Roche to acquire 89bio $ETNB"
X Link 2025-09-19T21:05Z 28.9K followers, 10.8K engagements
"📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral Presentations at WMS $AVXL 3% Successful Development of Oral Tablet $AVXL 3% Positive Topline Results from Phase [--] Study $GLPG 1% Update on Strategic Alternatives for Cell Therapy $ETNB 1% Commences tender offer for shares $WGS 1% First U.S. National Genomic Newborn Screening $ATXS 1% Enrolling HAE Patients for Phase [--] Trial $HCM 1% Clinical Data at ESMO Congress [----] $CATX 1% First Patient Dosed in Phase Study $TEM 0% Improved EHR-Integrated Breast Cancer Risk Assessment $SNY 0%"
X Link 2025-10-02T16:04Z 28.9K followers, 14.6K engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $LQDA Phase [--] $ATAI Phase 2b $INBX Phase [--] $SVRA Phase [--] $IDYA Phase [--] $IDYA Phase 2/3 $KYTX Phase [--] $VOR Phase [--] $JAGX Phase [--] $ALXO Phase [--] $PROK Phase [--] $VRCA Phase [--] $KZR Phase 2a $IFRX Phase 2a $IFRX Phase 2b $ELDN Phase [--] $OSTX Phase 2b $NKTR Phase 2b $RZLT Phase [--] $PVLA Phase [--] $ARGX Phase [--] $INCY Phase [--] $WVE Phase [--] $EWTX Phase [--] $RNAC Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $ANRO Phase [--] $PRAX Phase 2/3 $BHVN Phase [--] $COGT Phase [--] $ALKS Phase [--] $MRUS Phase [--] $MRUS Phase [--] $MRUS Phase 2"
X Link 2025-10-19T19:11Z 28.9K followers, 50.1K engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (3/3). $CALT Phase [--] $JAZZ Phase [--] $GNFT Phase [--] $NAMS Phase [--] $PBYI Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $LSTA Phase 2b $INKT Phase [--] $STOK Phase [--] $ADAG Phase [--] $PBYI Phase [--] $CNTA Phase 2a $RLMD Phase [--] $NAMS Phase [--] $ACLX Phase [--] $ELDN Phase [--] $BIVI Phase 2b $KPTI Phase [--] $CRVS Phase [--] Check out the image for more details https://twitter.com/i/web/status/1985069251166904456 https://twitter.com/i/web/status/1985069251166904456"
X Link 2025-11-02T19:39Z 28.9K followers, [---] engagements
"Avoro Capital 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 95.51% Qtr over Qtr Change**: 35.48% Top Holdings: $ASND $UTHR $MDGL $ARGX $KRYS $ARWR $KYMR $MRUS $RNA $APLS $CNTA $QURE $XENE $AKRO $VERA $SLNO $GPCR $TRML $OCUL $FOLD *Holdings as of 9/30/25 in SEC form 13F **Change in value of public company shares held See image for more details 👇 🚨 Hedge Fund Q3 holdings (13F) data drops tomorrow (11/14) We follow the top biopharma hedge funds. - capture their 13F data - & post it on our website Access our FREE biopharma hedge fund screener See comments below."
X Link 2025-11-14T16:23Z 28.9K followers, [----] engagements
"RA Capital 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 82.27% Qtr over Qtr Change**: 36.72% Top Holdings: $ASND (25.0%) $RYTM (7.1%) $PCVX (5.3%) $RNA (4.6%) $CDTX (4.0%) $SION (3.8%) $ETNB (3.6%) $NAMS (3.6%) $MLYS (3.4%) $JANX (3.4%) $ACLX (3.1%) $LENZ (2.4%) $TYRA (2.1%) $EWTX (2.1%) $WVE (1.6%) $SEPN (1.6%) $DNTH (1.4%) $BCAX (1.4%) $GHRS (1.4%) $SPRY (1.3%) *Holdings as of 9/30/25 in SEC form 13F *Change in value of public company shares held See image for more details 👇 EcoR1 Capital 🔔 🐳 Q3 25 Holdings Released Holdings: [--] Holdings in Top 20: 96.89% Qtr over"
X Link 2025-11-14T22:38Z 28.9K followers, [----] engagements
"Baker Brothers Advisors 🔔 🐳 Q3 25* Holdings Released Holdings: [--] Holdings in Top 20: 89.01% Qtr over Qtr Change**: 34.25% Top Holdings: $ONC (22%) $INCY (19%) $MDGL (7.1%) $INSM (7%) $ACAD (6.6%) $SMMT (5%) $RYTM (4.1%) $RVMD (3.2%) $CELC (2.8%) $KYMR (2.7%) $KOD (2%) $ALKS (1.8%) $ABCL (1%) $EWTX (0.9%) $KNSA (0.8%) $STOK (0.8%) $IMTX (0.7%) $GRAL (0.7%) $IDYA (0.6%) $IMVT (0.6%) Holdings as of 9/30/25 in SEC form 13F Change in value of public company shares held OrbiMed Advisors 🔔 🐳 Q3 25 Holdings Released Holdings: [---] Holdings in Top 20: 59.98% Qtr over Qtr Change: 6.28% Top"
X Link 2025-11-14T23:19Z 28.9K followers, 20.4K engagements
"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 11/21/25 📈 $RPTX 32% XenoTherapeutics to acquire $RPTX $ANVS 29% New Biomarker Data on Cognitive Decline $ZYME 29% Positive Ph3 Results for HER2 Agent $VNDA 22% Tradipitant Results Reported $CTXR 15% Advance Commercial Launch with AI 📉 $AGIO -51% Topline Results RISE UP Trial $KTTA -30% Ph1 Data for PAS-004 $HCWB -21% HCW9302 FIH trial Initiation $PHGE -16% 1-for-19 Reverse Stock Split $ENSC -12% FDA Feedback on PF614 See image below. ***** $AGIO sat under $23 this week. See @seedy19trons post for why its being"
X Link 2025-11-21T22:59Z 28.9K followers, [----] engagements
"🧬 Biotech Stock News 12/01 @ Open $QTTB 146% Sells Complement Inhibitor ADX-097 $MAIA 16% Open Market Purchases by CEO & Directors $BLTE 5% Positive Results from Phase [--] Trial $PMN 4% New Publication on Plasma pTau in Alzheimer's $RDHL 3% Regains Compliance with Nasdaq $OMER 2% Closing of Asset Purchase Agreement $AAPG 0% Webcast Highlighting Key Data from ASH [----] $BMY 0% Data Showcase Hematology Pipeline Potential $VTRS 0% Seeking Partnerships for Long-Acting Depot Drugs $MIRM 0% First Patient Enrolled in BLOOM Study $MNKD -1% FDA Review of FUROSCIX Autoinjector $BCDA -1% Present at Heart"
X Link 2025-12-01T15:51Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 12/3 @ Open $CAPR 246% Deramiocel Topline Results Reported $PHVS 17% Deucrictibant Topline Data Reported $TARA 8% TARA-002 Interim Data Reported $KURA 7% Virtual Investor Event on AML Data $CRNX 6% First Patient Dosed in Trial $CGTX 6% Zervimesine Full Enrollment Reached $RLMD 5% Presentation of NDV-01 Ph2 Data $BMY 5% Continuation of ADEPT-2 Ph3 Study $PYPD 5% D-PLEX FDA Pre-NDA Meeting Minutes $IXHL 4% FDA Fast Track for IHL-42X $XENE 3% Webinar on Azetukalner & Epilepsy Data $GLSI 3% Global Update on FLAMINGO-01 $BCRX 2% Early Termination of HSR Waiting Period $STRO"
X Link 2025-12-03T16:14Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $STOK Phase [--] $HRMY Phase [--] $RXRX Phase [--] $XCUR Phase [--] $IMMP Phase 2/3 $PVLA Phase [--] $LTRN Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $INSM Phase [--] $KMDA Phase [--] $MREO Phase [--] $RHHBY Phase [--] $TRAW Phase [--] $RARE Phase [--] $GPCR Phase 2b $ZBIO Phase [--] $SLS Phase [--] $MGTX Phase [--] $IDYA Phase 2/3 $DWTX Phase 2b $WVE Phase [--] $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $DBVT Phase [--] $VTGN Phase [--] $INBX Phase 2/3 $LSTA Phase 2a $ADVM Phase [--] $ALT Phase 2b $ACIU Phase [--] $RYTM Phase [--] $ATOS Phase 2"
X Link 2025-12-07T21:27Z 28.9K followers, 60.1K engagements
"📣 Biotech Stock News 12/08 @ Open $WVE 124% Positive Interim Data from INLIGHT Trial $GPCR 86% Positive Topline Data from ACCESS Program $IMMP 58% Strategic Collaboration for Oncology Drug $KYMR 47% Positive Results from Phase 1b Trial $OCUL 25% Accelerate NDA Submission Timeline for AXPAXLI $DYN 16% Positive Topline Results from DELIVER Trial $ARWR 13% Phase 1/2a Study of ARO-MAPT $CHRS 10% JUPITER-02 Follow-up Results Show Survival Increase $PRME 10% Publication of PM359 Clinical Data $PRAX 7% Best-in-Class Potential in Epilepsies $GLSI 6% Completion of Enrollment in FLAMINGO-01 $ABEO 5%"
X Link 2025-12-08T17:06Z 28.9K followers, 14.5K engagements
"📌 Biotech Stock News 12/10 @ Open $TERN 10% $650M Offering $DYN 9% $350M Public Offering $BRNS 3% VTP-1000 Trial Update $MDWD 3% Clinical Data on NexoBrid's Effectiveness $GPCR 3% Pricing of $650M Offering $SGMT 2% Denifanstat NDA Accepted by China NMPA $PTCT 1% Health Canada Approves Sephience $ALC 1% Response to Increased Acquisition Price $LXRX 1% ACSL5 Preclinical Data Publucation $PFE 1% TUKYSA Extends Survival 8mths $LLY 1% Build $6B facility in Alabama $KYMR 0% $602M Offering $AMRX 0% Epinephrine Injection FDA Approval $NCNA -1% NUC-7738 Latest Data $PRAX -1% Elsunersen Accelerated"
X Link 2025-12-10T16:32Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $LTRN Phase [--] $NKTR Phase 2b $PVLA Phase [--] $ARGX Phase [--] $INCY Phase [--] $ROIV Phase [--] $GLPG Phase [--] $BHVN Phase [--] $GNLX Phase [--] $VALN Phase [--] $IMCR Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV Phase 2a $DWTX Phase 2b $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $DBVT Phase [--] $VTGN Phase [--] $INBX Phase 2/3 $LSTA Phase 2a $ADVM Phase [--] $ALT Phase 2b $ATOS Phase [--] $INSM Phase [--] $MREO Phase [--] $RHHBY Phase [--] $TRAW Phase 2"
X Link 2025-12-14T20:12Z 28.9K followers, 58.1K engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (2/2). $IONS Phase [--] $REGN Phase 2/3 $CALT Phase [--] $GNFT Phase [--] $NAMS Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $INKT Phase [--] $ADAG Phase [--] $CNTA Phase 2a $NAMS Phase [--] $BIVI Phase 2b $CRVS Phase [--] Check out the image for more details https://twitter.com/i/web/status/2000297805605482863 https://twitter.com/i/web/status/2000297805605482863"
X Link 2025-12-14T20:12Z 28.9K followers, [---] engagements
"December Biotech PDUFA Update 📡 Whats on the FDA radar Approved (7) $AXGN - Avance Nerve Graft $BMY - Breyanzi (lisocabtagene maraleucel) $GSK - BLUJEPA (gepotidacin) $BCRX - ORLADEYO Oral Granules $MIST - CARDAMYST (etripamil) nasal spray $INVA - NUZOLVENCE (zoliflodacin) $GSK - Exdensur (depemokimab) severe eosinophilic asthma only) Extended (3) $AGIO - PYRUKYND (mitapivat) - timeline TBD $ALDX - Reproxalap - extended to Mar [--] [----] $SNY - Tolebrutinib - extended to Q1 [----] Pending FDA Decisions (8) $OMER - Narsoplimab (OMS721) $CYTK - Aficamten $CORT - Relacorilant $VNDA - Tradipitant"
X Link 2025-12-17T20:06Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 12/23 @ Open $IMRX 9% 12-Month Survival Data for Atebimetinib $ATAI 7% Added to Nasdaq Biotechnology Index $IVVD 4% Fast Track Designation for VYD2311 $IVVD 4% Initiation of DECLARATION Clinical Trial $LIXT 2% Expand Clear Cell Ovarian Cancer Trial $PBYI 2% Added to NASDAQ Biotechnology Index $COYA 1% COYA [---] ALSTARS Trial Acceptance $REGN 1% Dupixent approved for children in Japan $REGN 1% Dupixent Approved for Children with Asthma $AMRX 0% FDA Approval of Denosumab Biosimilars $RLFTF 0% Global Approach to Reimbursement $NBIX 0% Update on Valbenazine Phase [--] Study"
X Link 2025-12-23T15:58Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 12/24 @ Open $OMER 65% FDA Approves YARTEMLEA for TA-TMA $DVAX 39% Sanofi to Acquire Dynavax $EWTX 23% Completion of EDG-7500 Ph2 Study $RPTX 19% Acquisition of RP-3467 for $30M $AGIO 16% FDA Approves AQVESME for Anemia $DRMA 13% Up to $12.4M Private Placement $JANX 1% Program Update on Ph1 JANX008 M&A watch 👀 Great breakdown by @PersimmonTI on $SNY's acquisition of $DVAX: Adds a marketed Hep B vaccine + a promising shingles candidate Strengthens $SNY's vaccines pipeline & commercial footprint 💉📈 See the image and comments for more details 👇 $XBI $SNY to acquire"
X Link 2025-12-24T16:17Z 28.9K followers, [----] engagements
"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 12/26/25 📈 $OMER 76% FDA Approves YARTEMLEA for TA-TMA $DVAX 38% Sanofi to Acquire Dynavax $EWTX 25% Completion of EDG-7500 Ph2 Study $AGIO 19% FDA Approves AQVESME for Anemia $RPTX 18% Acquisition of RP-3467 for $30M 📉 $RVPH -46% Regulatory Update on Brilaroxazine $DWTX -25% Reported Ph2b Trial Results $ASRT -10% 1-for-15 Reverse Stock Split $PHIO -6% Step Forward in PH-762 Development $AGEN -6% Durable Responses in Ovarian Cancer See image below. $OMER announces FDA approval of YARTEMLEA (narsoplimab-wuug) 🧬 ✅"
X Link 2025-12-26T23:23Z 28.9K followers, [----] engagements
"🧬 Biopharma Weekly Recap 📝 This week in biotech: Bullish sentiment builds as FDA approvals hit [--] M&A chatter and options flow heat up obesity cash-pay shifts accelerate and a dense [----] catalyst calendar refocuses attention on data. @seedy19tron Saved the best for last - $SLNO: Bulletproof bull case (as promised) @LifeSciVC Biotech sentiment improves as cycle turns upward. @DrSamuelBHume [--] new medicines approved in [----] spanning first-in-disease and next-generation therapies. @NatRevDrugDisc FDA approves [--] new drugs in [----] despite regulatory turbulence. @BiopharmIQ Ph2 & Ph3 readouts in"
X Link 2026-01-03T15:51Z 28.9K followers, 21.4K engagements
"How many of the [--] biopharma hedge funds have positions in any of the tickers mentioned above 🤔 Based on latest Q3 [--] data 📊 $ABVX 18/36 🔥 $PEPG 14/36 🔥 $QURE 12/36 🔥 $SLNO 9/36 🔥 Access our FREE screener to check your fave stocks 👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-01-03T15:51Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist 📈 Ph2 & Ph3 readouts in Q1 [----] $ACTU Phase [--] $TRAW Phase [--] $DRUG Phase [--] $KOD Phase 2b $GOSS Phase [--] $AVBP Phase [--] $AGIO Phase 2b $IOVA Phase [--] $CRNX Phase [--] $CALC Phase [--] $BIVI Phase 2b $CRVS Phase [--] $KPTI Phase [--] $ALMS Phase [--] $IMMP Phase [--] $TBPH Phase [--] $VRDN Phase [--] $OCUL Phase [--] $QNCX Phase [--] $NMRA Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $PVLA Phase [--] $LSTA Phase 2b $NKTR Phase 2b $INSM Phase 2b $CADL Phase 2a $CMPX Phase 2/3 $IDYA Phase 2/3 $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $ANRO Phase [--] $PEPG Phase [--] $CLDX Phase [--] $NVCR Phase [--] $ZBIO"
X Link 2026-01-04T18:08Z 28.9K followers, 71.8K engagements
"📌 Biotech Stock News 1/9 @ Open $CGON 21% Updated Timeline for PIVOT-006 Data $PDSB 15% FDA Alignment on PFS as Endpoint $IBIO 14% $26M Private Placement $QURE 14% Type A Meeting Scheduled with FDA $KRYS 5% Positive Interim Clinical Update on KB407 $MPLT 3% Topline Results Timing Update $CATX 2% 212PbVMT--NET Updated Interim Data $INKT 2% Ph1 Trial of AgenT-797 $ATHA 1% Name Change to LeonaBio Inc. $CLNN 1% Registered Direct Offering Over $28M $CRIS 0% Closing of Private Placement $LLY 0% Taltz & Zepbound show superior efficacy $ASND 0% COACH Trial Results in Achondroplasia $EBS 0% Delivery"
X Link 2026-01-09T16:31Z 28.9K followers, [----] engagements
"1/ 📣 Biotech Stock News 01/12 @ Midday $BEAM 26% Strategic Priorities for Genetic Disease $DAWN 19% Preliminary [----] OJEMDA Revenue Guidance $BIOA 13% Positive Phase [--] Data for BGE-102 $MREO 11% Corporate Update $OCGN 9% Publication of Phase [--] GARDian1 Results $BMEA 6% Executing Icovamenib and BMF-650 Milestones $LPCN 5% Progress in LPCN [----] Phase [--] Trial $RGNX 5% Positive outcomes in Duchenne therapy $AMPH 5% Exclusive License for Synthetic Corticotropin $AGEN 5% Expands AAC Access for Botensilimab $CABA 5% [----] Strategic Priorities $CABA 5% IND Amendment Clearance for Rese-Cel $ORKA 4%"
X Link 2026-01-12T17:14Z 28.9K followers, [----] engagements
"2/ 📣 Biotech Stock News 01/12 @ Midday $DTIL 0% Strategic Priorities for [----] $BMY 0% Positive results from SCOUT-HCM trial $ABBV 0% Exclusive Licensing for Bispecific Antibody $KNSA 0% Corporate Update $ABBV 0% Acquire Arizona Manufacturing Facility $SRRK -1% Highlights [----] Strategic Priorities $NTRA -1% Scale AI in Precision Medicine $BNTC -1% Positive results for BB-301 trial $CASI -1% Update on CID-103 Phase [--] Study $RLMD -1% Regulatory update on NDV-01 $IRON -1% Recent Achievements and Objectives for [----] $ORIC -1% Operational Highlights and Milestones $VKTX -1% Results from Phase 2"
X Link 2026-01-12T17:14Z 28.9K followers, [---] engagements
"3/ 📣 Biotech Stock News 01/12 @ Midday $PRAX -5% Next Chapter Following Pivotal Year $LTRN -5% A.I. Center for RADR Platform $SLDB -5% First participant dosed in FALCON Trial $RIGL -5% Business Update and [----] Outlook $BCAX -6% Phase [--] Optimal Dose Announcement $NUVL -6% OnTarget [----] Plan Progress $ARQT -6% [----] Strategic Priorities and Milestones $TARA -6% Recent Updates and [----] Milestones $ANTX -8% FDA Clearance for Epetraborole Trial $AKBA -9% Corporate Updates and [----] Pipeline Outlook $ERAS -11% Early Clinical Data for ERAS-0015 $KPTI -12% Preliminary [----] Revenue and Phase [--] Data"
X Link 2026-01-12T17:14Z 28.9K followers, [---] engagements
"#JPM2026 Day [--] 👉 Free access to the JPM [----] conference calendar in the comments 🗓 $XBI SMID-cap biopharmas with commercial/marketed drugs presenting today: $ACAD $ALKS $HRMY $TGTX $JAZZ $ZLAB $AMRX $CHRS *** $BBIO #JPM26 #ATTRUBY key nuggets. Momentum building See @semodough for details from yesterdays presentation. 👇 $BBIO #JPM26 #ATTRUBY KEY NUGGETS solid performance appears to be driven by an acceleration in momentum of new patient adds (1370 new Rxs between last Oct 29th data-cut and Dec 31st = [---] new patients added per week (vs previous updates in the [---] new Rx per week range))."
X Link 2026-01-13T13:45Z 28.9K followers, [----] engagements
"$UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] Why verekitug is different Only clinical-stage TSLPR antagonist; fully human IgG1 enabling durable pathway blockade. Prior signal (VIBRANT Ph2 + Ph1 MAD) Ph2 met primary (NPS [---] p0.0001); key [--] incl. NCS [---] + 76% surgery/steroids Well tolerated; no SAEs Sustained TSLPR occupancy w/ FeNO & eos suppression up to 24w post-dose 4/7 https://twitter.com/i/web/status/2011123518633885713 https://twitter.com/i/web/status/2011123518633885713"
X Link 2026-01-13T17:09Z 28.9K followers, [---] engagements
"$IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / Non-small cell lung carcinoma (1L NSCLC) / Phase [--] Why efti is different Activates APCs via MHC Class II and is positioned as complementary to ICIs like KEYTRUDA. Prior signal (Ph2 TACTI-002/KEYNOTE-798) ORR: 31.3% / 44.7% / 55.0% by PD-L1 TPS (1% / 1-49% / 50%) mPFS: [---] / [---] / [----] mo; mOS: [----] / [----] / NR 5/7 https://twitter.com/i/web/status/2011123522463285359 https://twitter.com/i/web/status/2011123522463285359"
X Link 2026-01-13T17:09Z 28.9K followers, [---] engagements
"$KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR (NPDR) / Phase [--] Why tarcocimab is different Anti-VEGF ABC biologic engineered for high immediacy + long durability in the same therapy (unconjugated pulse + conjugated maintenance). Prior signal (Ph3 GLOW1 in DR) 2-step DRSS improvement @ W48: 41% vs [--] 90% risk reduction in pre-specified sight-threatening complications Potential for [--] doses/year after initiating doses 6/7 https://twitter.com/i/web/status/2011123526175232499 https://twitter.com/i/web/status/2011123526175232499"
X Link 2026-01-13T17:09Z 28.9K followers, [---] engagements
"$APGE (Q1 2026) Zumilokibart (APG777) / Atopic dermatitis / Phase [--] Why APG777 is different Anti-IL-13 built for long-interval maintenance dosing (Q12W-Q24W) targeting just 2-4 injections/yr vs 26/yr for DUPIXENT. Prior signal (APEX Part A W16) EASI-75: 66.9% vs 24.6% PBO ( 42.5) IGA 0/1: 31.8% vs 6.0% ( 25.8) Rapid itch relief within 48h 7/7 https://twitter.com/i/web/status/2011123529765548373 https://twitter.com/i/web/status/2011123529765548373"
X Link 2026-01-13T17:09Z 28.9K followers, [----] engagements
"January [----] Biotech PDUFA Update 📡 Whats on the FDA radar Recent Outcomes: $ATRA tab-cel (EBV+ PTLD) CRL $TVTX FILSPARI (FSGS) Extended 4/13/26 $FBIO ZYCUBO (copper histidinate) Approved Pending FDA Decisions: Jan [--] $AQST Anaphylm (Anaphylaxis) No AdCom Jan [--] $PHAR Joenja Pediatric APDS Priority Review See attached graphic for full January PDUFA calendar. January [----] Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Jan [--] $ATRA tab-cel (EBV+ PTLD) Priority Review Jan [--] $TVTX FILSPARI (FSGS) no AdCom Jan [--] $FBIO CUTX-101 (Menkes) Class [--] resubmission Jan [--] $AQST Anaphylm (anaphylaxis) no"
X Link 2026-01-15T15:51Z 28.9K followers, 23.1K engagements
"#JPM2026 Takeaways 💼 This week in biotech: JPM sparks cautious optimism as funding rebounds AI and obesity pipelines advance late-stage readouts stack up and Big Pharma signals renewed M&A urgency. See interesting posts/ppl to check out 👇 @zerohedge JPMorgan No Longer Expects Fed Rate Cut Predicts Hike in [----] @Biotech2k1 Post JPM Biotech Report @seedy19tron JPM Day [--] takeaway: DAWN Q4 beat shifts launch narrative; pLGG monopoly asset screens undervalued. @mathlonning $TMDX JPM HEALTHCARE CONFERENCE NOTES @ky_lahucik JPM setup: biotech funding surges pre-conference as private and public"
X Link 2026-01-16T16:04Z 28.9K followers, [----] engagements
"How many of the [--] biopharma hedge funds have positions in any of the tickers mentioned above that presented at #JPM26 🤔 Based on latest Q3 [--] data 📊 $INSM 8/36 🔥 $BBIO 6/36 🔥 $VKTX 6/36 🔥 $LQDA 4/36 $TMDX 0/36 🧊 Access our FREE screener 👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-01-16T18:41Z 28.9K followers, [----] engagements
"(March [--] 2026) KRESLADI (marne-cel; RP-L201) / Severe LAD-I / PDUFA Why KRESLADI is different One-time autologous LV gene-corrected HSC tx designed to restore CD18 & reconstitute immune function (potentially curative). Prior signal (pivotal LAD-I study) 9/9 survival w/ no graft failure; no drug-related SAEs 10% PMN CD18 expression at 1yr across cohort 100% HSCT-free survival + meaningful reduction in infection-related hospitalizations 3/7"
X Link 2026-01-16T22:48Z 28.9K followers, [---] engagements
"$UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] Why verekitug is different Only clinical-stage TSLPR antagonist; fully human IgG1 enabling durable pathway blockade. Prior signal (VIBRANT Ph2 + Ph1 MAD) Ph2 met primary (NPS [---] p0.0001); key [--] incl. NCS [---] + 76% surgery/steroids Well tolerated; no SAEs Sustained TSLPR occupancy w/ FeNO & eos suppression up to 24w post-dose 4/7 https://twitter.com/i/web/status/2012295999583305747 https://twitter.com/i/web/status/2012295999583305747"
X Link 2026-01-16T22:48Z 28.9K followers, [---] engagements
"$IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / Non-small cell lung carcinoma (1L NSCLC) / Phase [--] Why efti is different Activates APCs via MHC Class II and is positioned as complementary to ICIs like KEYTRUDA. Prior signal (Ph2 TACTI-002/KEYNOTE-798) ORR: 31.3% / 44.7% / 55.0% by PD-L1 TPS (1% / 1-49% / 50%) mPFS: [---] / [---] / [----] mo; mOS: [----] / [----] / NR 5/7 https://twitter.com/i/web/status/2012296011058921477 https://twitter.com/i/web/status/2012296011058921477"
X Link 2026-01-16T22:48Z 28.9K followers, [---] engagements
"$KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR (NPDR) / Phase [--] Why tarcocimab is different Anti-VEGF ABC biologic engineered for high immediacy + long durability in the same therapy (unconjugated pulse + conjugated maintenance). Prior signal (Ph3 GLOW1 in DR) 2-step DRSS improvement @ W48: 41% vs [--] 90% risk reduction in pre-specified sight-threatening complications Potential for [--] doses/year after initiating doses 6/7 https://twitter.com/i/web/status/2012296023776051696 https://twitter.com/i/web/status/2012296023776051696"
X Link 2026-01-16T22:48Z 28.9K followers, [---] engagements
"$APGE (Q1 2026) Zumilokibart (APG777) / Atopic dermatitis / Phase [--] Why APG777 is different Anti-IL-13 built for long-interval maintenance dosing (Q12W-Q24W) targeting just 2-4 injections/yr vs 26/yr for DUPIXENT. Prior signal (APEX Part A W16) EASI-75: 66.9% vs 24.6% PBO ( 42.5) IGA 0/1: 31.8% vs 6.0% ( 25.8) Rapid itch relief within 48h 7/7 https://twitter.com/i/web/status/2012296036036001880 https://twitter.com/i/web/status/2012296036036001880"
X Link 2026-01-16T22:48Z 28.9K followers, [----] engagements
"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 01/16/26 📈 $IBRX 34% Durable response w/ CD19 CAR-NK therapy $BIOA 27% Positive Phase [--] Data for BGE-102 $DAWN 27% Prelim. [----] OJEMDA Revenue Guidance $BEAM 22% Strategic Priorities for Genetic Disease $OCGN 19% Publication of Ph1 GARDian1 Results 📉 $ATRA -57% Regulatory & Business Update on EBVALLO $LYRA -45% Corporate Update $PSTV -38% Pricing of $15M Offering $LXEO -23% Phase 1/2 Data for LX2020 $AGEN -21% Advance BOT+BAL & Manufacturing Readiness See image below. $IBRX Announces Durable Complete Response of 15"
X Link 2026-01-17T12:09Z 28.9K followers, [----] engagements
"🧬 Clinical & guidance headlines drove biotech this week: $IBRX $BIOA $OCGN positive clinical updates $DAWN $BEAM strategic/guidance catalysts $PSTV $LYRA offerings & corporate resets $ATRA $LXEO $AGEN regulatory/data pressure https://twitter.com/i/web/status/2012497605180420151 https://twitter.com/i/web/status/2012497605180420151"
X Link 2026-01-17T12:09Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 01/20 @ Open $CRVS 103% Positive data for Soquelitinib trial $IBRX 20% Regulatory Discussions on ANKTIVA $MAIA 16% Advances Ateganosine Cancer Treatment Program $BTAI 8% Supplemental Drug Application for IGALMI $NVAX 4% Entering License Agreement $BOLD 4% Advances Kinesin Degrader Program BBI-940 $THAR 3% Pricing of $55 Million Offering $COGT 3% NDA Submission for Bezuclastinib $BIOA 2% Indication Expansion for BGE-102 $LTRN 1% LP-284 Receives FDA Orphan Designation $RHHBY 1% Doubles Investment in Manufacturing Facility $QNRX 0% Breakthrough Medicine Designation for"
X Link 2026-01-20T16:50Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 1/21 @ Open $LSTA 86% To be Acquired by Kuva Labs $LXRX 12% Successful End-of-Ph2 for Pilavapadin $ARTV 6% Presentations on AlloNK cost-effectiveness $SCYX 5% FDA Designations for SCY-247 $ALGS 5% Ph2 B-SUPREME Study Updates $ENGN 4% Expanded $125M Debt Facility $CRVS 4% Proposed Public Offering and Warrants $ENTX 3% Upcoming Q1 [----] Priorities and Outlook $ACTU 3% Expand Clinical Pipeline for Elraglusib $ALC 3% Completes $750M Share Repurchase $GSK 1% Second Exit from Growth Fund III $IONS 1% Donidalorsen approved in EU for HA $XCUR 1% Data from Burixafor Ph2 Trial"
X Link 2026-01-21T15:42Z 28.9K followers, [----] engagements
"🧬 Biotech M&A Is Back M&A roars back as $GSK buys $RAPT premiums surge across microcaps deal rumors swirl and sentiment-driven valuations reshape the $XBI landscape. See interesting posts/ppl to check out 👇 @LifeSciVC $RAPT acquired by GSK for $2.2B ($58/share) after late-stage pivot to anti-IgE allergy asset. @seedy19tron $RAPT surges on $GSK deal as biotech M&A re-emerges post-JPM; focus shifts to $XBI and new takeout speculation. @A_May_MD $ABVX M&A chatter debated as unusual call buying fuels questions around La Lettre reporting credibility. @RNAiAnalyst Macro tailwinds favor biotech"
X Link 2026-01-22T20:26Z 28.9K followers, [----] engagements
"📢 M&A News: $BCRX Completes Acquisition of Astria Therapeutics $700M Implied transaction value Adds navenibart for HAE Expands portfolio to oral (ORLADEYO) + injectable prophylaxis options Acquires early-stage atopic dermatitis program STAR0310 (strategic alternatives planned) See images for more details 👇 📢 M&A News: $LSTA to be Acquired by Kuva Labs $4.00/sh all-cash tender offer + [--] CVRs ($1.00 each) up to 180% premium CVRs tied to certepetide milestones (China rights reversion + NDA filing) Lead asset certepetide: solid tumors Fast Track + Orphan designations https://t.co/ulcmwMXwhb 📢"
X Link 2026-01-23T16:48Z 28.9K followers, [----] engagements
"🧬 Biopharma Weekly Recap 📝 This week in biotech: JPM buzz fuels M&A chatter AI drug discovery credibility rises GLP-1/oral obesity data accelerates stock-specific volatility and infrastructure gaps dominate sentiment. See interesting posts/ppl to check out 👇 @m_goes_distance Biotech VC overcrowded in therapeutics; infrastructure remains underfunded. @Mr_Derivatives $SMMT trades below insider buy level; M&A optionality cited. @Prof_Oak_ Scattered compilation of between-the-lines tidbits that stood out amongst the thousands of JPM slides ingested last week $XBI @yaireinhorn Prime Medicine's"
X Link 2026-01-24T16:35Z 28.9K followers, 12.8K engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $ASND: TransCon CNP PDUFA $NKTR: Rezpegaldesleukin (NKTR-358) Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-24T16:35Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $PEPG PGN-EDODM1 $ANRO ALTO-101 $TBPH Ampreloxetine Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-25T19:38Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 01/26 @ Open $SRPT 9% Positive EMBARK Results for ELEVIDYS $LGVN 4% FDA Grants Type C Meeting $NERV 3% Discussing Roluperidone for Schizophrenia $COGT 1% Breakthrough Therapy Designation for Bezuclastinib $MIST 1% U.S. Availability of CARDAMYST Nasal Spray $TRAW 1% Enrollment of Ratutrelvir Clinical Study $MNKD 1% FDA Approves Updated Afrezza Label $GRI 1% New U.S. Patent for Novel Compounds $ZVRA 1% Present Analyses on MIPLYFFA $NTRA 1% Landmark Study Advancing Lung Transplant $UTHR 1% Positive results from miroliverELAP study $BMRN 0% Proposed Private Offering of Notes"
X Link 2026-01-26T15:07Z 28.9K followers, [----] engagements
"🧬 Biotech Conviction Board: [----] High-conviction longs to watch analyst top picks oral immunology momentum AI platforms and catalyst-loaded setups. $XBI $IBB See interesting posts/ppl to check out 👇 🔥 High Conviction @A_May_MD $TENX Underfollowed Biotech With [----] Catalyst Not an Official Pitch @princetongb #biopick2026 contest pick Kyverna Therapeutics $KYTX. @seedy19tron $Abvx (Long) Ph3 topline for Obe coming up. Exp early to mid Aug @WassimLaroussi3 Why $APGE is my number [--] pick in this race @Biotech2k1 My top pick is $PTGX as they are making oral forms of all these IL drugs."
X Link 2026-01-29T18:42Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🚨 Likely to move the stock +/- by 20% $AQST: Anaphylm (dibutepinephrine) sublingual film PDUFA $KOD: KSI-101 Ph2b $APGE: APG777 Ph2 Access our FREE Big Mover Report below 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-29T18:42Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/3 @ Open $PRLD 15% FDA Clearance for PRT12396 $IVVD 6% Ph3 Trial for VYD2311 $RLAY 5% Breakthrough Tx Desig for Zovegalisib $TOVX 4% Presentation of VCN-01 data $ATYR 3% Scheduling FDA Meeting for Efzofitimod $MGTX 2% Exclusive License for AAV Gene Therapy $RARE 2% Positive data for UX111 gene therapy $HOOK 1% Sale of Oncology Assets $VTRS 1% New data from Glatiramer Acetate $MIRA 1% Final Cohort of Ketamir-2 Study $AZN 1% Priority Review for datopotamab deruxtecan $ABBV 0% Regulatory Applications for Upadacitinib $ARDX 0% New Patent for Tenapanor $APLT 0% Cycle Pharma"
X Link 2026-02-03T16:17Z 28.9K followers, [----] engagements
"💰 Cycle Group acquired $APLT Adds govorestat a CNS-penetrant ARI Expands into rare metabolic & CNS diseases Strengthens long-term orphan drug pipeline Check out our free biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun"
X Link 2026-02-03T16:17Z 28.9K followers, [----] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-03T16:17Z 28.9K followers, [---] engagements
"Check out our FREE biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun"
X Link 2026-02-03T16:50Z 28.9K followers, [----] engagements
"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175 Million Offering $ROIV 22% Mosliciguat & Brepocitinib Trial Updates $RNAZ 16% IND Amendment for Phase 2a Trial $PRLD 13% FDA Clearance for PRT12396 📉 $ANEB -39% Intention to Voluntarily Delist $SGMO -32% Pricing of $25 Million Offering $ADIL -26% Advancing Clinical Trial Endpoints $PHAR -17% Complete Response Letter for Joenja $SXTP -12% Expands Access to ARAKODA See image below. *** Decoding AQSTs clean CRL and the FDAs endgame for"
X Link 2026-02-07T10:58Z 28.9K followers, [----] engagements
"🧬 Weekly & YTD Biotech Moves Week ending 02/06/26 $XBI: 0.61% ($125.51) 🟢 $IBB: 1.48% ($174.98) 🟢 Year-to-date $XBI: 2.94% 🟢 $IBB: 3.68% 🟢 See image below. 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175 Million Offering $ROIV 22% Mosliciguat & Brepocitinib Trial Updates $RNAZ 16% IND Amendment for Phase 2a Trial $PRLD 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/06/26 📈 $AQST 39% FDA Issues Complete Response Letter $CATX 34% Pricing of $175"
X Link 2026-02-07T11:06Z 28.9K followers, [----] engagements
"Try BPIQ API Free Get catalyst & pipeline data integrate seamlessly craft custom spreadsheets 📊 🔑 Premium API access unlocks - Full platform access - Updated catalysts/pipeline data - Historical data for robust testing Check link below 👇 https://www.bpiq.com/bpiq-api https://www.bpiq.com/bpiq-api"
X Link 2026-02-07T11:06Z 28.9K followers, [----] engagements
"$EVMN up 53% 📈 Ph2a of EVO301hit primary endpoint in AD Fast EASI improvements vs placebo (W4 W8 W12) Moving into Phase 2b dose-range trial Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-10T16:12Z 28.9K followers, [----] engagements
"6 Stocks Likely to Move Big in Q1 [--] See 🧵 for more details about each asset/readout: $RGNX (February [--] 2026) Clemidsogene lanparvovec (RGX-121) / Hunter syndrome (MPS II) / PDUFA $RCKT (March [--] 2026) KRESLADI (RP-L201) / Severe LAD-I / PDUFA $UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] $IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / 1L NSCLC) / Phase [--] $KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR / Phase [--] $APGE (Q1 2026) APG777 / Atopic dermatitis / Phase [--] 1/7 https://twitter.com/i/web/status/2012295963503902944 https://twitter.com/i/web/status/2012295963503902944"
X Link 2026-01-16T22:48Z 28.9K followers, 107.4K engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $KOD Phase 2b $MDNAF Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP Phase [--] $PVLA Phase [--] $ARQT"
X Link 2026-02-01T19:57Z 28.9K followers, 105.7K engagements
"📌 Biotech Stock News 2/4 @ Open $ONCY 16% FDA Fast Track for Pelareorep $CPIX 7% FDA Fast Track for Ifetroban $BMY 2% Multi-Year Commercial Supply Agreement $ENTX 1% Advance Oral Long Acting PTH Tablet $INKT 1% New data on allo-iNKT Cell Therapy $SRPT 1% Approval of Clinical Trial for SRP-1005 $TEVA 1% Approval of AJOVY for Pediatric Migraine $ACLX 0% Late-Breaking Presentation on anito-cel $KOD -1% Final Ph1b Results for KSI-101 $CRBU -2% ASTCT and CIBMTR Presentations $SGMO -2% Data from STAAR Study in Fabry $IMUX -3% Ph2 CALLIPER Trial Data $ZVRA -3% Positive data on MIPLYFFA in NPC $ADIL"
X Link 2026-02-04T15:40Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 02/12 @ Open $NVCR 29% FDA Approves Optune Pax for Cancer $BBIO 9% Positive Phase [--] Results for Infigratinib $ANVS 6% DSMB Approval for Buntanetap Trial $TECX 5% Discussion of TX2100 for treatment $ANL 4% First Patient Enrolled in AN9025 Trial $NKTR 2% Pricing of $400 Million Offering $PCRX 1% New NOPAIN Act Survey Data $MRK 0% Advances in Bladder and Kidney Cancer $XLO 0% Pricing of Underwritten Offering $LYEL 0% Initiation of Patient Dosing $PCVX -1% Doses First Participants in OPUS-3 Trial $APRE -1% Strengthens Global Patent Portfolio $BTAI -2% Advances"
X Link 2026-02-12T15:40Z 28.9K followers, [----] engagements
"6/ 👉 What this means: Our hedge-fund favorites framework has worked across start dates and market regimes This is not a one-off result. Its sustained outperformance across portfolios"
X Link 2026-02-12T19:34Z 28.9K followers, [---] engagements
"📢 M&A News: Novartis ($NVS) to acquire Tourmaline Bio ($TRML) 💵 $48/sh in cash ($1.4B FD) closing expected Q4 [----] 🔬 Adds pacibekitug (anti-IL-6 mAb) Ph3-ready targeting ASCVD Ph2 data: 8586% hs-CRP reduction; safety comparable to placebo; convenient quarterly dosing 🫀 Strengthens Novartis cardiovascular pipeline tackling residual inflammatory risk See image for more info 👇 📢 M&A News: MannKind $MNKD Acquires scPharmaceuticals $SCPH $5.35/sh upfront + $1/sh CVR ($360M a 3136% premium); $SCPH up 14% at open Adds FUROSCIX FDA-approved CHF/CKD therapy with $10B U.S. market FUROSCIX"
X Link 2025-09-09T14:55Z 28.9K followers, 14.2K engagements
"📣 Biotech Stock News 09/09 @ Open $TRML 58% Novartis Acquires Tourmaline Bio $TELO 12% New Cancer Data on Prostate Cells $XLO 11% Initiation of Phase [--] Trial $MBRX 8% Accelerates Recruitment in Phase [--] Trial $AGEN 6% Reimbursed Compassionate Access for BOT/BAL $DNTH 5% Proposed $150 Million Public Offering $NKGN 5% Completion of Acquisition and Control $NKTR 4% REZOLVE-AD Phase 2b Results Presented $AVXL 4% Cognitive Resilience Results in Alzheimer's Trial $IONS 3% FDA Breakthrough Therapy designation for ION582 $EVFM 2% Anticipates Merger Approval at Meeting $ACRS 1% Late-Breaking Abstract"
X Link 2025-09-09T15:46Z 28.9K followers, 10K engagements
"🧬 Biotech Weekly News 9/8/25 - 9/12/25 Major Movers 📈 $RAPP 119% Topline Data RAP-219 Ph2a Trial $TRML 58% Novartis Acquires Tourmaline Bio $MAZE 55% MZE782 Ph1 Trial Results $TVTX 26% FDA AdCom Meeting Update $ONCY 21% Highlights Data in CRC 📉 $SMMT -25% Longer-Term Data in NSCLC $ACTU -19% Pricing $15M Public Offering $IDYA -14% Multiple Trial Readouts $NUVB -11% New Data from NSCLC Studies $TIL -10% Presentation [----] Monotherapy Data ***** Impressive data drop from $RAPP 🔥 RAP-219 - strong seizure reduction in Focal Onset Epilepsy See @PersimmonTI post below. $XBI $RAPP $xbi RAP-219"
X Link 2025-09-12T22:44Z 28.9K followers, 11.3K engagements
"📌 Biotech Stock News 10/10 @ Open $CDTX 4% Present @ 10th ESWI Influenza Conf. $AZN 0% Expand VA Manuf. Facility $OSTX 0% OST-HER2 Ph2b OS Data $JNJ 0% MDD Portfolio @ [----] ECNP Congress $CRSP 0% New Preclinical CTX460 Data $BIIB -1% New Zorevunersen Data @ 54th CNS Mtg. $BMY -2% To Acquire Orbital Therapeutics $ASMB -3% ABI-5366 Interim Ph1b Data @ IUSTI-EU $VIR -3% First Participant Dosed for VIR-5500 Trial $QNCX -4% Present Data @ 54th CNS Mtg. $CABA -9% Rese-cel Data @ ESGCT'25 $ANVS -21% $6M Direct Offering See the image and comments for more details"
X Link 2025-10-10T15:53Z 28.9K followers, [----] engagements
"🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted 180-Day Extension by Nasdaq $OSTX 6% Overall & Event Free Survival Data $NRIX 5% Initiates Pivotal Study of Bexobrutideg $SMMT 2% Raises $500 Million in Placement $SNY 2% High-dose flu vaccine shows superior protection $ANL 2% Short Talk on AN4035 Preclinical Results $BIIB 1% Additional Results from Phase [--] Study $COLL 1% Poster Presentations at Conferences $ALKS 0% Agreement to Acquire Pharmaceuticals $IPSEY 0% Acquisition to strengthen oncology pipeline $EGRX 0% Results of [----] Annual"
X Link 2025-10-22T15:45Z 28.9K followers, 10K engagements
"🧬 Biotech Stock News 10/22 Brought to you by Barb On the rise 📈 $GRTX 61% $IXHL 7% $OSTX 6% Under pressure 📉 $RAPT -12% $ALEC -51% $ARCT -58% Catch the full breakdown in the latest video 🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted 180-Day Extension by Nasdaq $OSTX 6% Overall & Event Free Survival Data $NRIX 5% Initiates Pivotal Study of Bexobrutideg $SMMT 2% Raises $500 Million in Placement $SNY 2% https://t.co/sFPloOyKuL 🧬 Biotech Stock News 10/22 @ Open $GRTX 61% Acquisition of Dismutase Mimetics Portfolio $IXHL 7% Granted"
X Link 2025-10-22T17:31Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 10/31 @ Open $NBTX 11% $71M Royalty Agreement $DNA 9% Ginkgo Bio & Bayer Multi-Year Partnership $OLMA 7% Palazestrant+Ribociclib Poster @ SABCS'25 $FDMT 4% 4D-150 Exclusive License Agreement $NTRA 3% Expansion to [--] Genes for NIPT $CLDX 2% CDX-622 Ph1 Trial Results $TRAW 2% Extended Ratutrelvir CMC Services Collab $SMMT 2% HARMONi-A OS Data @ SITC'25 $AMGN 1% Repatha Data @ AHA'25 $ATXS 1% Presenting @ ACAAI'25 $HOOK 1% Completion of Sale of Assets to Gilead $AZN 0% DESTINY-Lung06 Ph3 Trial Initiated $ADAG -1% First Patient Dosed in Ph2 Study $VERU -3% Presenting Two"
X Link 2025-10-31T16:03Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 11/12 @ Open $LPTX 121% Rebrands as Cypherpunk $CNTA 13% $250M Public Offering $NXTC 11% $21.5M Private Placement $MOLN 7% MP0712 New Data $PEPG 7% PGN-EDODM1 U.S. Patent $IMTX 6% IMA402 & IMA401 Achieves PoC $DBVT 6% VITESSE Ph3 Trial LPLV $RVPH 3% Brilaroxazine Data @ Neuroscience'25 $MBRX 3% Annamycin Grant @ UNC-Chapel Hill $ABBV 2% New Data @ ASDS $LGVN 1% U.S. Patent for Proprietary Stem Cell Tx $TELO 1% Telomir-1 Outperforms Gold-Standard Chelator $APLS 1% 5-Year GALE Data on SYFOVRE $IONS 1% $700M Convertible Offering $COGT -2% $200M Public Offerings $ANIX -3%"
X Link 2025-11-12T16:32Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/2). $LGVN Phase 2a $INMB Phase [--] $AVXL Phase 2/3 $STOK Phase [--] $ACLX Phase [--] $IRON Phase [--] $GLPG Phase [--] $NRIX Phase [--] $XCUR Phase [--] $PVLA Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $ARGX Phase [--] $INCY Phase [--] $EWTX Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $BHVN Phase [--] $ZNTL Phase [--] $IOVA Phase [--] $GNLX Phase [--] $RXRX Phase [--] $PRTA Phase [--] $VALN Phase [--] $CGON Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $IMVT Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV"
X Link 2025-11-30T21:25Z 28.9K followers, 75.6K engagements
"📣 Biotech Stock News 12/18 @ Open $KMDA 5% Extension of Canadian Supply Tender $IMRX 5% Dosing First Patient in Atebimetinib Trial $COCP 5% IRB Approval for CDI-988 Study $CRMD 4% Positive Data DefenCath Study $CYBN 3% Transfer U.S. Stock Exchange Listing $ABVX 3% [--] Abstracts on Obefazimod at ECCO $SGMO 3% Rolling Submission of BLA for ST-920 $TELO 2% Favorable IND-Enabling Safety Results $LLY 2% Orforglipron maintains weight loss $MRNA 2% Fund Phase [--] Trial for mRNA Vaccine $AVXL 1% Request for EMA Re-Examination $BFRI 1% Transfer of Ameluz and RhodoLED $MNOV 1% Completion of Enrollment"
X Link 2025-12-18T16:00Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 12/22 @ Open $CYTK 12% MYQORZO FDA Approval $ENTX 7% EB612 program New Data $IMMP 5% IMP761 Update $GLSI 5% FLAMINGO-01 Updates $KALV 4% EKTERLY Approval in Japan $AVBP 3% ALPACCA Trial First Patient Dosed $SVRA 3% MOLBREEVI BLA Resubmission $CRSP 3% Zugocaptagene Geleucel (zugo-cel) Update $VRDN 2% Veligrotug BLA Acceptance $PTCT 2% Sephience Approval in Japan $AVIR 1% Completes Patient Enrollment in Ph3 Trial $ALVO 1% Simponi Launch in Europe $ASMB 1% Helicase-Primase Inhibitor Licensing $AZN 0% ENHERTU FDA BTxD; Ph3 Trial Initiated $GSK 0% Samsung Expands U.S. Manuf."
X Link 2025-12-22T16:03Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 12/29 @ Open $PRAX 14% FDA Grants Breakthrough for Ulixacaltamide $PHGE 9% Private Placement of $3M $TOVX 5% Positive EMA Advice on VCN-01 Trial $TNXP 3% Program Updates on TNX-4800; Pricing of $20M Offering $TLSA 2% Files Annual Safety Report for Foralumab $SPRY 1% neffy Approved for Allergic Reactions $UNCY 1% Resubmission of NDA for OLC $JNJ 1% Acquisition to revolutionize cancer treatment $ZVRA 0% Distribution Agreement for MIPLYFFA $SXTP -1% Detection of Babesia in Patients $SLS -1% Update on Phase [--] REGAL Trial $GMAB -1% Portfolio Prioritization Update $HCM -3% NDA"
X Link 2025-12-29T15:55Z 28.9K followers, [----] engagements
"🟢 Praxis Precision Medicines $PRAX +14% - FDA grants Breakthrough Therapy Designation to ulixacaltamide HCl in essential tremor - supported by positive Essential3 Ph3 topline data 🔴 Ultragenyx Pharmaceutical $RARE -90% - Ph3 Orbit and Cosmic studies of setrusumab (UX143) missed the primary fracture endpoint despite statistically significant improvements in BMD https://twitter.com/i/web/status/2005669032230584715 https://twitter.com/i/web/status/2005669032230584715"
X Link 2025-12-29T15:55Z 28.9K followers, [---] engagements
"📢 M&A News: $LLY to Acquire $VTYX Lilly to acquire Ventyx Biosciences for $14.00/sh ($1.2B). Adds oral small-molecule programs targeting inflammatory diseases. Strengthens $LLY's immunology & inflammation pipeline. Transaction expected to close in 1H [----] subject to approvals. See images for more details 👇 📢 M&A News: $MRK to Acquire $CDTX Merck to complete acquisition of Cidara Therapeutics Brings in CD388 a Ph3 long-acting antiviral for influenza prevention. Strengthens $MRK infectious disease portfolio. Transaction expands $MRK's reach in seasonal & pandemic https://t.co/I6pTPt7ivU 📢"
X Link 2026-01-07T23:17Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $KOD Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP"
X Link 2026-01-11T19:51Z 28.9K followers, 126.8K engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $KOD Tarcocimab (KSI-301) $UPB Verekitug $ANRO ALTO-101 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-11T19:51Z 28.9K followers, [----] engagements
"Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $KOD 6/34 🔥 $UPB 6/34 🔥 $ANRO 3/34 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-01-11T19:51Z 28.9K followers, [----] engagements
"6 Stocks Likely to Move Big in Q1 [--] 📈 📉 See 🧵 for more details about each asset/readout 👇 $RGNX (February [--] 2026) Clemidsogene lanparvovec (RGX-121) / Hunter syndrome (MPS II) / PDUFA $RCKT (March [--] 2026) KRESLADI (RP-L201) / Severe LAD-I / PDUFA $UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] $IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / 1L NSCLC) / Phase [--] $KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR / Phase [--] $APGE (Q1 2026) APG777 / Atopic dermatitis / Phase [--] 1/7 https://twitter.com/i/web/status/2011123506180935882"
X Link 2026-01-13T17:09Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📉📈 Prev. Qtr Movers: 🟢 $COGT 119.03% 🟢 $ANRO 80.92% 🔴 $VKTX -40.00% 🔴 $ALEC -50.62% Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lp https://www.offers.bpiq.com/big-mover-lp"
X Link 2026-01-13T17:09Z 28.9K followers, [----] engagements
"#JPM2026 Day [--] 🗓 Free access to the J.P. Morgan [----] conference calendar in the comments. 👇 $XBI smid-cap biopharmas presenting today with commercial/marketed drugs: $AGIO $IMCR $NVCR $VCEL $MIRM $PCRX $ESPR $AMPH $IRON $RIGL $NVAX $EBS $OPK $LEGN ***** Great thread by @yaireinhorn breaking down @BeamTxs #JPM26 presentation. Clear overview of BEAMs pipeline regulatory progress with the FDA and key [----] milestones. Well worth the read. 🧵👇 1/@BeamTxs #JPM26 excellent presentation emphasised its strategic priorities & future milestones for [----]. Heres my🧵👇which elaborates on BEAMs current"
X Link 2026-01-14T11:33Z 28.9K followers, [----] engagements
"The 44th J.P. Morgan Healthcare Conference runs through tomorrow in San Francisco CA 🔍 $NTLA $FDMT $IMCR $LEGN $SANA are presenting today Access our free #JPM2026 Conference Calendar. See link below 👇 https://www.bpiq.com/jpmorgan-conference-sign-up https://www.bpiq.com/jpmorgan-conference-sign-up"
X Link 2026-01-14T11:33Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 1/14 @ Open $IBRX 8% Accelerated Approval for ANKTIVA $SLDB 6% AAV-SLB101 Expanded Access $ANRO 3% ALTO-207 New Patent $SLS 3% SLS009 Expansion in EU $CCCC 2% Cemsidomide Strategic Milestones $EBS 1% NARCAN Nasal Spray FDA Approval $REVB 0% Present @ AKI & CRRT [----] $SNTI 0% Present AML data & RMAT Designation $IPSEY 0% Data @ TOXINS & IPN60340 BTD $TVTX -3% FDA Extends Review of FILSPARI $NRXP -5% 70K Patient Data on Ketamine $PSTV -39% Pricing of $15M Offering 🚀 SGT-003 update via @semodough $SLDB (2026 outlook) INSPIRE DUCHENNE fully enrolled [--] pts dosed in Ph1/2"
X Link 2026-01-14T15:56Z 28.9K followers, [----] engagements
"$RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) BSID-III skill acquisition/stability at 1Y Wk16 CSF HS D2S6 strongly correlated w/ 1Y cognition (r 0.97) 2/7 https://twitter.com/i/web/status/2012295973645729889 https://twitter.com/i/web/status/2012295973645729889"
X Link 2026-01-16T22:48Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% 📉📈 Prev. Qtr Movers: 🟢 $COGT 119.03% 🟢 $ANRO 80.92% 🔴 $VKTX -40.00% 🔴 $ALEC -50.62% Access our FREE Big Mover Report 👇 https://offers.bpiq.com/big-mover-lp https://offers.bpiq.com/big-mover-lp"
X Link 2026-01-16T22:48Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $KOD Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP"
X Link 2026-01-18T18:56Z 28.9K followers, 62.5K engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $TRAW Phase [--] $IBRX Phase [--] $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KOD Phase 2b $MDNAF Phase 2b $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $CALC Phase [--] $CRVS Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $QNCX Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR"
X Link 2026-01-25T19:38Z 28.9K followers, 54.9K engagements
"Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $PEPG 14/36 🔥🔥 $ANRO 3/36 $TBPH 1/36 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-01-25T19:38Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 1/28 @ Open $PDSB 10% Preliminary results for PDS01ADC $OKYO 9% Successful Type C Meeting with FDA $GKOS 7% FDA Approval for iDose TR $JNJ 1% Quadruplet regimen approved for myeloma $NTRA -1% ACES-EMB enrollment completion $SPRB -1% Data Presentations @ WORLDSymp $INSM -1% Treprostinil presentation @ PVRI $BIIB -2% Litifilimab receives FDA BTD $SCYX -2% SCY-247 presentation @ IMARI $ABBV -2% New data on facial injectables $ARDX -2% First Patient Dosed in ACCEL Study $ENSC -4% Enrollment update on PF614 trial $GRI -6% Ph2a Gene Expression Data $ALT -7% Pricing of $75M"
X Link 2026-01-28T16:07Z 28.9K followers, [----] engagements
"$RGNX down -18% 📉 FDA clinical holds on RGX-111 & RGX-121 (MPS) Single neoplasm finding under review RGX-202 (DMD) unaffected; pivotal data in early Q2 Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-28T16:07Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 1/30 @ Open $ALXO 11% Pricing of $150M; Evorpacept Data $PLX 8% Positive CHMP Opinion for Elfabrio $MNOV 2% [---] Patients Enrolled in MN-166 Study $ALT 2% Closing of $75M Offering $DNLI 1% TransportVehicle Enzyme Presentation $COYA -1% $11.1M Private Placement $INCY -1% Positive CHMP Opinion for Zynyz $PCVX -3% Pricing of $550M Offering $BMRN -3% Pricing of Private Offering $SCLX -3% Preventive Diagnosis Strategic Investment $RARE -4% UX111 Tx BLA Resubmission $MRNA -4% mRNA-3927 Commercial Collaboration $TNXP -4% Ph3 RESILIENT Data on TONMYA $KZIA -12% Preclinical data"
X Link 2026-01-30T15:59Z 28.9K followers, [----] engagements
"$ALXO up 11% 📈 CD47 levels predict response to evorpacept + Ziihera Supports biomarker-driven patient selection Strengthens confidence in ongoing HER2+ trials Dont miss out on future Big Movers Access our FREE Big Mover Report 👇 https://twitter.com/i/web/status/2017266543848296584 https://www.offers.bpiq.com/big-mover-lpmo=jun https://twitter.com/i/web/status/2017266543848296584 https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-01-30T15:59Z 28.9K followers, [----] engagements
"📢 M&A News: Cycle Group Acquires $APLT Cycle completes acquisition of $APLT Adds govorestat for rare metabolic & neurologic diseases Targets Classic Galactosemia CMT-SORD & PMM2-CDG (no FDA-approved therapies) Deal funded with cash on hand See images for more details 👇 📢 M&A News: $BCRX Completes Acquisition of Astria Therapeutics $700M Implied transaction value Adds navenibart for HAE Expands portfolio to oral (ORLADEYO) + injectable prophylaxis options Acquires early-stage atopic dermatitis program STAR0310 (strategic alternatives https://t.co/FORmlQBoMf 📢 M&A News: $BCRX Completes"
X Link 2026-02-03T16:50Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 02/05 @ Open $RNAZ 37% IND Amendment for Phase 2a Trial $XCUR 6% Rapid Stem Cell Mobilization with Burixafor $CGTX 5% Extends Access Program for Zervimesine $MRK 3% Health Canada approves ENFLONSIA $IMNN 2% Focus on pivotal phase [--] study $ALVO 1% Positive results for proposed biosimilar $LGVN 1% Passage of Pediatric Disease Act $ATOS 1% Strong market position for (Z)-Endoxifen $OSTX -1% Reauthorization of Pediatric Priority Review $TELO -1% New data on epigenetic modulation $MIRM -1% Health Canada Authorizes LIVMARLI Tablet $MIRM -1% Health Canada Authorizes LIVMARLI See"
X Link 2026-02-05T15:04Z 28.9K followers, [----] engagements
"Each quarter we identify major catalyst events 🥳 Likely to move the stock +/- by 20% $XENE XEN1101 $INSM Brensocatib $ANRO ALTO-101 Access our FREE Big Mover Report https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-08T18:59Z 28.9K followers, [----] engagements
"Let's see how many of the [--] biopharma-focused hedge funds hold these tickers (5 is 🔥). $XENE 8/36 🔥 $INSM 8/36 🔥 $ANRO 3/36 Access our FREE hedge fund screener & search your fav tickers https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-02-08T18:59Z 28.9K followers, [----] engagements
"📣 M&A News: 🧬 Eli Lilly and Company $LLY to acquire Orna Therapeutics a private in vivo cell engineering biotech Deal boosts in vivo CAR-T programs targeting B celldriven autoimmune diseases Orna tech: circular RNA (oRNA) + LNPs enabling the body to generate its own cell therapies 🧪 Lead asset ORN-252: clinical-ready CD19-targeting in vivo CAR-T Orna shareholders eligible for up to $2.4B (upfront + milestones) 💰 See image for more details 👇 📢 M&A News: Cycle Group Acquires $APLT Cycle completes acquisition of $APLT Adds govorestat for rare metabolic & neurologic diseases Targets Classic"
X Link 2026-02-09T15:48Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 02/09 @ Open $HUMA 26% New Defense Funding for Blood Vessels $VRCA 3% Launch of YCANTH in Japan $MNKD 2% First Patient Enrolled in INHALE-1ST $ZBIO 2% Phase [--] results for Obexelimab $SLDB 1% Positive FDA feedback for SGT-003 $TMDX 1% FDA IDE Approval for OCS Heart Trial $LLY 1% Acquire Orna Therapeutics for therapies $ASND 0% Health Canada Approval of Yorvipath $KRYS 0% RMAT Designation for KB707 Granted $RHHBY 0% Fenebrutinib reduces disability progression $JNJ 0% Early Outcomes from OMNY-AF Study $NUVB -1% Pivotal Phase [--] Trial for Safusidenib $LXRX -2% Closing of"
X Link 2026-02-09T15:58Z 28.9K followers, [----] engagements
"Humacyte Inc. $HUMA secures new FY26 U.S. Department of Defense funding - funding supports procurement of bioengineered blood vessels for traumatic vascular injuries Check out our catalyst calendar 📅 👇 & stay on top of key biopharma readouts https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar"
X Link 2026-02-09T16:20Z 28.9K followers, [----] engagements
"$RGNX (February [--] 2026) RGX-121 / Hunter syndrome / PDUFA Why RGX-121 is different One-time CNS AAV9 gene therapy targeting the genetic cause of neuronopathic MPS II. Pivotal CAMPSIITE signal Primary endpoint met; CSF HS D2S6 82% through 1Y (80% maintained) BSID-III skill acquisition/stability at 1Y Wk16 CSF HS D2S6 strongly correlated w/ 1Y cognition (r 0.97) 2/7 https://twitter.com/i/web/status/2011123510970892403 https://twitter.com/i/web/status/2011123510970892403"
X Link 2026-01-13T17:09Z 28.9K followers, [----] engagements
"Check out our FREE biopharma M&A tracker: 👇 Provides info on past M&A activity https://www.offers.bpiq.com/m-and-a-download-signupmo=jun https://www.offers.bpiq.com/m-and-a-download-signupmo=jun"
X Link 2026-02-09T15:59Z 28.9K followers, [----] engagements
"1/ BPIQ Model Portfolios continue to crush biotech benchmarks 🧬📈 $XBI $IBB Since launching our first consensus-based portfolio (Top 20s) on April [--] [----] our hedge-fund consensus strategy has consistently outperformed. Heres the data 👇 https://twitter.com/i/web/status/2022031587945447559 https://twitter.com/i/web/status/2022031587945447559"
X Link 2026-02-12T19:34Z 28.9K followers, [----] engagements
"7/ Want access to our portfolio holdings and other portfolios info/tools to help you make better biopharma investment decisions Upgrade to Elite or APEX today. 💌 Limited-Time Valentines Sale: 50% OFF Elite 40% OFF APEX https://www.bpiq.com/pricingmo=021226 https://www.bpiq.com/pricingmo=021226"
X Link 2026-02-12T19:34Z 28.9K followers, [---] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $PTGX Phase 2b $EVAX Phase [--] $DCTH Phase [--] $CELC Phase [--] $IDYA Phase [--] $IDYA Phase 2/3 $KYTX Phase [--] $VOR Phase [--] $INBX Phase [--] $ATAI Phase 2b $LQDA Phase [--] $PROK Phase [--] $KZR Phase 2a $ALXO Phase [--] $ELDN Phase [--] $IFRX Phase 2a $IFRX Phase 2b $NKTR Phase 2b $RZLT Phase [--] $PVLA Phase [--] $BDTX Phase [--] $RNA Phase [--] $CAPR Phase [--] $TARA Phase [--] $ZVSA Phase 2a $CGON Phase [--] $VTYX Phase [--] $DBVT Phase [--] $PHVS Phase [--] $VTGN Phase [--] $TERN Phase [--] $ALEC Phase [--] $ZBIO Phase [--] $IRON Phase [--] $INBX Phase 2/3 $MLTX Phase [--] $ANAB Phase 2"
X Link 2025-10-05T20:24Z 28.9K followers, 56.1K engagements
"🧬 Biotech Stock News 10/13 Brought to you by Barb On the rise 📈 $CGEN13% $RCUS7% $ANAB6% Under pressure 📉 $ADCT-2% $FDMT-3% $PALI-12% Catch the full breakdown in the latest video. 📌 Biotech Stock News 10/13 @ Midday $CGEN 13% COM701 Pooled Analysis $RCUS 7% Median OS Data in Ph2 Study $ANAB 6% Late-Breaking Presentation at ACR $BCAX 3% Ficerafusp Alfa Granted Breakthrough Designation $MNKD 3% FDA Review for Inhaled Insulin in Youth $ADGM 3% Preliminary https://t.co/q5BWCrtydz 📌 Biotech Stock News 10/13 @ Midday $CGEN 13% COM701 Pooled Analysis $RCUS 7% Median OS Data in Ph2 Study $ANAB"
X Link 2025-10-13T17:28Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q4 [----] (1/3). $INAB Phase [--] $CRDL Phase [--] $ACLX Phase [--] $IRON Phase [--] $NUVL Phase [--] $XCUR Phase [--] $STOK Phase [--] $GLPG Phase [--] $NRIX Phase [--] $PVLA Phase [--] $COGT Phase [--] $NKTR Phase 2b $RZLT Phase [--] $ARGX Phase [--] $INCY Phase [--] $EWTX Phase [--] $RNAC Phase [--] $ROIV Phase [--] $GLPG Phase [--] $MGNX Phase [--] $BHVN Phase [--] $PRAX Phase 2/3 $BHVN Phase [--] $ZNTL Phase [--] $IOVA Phase [--] $GNLX Phase [--] $RXRX Phase [--] $PRTA Phase [--] $VALN Phase [--] $CGON Phase [--] $GNLX Phase [--] $EXEL Phase [--] $PCSA Phase [--] $IMVT Phase [--] $BMEA Phase [--] $EXEL Phase [--] $JAZZ Phase [--] $HOOK"
X Link 2025-11-16T20:34Z 28.9K followers, 32.6K engagements
"📌 Biotech Stock News 1/2 @ Open $CORT 9% Complete Response Letter for Relacorilant $BCAB 4% Advance Ozuriftamab Vedotin into Trial $JAGX 2% FDA Grant for Canalevia-CA1 $CYBN 1% Initiates At-The-Market Equity Program $RARE 0% Rolling Submission for DTX401 BLA $LNTH 0% Closing of SPECT Business Sale $DCTH 0% Publication of FOCUS Study Analyses $ALVO -3% Secures Term Loan Facility $AXSM -3% AXS-05 & AXS-12 FDA Updates $VNDA -4% FDA Approves NEREUS for MS $OTLK -58% Regulatory Update on ONS-5010 🔍 Worth a closer look 👀 via @BioStocks on $OTLK: New BLA data does not change FDA view Confirmatory"
X Link 2026-01-02T15:34Z 28.9K followers, [----] engagements
"📣 Biotech Stock News 01/08 @ Open $ELVN 46% Positive Ph1b Data for ELVN-001 $ARDX 16% Preliminary [----] Revenue & [----] Outlook $ALXO 6% Clinical Trials for Evorpacept & ALX2004 $GLUE 5% Proposed Public Offering and Warrants $RANI 4% Phase [--] Study of RT-114 $PHAR 3% Preliminary [----] revenues announced $GRI 2% Positive Data from Phase 2a Study $COYA 2% Results of LD IL-2 and CTLA4-Ig $KRYS 2% Interim Clinical Update on KB407 $ENSC 2% EU Patent for ADHD Therapy $SGMT 2% Poster Presentation at MASH-TAG [----] $XLO 1% Upcoming Milestones and Updates $ARWR 1% Prices Upsized Offerings of Notes $BFRI"
X Link 2026-01-08T16:57Z 28.9K followers, [----] engagements
"$RCKT (March [--] 2026) KRESLADI (marne-cel; RP-L201) / Severe LAD-I / PDUFA Why KRESLADI is different One-time autologous LV gene-corrected HSC tx designed to restore CD18 & reconstitute immune function (potentially curative). Prior signal (pivotal LAD-I study) 9/9 survival w/ no graft failure; no drug-related SAEs 10% PMN CD18 expression at 1yr across cohort 100% HSCT-free survival + meaningful reduction in infection-related hospitalizations 3/7 https://twitter.com/i/web/status/2011123515072921907 https://twitter.com/i/web/status/2011123515072921907"
X Link 2026-01-13T17:09Z 28.9K followers, [---] engagements
"🧬 Biotech Stock News 08/26 Brought to you by Barb [--] stocks on the rise 📈 $IXHL $JUNS $PSTV [--] under pressure 📉 $LPCN $MRKR $EPIX Catch the full breakdown in the latest video 🎥 📣 Biotech Stock News 8/26 @ Open $IXHL 15% Positive Ph2 Results for PSX-001 $JUNS 8% Launches Nugevia Website & Pre-Orders $PSTV 6% Regains Compliance with Nasdaq Criteria $LCTX 6% Research Collaboration for Hearing Loss $OSTX 6% Terminates Equity Line of Credit $CYBN 4% https://t.co/cVxFjAxmsj 📣 Biotech Stock News 8/26 @ Open $IXHL 15% Positive Ph2 Results for PSX-001 $JUNS 8% Launches Nugevia Website & Pre-Orders"
X Link 2025-08-26T17:31Z 28.9K followers, [----] engagements
"🧬 Biotech Stock News 09/11 Brought to you by Barb On the rise 📈 $MAZE 43% $GRI39% $RVMD 15% Under pressure 📉 $VXRT -1% $KAPA -10% $BDSX -17% Catch the full breakdown in the latest video 🎥 🧬 Biotech Stock News 09/11 @ Open $MAZE 43% MZE782 Ph1 Trial Results $GRI 39% 6-Week Interim Lung Function Data $RVMD 15% New Daraxonrasib Clinical Results $TEM 14% FDA Clearance for Updated Device $PSNL 11% Trial Launched for ctDNA-Guided Treatment $MAIA 5% Efficacy Data from https://t.co/dVDH3iBWIh 🧬 Biotech Stock News 09/11 @ Open $MAZE 43% MZE782 Ph1 Trial Results $GRI 39% 6-Week Interim Lung"
X Link 2025-09-11T20:27Z 28.9K followers, [----] engagements
"🧬 Biotech Stock News 10/02 Brought to you by Barb On the rise 📈 $TSHA 41% $NBTX 9% $PEPG 4% Under pressure 📉 $SION -5% $DNTH -6% $BOLT -13% Catch the full breakdown in the latest video. 📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral Presentations at WMS $AVXL 3% Successful Development of Oral Tablet $AVXL 3% Positive Topline Results from Phase [--] Study $GLPG 1% Update on Strategic Alternatives for https://t.co/V3R1mSRELl 📣 Biotech Stock News 10/02 @ Open $TSHA 41% FDA BTD Granted $NBTX 9% First Data From Ph1 Study $PEPG 4% Oral"
X Link 2025-10-02T17:30Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist 🎯 Ph2 & Ph3 readouts in Q4 [----] $LTRN Phase [--] $ARGX Phase [--] $INCY Phase [--] $ROIV Phase [--] $GLPG Phase [--] $BHVN Phase [--] $GNLX Phase [--] $VALN Phase [--] $IMCR Phase [--] $GNLX Phase [--] $EXEL Phase [--] $BMEA Phase [--] $EXEL Phase [--] $HOOK Phase [--] $AMGN Phase [--] $INCY Phase [--] $BINV Phase 2a $DWTX Phase 2b $EWTX Phase [--] $ZYME Phase [--] $ZVSA Phase 2a $BHVN Phase [--] $VTYX Phase [--] $LSTA Phase 2a $ALDX Phase [--] $ALNY Phase [--] $LLY Phase [--] $MRNA Phase [--] $IONS Phase [--] $REGN Phase 2/3 $CALT Phase [--] $GNFT Phase [--] $NAMS Phase [--] $KZIA Phase [--] $NVS Phase [--] $NAMS Phase [--] $DNLI Phase 2/3 $INKT"
X Link 2025-12-21T19:44Z 28.9K followers, 104.7K engagements
"📌 Biotech Stock News 1/23 @ Open $ADAG 7% Business Update and [----] Objectives $BCRX 4% Completes Acquisition of Astria Tx $PCVX 2% Advances Programs for VAX-31 Vaccine $IBRX 2% Survival Not Yet Reached in Glioblastoma $OKYO 0% FDA Approves Urcosimod for Pain $OCGN -2% Closing of $22.5M Offering $ELDN -2% Long-Term Ph1b Data for Tegoprubart $THAR -2% Closing of $55M Offering $CRNX -2% Ph2/3 Trial for Atumelnant $TRVI -4% Publication of nalbuphine ER data 🚀 Shoutout to @doepke_michel on $BCRX announcement of the planned acquisition of Astria Tx: Deal officially closed today (1-23-26) $700M"
X Link 2026-01-23T15:42Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/6 @ Open $ROIV 18% Mosliciguat & Brepocitinib Trial Updates $DNLI 5% TransportVehicle Progress Update $IOVA 5% Amtagvi Treatment RWD $QURE 4% Updated AMT-191 Ph1/2a Data $SPRB 4% Tralesinidase Alfa shows potential $PFE 2% Priority Review for HYMPAVZI $TGTX 1% Presentation of Data for BRIUMVI $GILD 0% Label update for Yescarta approved $IMMP 0% TACTI-004 Trial 50% Enrolment $NTRA -1% Launches EDEN Study on Preeclampsia $AAPG -2% APG-3288 IND Clearance $ANEB -33% Intention to Voluntarily Delist See the image and comments for more details 👇 $ROIV Positive Phase [--] Results"
X Link 2026-02-06T15:30Z 28.9K followers, [----] engagements
"2/ We expanded the hedge-fund favorites framework across: Run-Up Top [--] Top [--] Top [--] (refined Nov 2024) The results have been clear. And consistent"
X Link 2026-02-12T19:34Z 28.9K followers, [---] engagements
"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 01/09/26 📈 $ALMS 95% Envudeucitinib leads in skin clearance $ELVN 50% Positive Ph1b Data ELVN-001 $GLUE 45% Positive Ph1 Data MRT-8102 $CGON 29% Updated Timeline PIVOT-006 Data $ARDX 20% Prelim. [----] Revenue & [----] Outlook 📉 $ZBIO -52% Results for Obexelimab trial $TIL -46% AXN-2510 Clinical Dev Discontinuation $IMRX -43% OS 64% in Pancreatic Cancer $AQST -37% Regulatory Development for Anaphylm $JSPR -19% Data from Briquilimab studies See image below. ***** $ALMS Envudeucitinib PASI 75/90/100 data versus oral TYK2"
X Link 2026-01-10T15:17Z 28.9K followers, [----] engagements
"Clinical data driving moves this week: $ALMS Envudeucitinib PASI skin clearance data $ELVN $GLUE $CYCN Positive Ph1/2 readouts $RDHL $RZLT $DRUG Mid-stage efficacy updates Track upcoming readouts with our catalyst calendar 📅 $XBI $IBB https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar"
X Link 2026-01-10T15:17Z 28.9K followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $MDNAF Phase 2b $GOSS Phase [--] $BFRI Phase [--] $MLTX Phase [--] $BFRI Phase [--] $BCDA Phase [--] $KPTI Phase [--] $IOVA Phase [--] $XENE Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP Phase [--] $PVLA"
X Link 2026-02-08T18:59Z 28.9K followers, [----] engagements
"$UPB down -52% 📉 Ph2 VALIANT met primary endpoint in severe asthma AAER 56% (100 mg q12w) & 39% (400 mg q24w) vs placebo Advancing to Ph3 in asthma & CRSwNP Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-11T16:29Z 28.9K followers, [----] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-11T16:29Z 28.9K followers, [---] engagements
"$BBIO +9% 🟢 Infigratinib delivers a home run 🏆 - Phase [--] hits primary + key secondary endpoints first-ever improvement in body proportionality in achondroplasia. - NDA planned H2 [----]. Check out our catalyst calendar below. 📅 https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar"
X Link 2026-02-12T15:40Z 28.9K followers, [---] engagements
"4/ 📊 Since 12/31/2023 Every portfolio outperformed $XBI and $IBB [--] XBI [----] IBB (see image [--] 👇)"
X Link 2026-02-12T19:34Z 28.9K followers, [--] engagements
"5/ 📊 [----] Performance (Since 12/31/2024) Every portfolio outperformed $XBI and $IBB 1.451.80 XBI 1.63.4 IBB Top [--] delivered 200% of both benchmarks (see image [--] 👇)"
X Link 2026-02-12T19:34Z 28.9K followers, [--] engagements
"📣 Biotech Stock News 01/22 @ Midday $SXTP 135% Partnership for ARAKODA Access $CRVS 16% Pricing of Upsized Public Offering $GLSI 14% FDA Approves Commercially Manufactured GP2 $CORT 14% Overall Survival Met in ROSELLA Trial $JANX 9% Collaboration for Tumor-Activated Therapeutic $TARA 6% Updated Interim Data for TARA-002 $PDSB 5% New U.S. Patent for PDS0101 $IVVD 3% Partnership to Educate on Antibodies $ERAS 2% Pricing of Upsized Public Offering $GILD 2% Trodelvy Plus Keytruda in Breast Cancer $IPSEY 2% Arbitration upholds R&D agreement termination $ATXS 0% Stockholders Approve Acquisition"
X Link 2026-01-22T17:50Z 28.9K followers, [----] engagements
"February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder / schizophrenia) Feb [--] $ETON ET-600 (central diabetes insipidus) Feb [--] $ASND TransCon CNP (achondroplasia) Priority Review Feb [--] $BMRN PALYNZIQ (PKU adolescents) Priority Review (label expansion) See the attached graphic for the full February PDUFA calendar. https://twitter.com/i/web/status/2016215337554083884"
X Link 2026-01-27T18:22Z 28.9K followers, 85.9K engagements
"📣 Biotech Stock News 02/02 @ Open $AQST 45% FDA Issues Complete Response Letter $CATX 31% Pricing of $175 Million Offering $CRMD 10% Share Repurchase Program Announced $SGMT 6% Positive 52-Week Data for ASC40 $PVLA 5% Scientific Publication on Porokeratosis $MLTX 5% FDA Fast Track for Sonelokimab $MOLN 5% First Imaging Data of MP0712 $DNLI 4% Webcast on Enzyme TransportVehicle Programs $VTVT 3% Amends License Agreement for HPP737 $ETON 3% Licensing of Rare Disease Product $REGN 2% EYLEA HD clinical profile presentation $DWTX 2% 50% Enrollment in Halneuron Phase 2b $WVE 2% Accelerate"
X Link 2026-02-02T16:11Z 28.9K followers, [----] engagements
"❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration; resubmission planned as early Q3 [----]. $PHAR also received an FDA CRL for Joenja pediatric sNDA (ages 411) citing the need for additional pediatric PK data and clarification on analytical testing method. See images for details. 👇 January [----] Biotech PDUFA Update 📡 Whats on the FDA radar Recent Outcomes: $ATRA tab-cel (EBV+ PTLD) CRL $TVTX FILSPARI (FSGS) Extended 4/13/26 $FBIO ZYCUBO (copper histidinate) Approved Pending FDA Decisions: Jan [--] $AQST Anaphylm (Anaphylaxis) No"
X Link 2026-02-02T17:13Z 28.9K followers, 10.5K engagements
"FDA CRLs issued to $AQST and $PHAR different issues different paths forward. 👇 https://x.com/BiopharmIQ/status/2018372259208159449 ❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration; resubmission planned as early Q3 [----]. $PHAR also received an FDA CRL for Joenja pediatric sNDA (ages 411) citing the need for additional pediatric PK data and https://t.co/4jrSzXa7pP https://x.com/BiopharmIQ/status/2018372259208159449 ❌ FDA CRL updates: $AQST received CRL for Anaphylm with deficiencies related to packaging and administration;"
X Link 2026-02-02T17:26Z 28.9K followers, [----] engagements
"FDA decisions move markets 🎯 $AQST +42% on CRL $PHAR 18% on CRL Track upcoming PDUFAs CRLs & approvals with our free PDUFA Report 👇 https://www.offers.bpiq.com/pdufa-report https://www.offers.bpiq.com/pdufa-report"
X Link 2026-02-02T17:26Z 28.9K followers, [----] engagements
"🧬 Biopharma Weekly Recap 📝 This week in biotech: $ANL financing sparks biopick buzz M&A chatter heats up GLP-1 differentiation sharpens OX40 stumbles gene therapy debate grows XBI inflows strong. See interesting posts/ppl to check out 👇 @seedy19tron $ANL Raises $140M @ $6.50; Top Funds In $525M MC vs $ERAS ($3.7B) IND-Cleared US Trial Next; Preclin Data Fuels Biopick [----] Buzz @PersimmonTI $XBI the M&A Playbook GPCRMRK ABVXLLY CTMXMRK CYTKNVS MLYSPFE/NVO RYTMNVO TERNBMY NKTRAMGN ORICJNJ SNDXINCY RCUSGILD RVMDJNJ @yaireinhorn CRISPR/Gene Tx Blocked by Economics Not Science: David Liu ($BEAM"
X Link 2026-02-07T13:04Z 28.9K followers, [----] engagements
"$RGNX -15% 🔴 FDA issued a CRL for RGX-121 in MPS II / Hunter syndrome ⚠ Key issues: pt selection external control comparability and CSF biomarker not accepted as surrogate. ❌ No approval; FDA suggests more data/new study. Plans BLA resubmission. See image for details. February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder https://t.co/jRQJdkbvdw February Biotech PDUFA Pulse: 📡 Whats on"
X Link 2026-02-10T17:40Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/11 @ Open $NKTR 17% Proposed Public Offering $AZN 4% Programs to improve healthcare access $DTIL 4% FDA Clearance for PBGENE-DMD $OTLK 2% Submits Type A Meeting Request $MRK 1% KEYTRUDA and Paclitaxel Approved $SNTI 1% Enrollment in Ph1 Trial of SENTI-202 $BCRX 1% New HAE Data from ORLADEYO $MDGL -2% Exclusive Licensing for Novel siRNA $STOK -4% First Patient Dosed in STK-002 Study $CADL -6% Present at Glioblastoma Drug Summit $GLTO -6% Pricing of $275M Offering $BFRI -6% FDA Filing Acceptance for Ameluz $DBVT -7% Additional data from VITESSE study $OKYO -7% Transition"
X Link 2026-02-11T16:29Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/13 @ Open $IMUX 26% $400M Private Placement $EVMN 14% $125M Private Placement $ANRO 5% Completion of Ph2 Study ALTO-101 $EBS 3% sNDA Approval for NARCAN Nasal Spray $GLTO 2% Closing of Public Offering $AZN 1% Results from KALOS and LOGOS trials $PTCT 0% Regulatory Update on Translarna $ITRM -5% Business Update $CHRS -13% Pricing of Public Offering $OKYO -25% Pricing of $20M Offering See the image and comments for more details 👇 https://twitter.com/i/web/status/2022352228829532451 https://twitter.com/i/web/status/2022352228829532451"
X Link 2026-02-13T16:48Z 28.9K followers, [----] engagements
"$ANRO up 5% 📈 Completed Ph2 PoC enrollment for ALTO-101 in CIAS Novel transdermal PDE4 inhibitor targeting cognitive deficits in schizophrenia Topline data by end of Q1 Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-13T16:48Z 28.9K followers, [---] engagements
"February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder / schizophrenia) Feb [--] $ETON ET-600 (central diabetes insipidus) Feb [--] $ASND TransCon CNP (achondroplasia) Priority Review Feb [--] $BMRN PALYNZIQ (PKU adolescents) Priority Review (label expansion) See the attached graphic for the full February PDUFA calendar. https://twitter.com/i/web/status/2016215337554083884"
X Link 2026-01-27T18:22Z 28.9K followers, 85.9K engagements
"🚨 Hedge Fund Q4 holdings (13F) data drops next week (2/17) We follow the top biopharma hedge funds. - capture their 13F data - & post it on our website Access our FREE biopharma hedge fund screener See comments below"
X Link 2026-02-13T22:36Z 28.9K followers, [---] engagements
"Check out our biopharma hedge fund screener & get insights on top biopharma funds💡 Which of them own your favorite smid-caps Start by checking out our free screener.👇 https://app.bpiq.com/hedgefunds https://app.bpiq.com/hedgefunds"
X Link 2026-02-13T22:36Z 28.9K followers, [---] engagements
"Part of being a content creator on should be to promote other valuable creators as much as possible. So here is a list of top tier accounts who create exceptional content & who are A MUST FOLLOW in BioTech and the financial markets👇 BioTech: @Biotech2k1 @BiopharmIQ @Maximus_Holla @Pharmdca @BiomedicalRX @learnbiotech @CrisprGlenn @Andre_AGTC @ablidy @AppleHelix @JessieChimni @TohJah7809 @JohnPDalyJr @BowTiedBiotech @3primeAnalytica @jfais20 @drrichjlaw @GeneInvesting @zhaoweiasu @chuminhua432 Global Economy & Financial Markets: @LeoNelissen @WallStSai @BrandonVanZee @erwtrades @jimbo6607"
X Link 2026-02-13T19:21Z 18.5K followers, [----] engagements
"📌 Biotech Stock News 2/13 @ Open $IMUX 26% $400M Private Placement $EVMN 14% $125M Private Placement $ANRO 5% Completion of Ph2 Study ALTO-101 $EBS 3% sNDA Approval for NARCAN Nasal Spray $GLTO 2% Closing of Public Offering $AZN 1% Results from KALOS and LOGOS trials $PTCT 0% Regulatory Update on Translarna $ITRM -5% Business Update $CHRS -13% Pricing of Public Offering $OKYO -25% Pricing of $20M Offering See the image and comments for more details 👇 https://twitter.com/i/web/status/2022352228829532451 https://twitter.com/i/web/status/2022352228829532451"
X Link 2026-02-13T16:48Z 28.9K followers, [----] engagements
"$ANRO up 5% 📈 Completed Ph2 PoC enrollment for ALTO-101 in CIAS Novel transdermal PDE4 inhibitor targeting cognitive deficits in schizophrenia Topline data by end of Q1 Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-13T16:48Z 28.9K followers, [---] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-13T16:48Z 28.9K followers, [---] engagements
"1/ BPIQ Model Portfolios continue to crush biotech benchmarks 🧬📈 $XBI $IBB Since launching our first consensus-based portfolio (Top 20s) on April [--] [----] our hedge-fund consensus strategy has consistently outperformed. Heres the data 👇 https://twitter.com/i/web/status/2022031587945447559 https://twitter.com/i/web/status/2022031587945447559"
X Link 2026-02-12T19:34Z 28.9K followers, [----] engagements
"6/ 👉 What this means: Our hedge-fund favorites framework has worked across start dates and market regimes This is not a one-off result. Its sustained outperformance across portfolios"
X Link 2026-02-12T19:34Z 28.9K followers, [---] engagements
"7/ Want access to our portfolio holdings and other portfolios info/tools to help you make better biopharma investment decisions Upgrade to Elite or APEX today. 💌 Limited-Time Valentines Sale: 50% OFF Elite 40% OFF APEX https://www.bpiq.com/pricingmo=021226 https://www.bpiq.com/pricingmo=021226"
X Link 2026-02-12T19:34Z 28.9K followers, [---] engagements
"📣 Biotech Stock News 02/12 @ Open $NVCR 29% FDA Approves Optune Pax for Cancer $BBIO 9% Positive Phase [--] Results for Infigratinib $ANVS 6% DSMB Approval for Buntanetap Trial $TECX 5% Discussion of TX2100 for treatment $ANL 4% First Patient Enrolled in AN9025 Trial $NKTR 2% Pricing of $400 Million Offering $PCRX 1% New NOPAIN Act Survey Data $MRK 0% Advances in Bladder and Kidney Cancer $XLO 0% Pricing of Underwritten Offering $LYEL 0% Initiation of Patient Dosing $PCVX -1% Doses First Participants in OPUS-3 Trial $APRE -1% Strengthens Global Patent Portfolio $BTAI -2% Advances"
X Link 2026-02-12T15:40Z 28.9K followers, [----] engagements
"$BBIO $XBI Infigratinib with home run data: BridgeBio Reports Positive Phase [--] Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - NDA and MAA submissions planned in second half of [----] for achondroplasia; oral infigratinib is the only therapeutic option in development for achondroplasia to have Breakthrough Therapy Designation from the FDA - Given the strength of these data BridgeBio plans to accelerate the development of oral infigratinib in hypochondroplasia and is enrolling the observational run-in for the"
X Link 2026-02-12T12:37Z 10.9K followers, [----] engagements
"$BBIO +9% 🟢 Infigratinib delivers a home run 🏆 - Phase [--] hits primary + key secondary endpoints first-ever improvement in body proportionality in achondroplasia. - NDA planned H2 [----]. Check out our catalyst calendar below. 📅 https://app.bpiq.com/catalyst-calendar https://app.bpiq.com/catalyst-calendar"
X Link 2026-02-12T15:40Z 28.9K followers, [---] engagements
"📌 Biotech Stock News 2/11 @ Open $NKTR 17% Proposed Public Offering $AZN 4% Programs to improve healthcare access $DTIL 4% FDA Clearance for PBGENE-DMD $OTLK 2% Submits Type A Meeting Request $MRK 1% KEYTRUDA and Paclitaxel Approved $SNTI 1% Enrollment in Ph1 Trial of SENTI-202 $BCRX 1% New HAE Data from ORLADEYO $MDGL -2% Exclusive Licensing for Novel siRNA $STOK -4% First Patient Dosed in STK-002 Study $CADL -6% Present at Glioblastoma Drug Summit $GLTO -6% Pricing of $275M Offering $BFRI -6% FDA Filing Acceptance for Ameluz $DBVT -7% Additional data from VITESSE study $OKYO -7% Transition"
X Link 2026-02-11T16:29Z 28.9K followers, [----] engagements
"$UPB down -52% 📉 Ph2 VALIANT met primary endpoint in severe asthma AAER 56% (100 mg q12w) & 39% (400 mg q24w) vs placebo Advancing to Ph3 in asthma & CRSwNP Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-11T16:29Z 28.9K followers, [----] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-11T16:29Z 28.9K followers, [---] engagements
"$RGNX -15% 🔴 FDA issued a CRL for RGX-121 in MPS II / Hunter syndrome ⚠ Key issues: pt selection external control comparability and CSF biomarker not accepted as surrogate. ❌ No approval; FDA suggests more data/new study. Plans BLA resubmission. See image for details. February Biotech PDUFA Pulse: 📡 Whats on the FDA Radar Feb [--] $RGNX RGX-121 (MPS II / Hunter syndrome) Priority Review Feb [--] $MRK Keytruda (platinum-resistant recurrent ovarian cancer) Priority Review (label expansion) Feb [--] $VNDA Bysanti (bipolar I disorder https://t.co/jRQJdkbvdw February Biotech PDUFA Pulse: 📡 Whats on"
X Link 2026-02-10T17:40Z 28.9K followers, [----] engagements
"📌 Biotech Stock News 2/10 @ Open $PHIO 53% Positive SMC wrap-up on PH-762 $EVMN 53% EVO301 Topline data $NKTR 44% REZOLVE-AD Maintenance Data $STRO 10% Pricing of $110M Offering $INMB 9% Advances CORDStrom for RDEB $AGEN 4% New data on BOT/BAL biomarkers $BCDA 2% Pre-Submission for FDA Approval $SPRY 2% Showcase Clinical Data on neffy $SEPN 2% Data from Ph1 Trial of SEP-631 $GNPX 2% Patent Intent for Reqorsa Gene Tx $LTRN 1% Present at Glioblastoma Drug Summit $CRDL 1% ARCHER Ph2 Trial Results Published $ENTA 1% Preclinical data for EDP-978 $PHVS 0% Present Clinical Data at AAAAI Mtg $COGT"
X Link 2026-02-10T16:12Z 28.9K followers, [----] engagements
"$NKTR upcoming milestones. https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88 https://ir.nektar.com/static-files/1432c99b-ce12-46c5-9aef-ba5487f06a88"
X Link 2026-02-10T13:03Z [----] followers, [----] engagements
"$EVMN up 53% 📈 Ph2a of EVO301hit primary endpoint in AD Fast EASI improvements vs placebo (W4 W8 W12) Moving into Phase 2b dose-range trial Don't miss out on future Big Movers Access our FREE Big Mover Report 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"
X Link 2026-02-10T16:12Z 28.9K followers, [----] engagements
"📣 Join our Biotech Daily Stock Moves community. 📌 hottest headlines 🔥 📌 stock moves 📈📉 Stay informed and make smarter investing Visit the link to join our community.👇 https://x.com/i/communities/1808525734627233958 https://x.com/i/communities/1808525734627233958"
X Link 2026-02-10T16:12Z 28.9K followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing